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Abstract 
Telomeres are tandem repeats of DNA associated with specific proteins. These structures 
cap eukaryotic chromosomes and have many functions, including maintaining the integrity 
of the chromosome ends. Telomeres in somatic cells shorten with cell division due to the 
end replication problem. In the germ line and in embryonic life this is circumvented by the 
enzyme telomerase, which shows reduced activity in normal somatic cells. Human 
tumours, including squamous cell carcinoma of the head and neck (SCCHN), must 
maintain telomere function during very many cell divisions and in most cases this is 
achieved by the upregulation of the telomerase enzyme. Inhibiting telomerase has been 
shown to lead to apoptosis in tumour derived cells. Furthermore, as most tumour cells 
have very short telomeres, they are more likely to succumb to telomerase inhibition than 
normal cells. This renders telomerase a potential, highly selective anti-cancer target. The 
telomere is also involved in the repair of DNA double strand breaks, which are the lethal 
chromosomal lesion produced by exposure of the cell to ionising radiation. Proteins 
involved in DSB repair are known to be associated with the telomere and telomere 
dysfunction has been shown to produce radio-sensitivity in mice. 
This thesis considers whether the alteration of telomere function by manipulation of the 
telomerase enzyme can affect the radiosensitivity of in vivo derived SCCHN cells and 
hence whether telomere dysfunction inducing strategies are likely to be synergistic with 
ionising radiation in the management of SCCHN. The role of telomerase in radioprotecting 
cancer cells is investigated using the ectopic expression of hTERT in cell lines with high 
and low levels of telomerase. The effect of inhibiting telomerase expression is examined 
using a dominant negative telomerase gene. This approach had little success in SCCHN 
cells and so further experiments designed to elaborate the effect of telomerase inhibition on 
radiosensitivity were carried out using the small molecule reverse transcriptase inhibitor 
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3'- azido, 3'- deoxythymidine (AZT). These showed both telomerase suppression and 
increased radiosensitivity in cells exposed to AZT in culture. 
Other suggested factors which may affect the success of radiotherapy for cancer include 
the missense mutation of the p53 gene. A common polymorphism at codon 72 gives rise to 
Arginine or proline forms of the protein. This thesis investigates whether this variation 
affects radiosensitivity in SCCHN cells by assessing a panel of in vivo derived SCCHN 
cell lines. 
If the level of telomerase expression does have impact on radiosensitivity, then the use of 
antitelomerase strategies may be less effective with higher levels of telomerase expression 
in tumours. Continued selective pressure during tumour progression may mean the 
emergence of clonal variants with improved telomere function via greater levels of 
telomerase. This is investigated by anaphase bridge scoring of primary and recurrent 
archival tumour material. Analysis of cells from primary lesions and then from recurrent 
disease in the same patient provides information in this regard. This information is of 
particular relevance since any new therapeutic antitelomerase agent will be administered in 
phase 1 and phase 2 trials to patients with advanced and/ or recurrent disease. 
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1. Introduction 
1.1 Squamous carcinoma of the head and neck 
The term squamous carcinoma of the head and neck defines both the tissue of origin and 
anatomical site of this disease. This is therefore a distinct entity in terms of the cell of 
origin. In terms of anatomical site, this tumour may arise from the squamous epithelium of 
the lip, tongue, floor of mouth, nasopharynx, oropharynx, hypopharynx or larynx and still 
be included within this tumour type. By far the most frequent site involved in this cancer 
group in Scotland is the epithelium of the oral cavity. (Scottish Cancer Registry 2004) 
1.2 Epidemiology and prognosis of squamous carcinoma of the 
head and neck 
The overall 5-year survival for squamous carcinoma of the head and neck (SCCHN) has 
not altered in more than 30 years. Despite advances in surgical management and radiation 
and medical oncology the figure of 45 - 50% survival remains static across the developed 
world. (Jefferies and Foulkes 2001) Worldwide, SCCHN is the fourth most common 
malignancy in men and the sixth most common malignancy in women, with approximately 
500,000 cases being registered in 2000. (Gasco and Crook 2003) In the Scottish context, 
figures from the Cancer Intelligence Unit of ISD Scotland reveal an incidence of disease 
which is higher than the UK and is increasing and survival which is poorer. Cancer of the 
head and neck has an incidence of 23/100,000/ year for males and 8/100,000/year for 
females. Incidence has increased between 1990 and 2000 in men by 17.4% and in women 
by 20.2% (Scottish Cancer Registry 2004) Survival overall and in particular for certain age 
ranges appears to be static or possibly worsening. Simultaneously, there is a rising 
incidence of this disease in the UK and more markedly in Scotland (Scottish Cancer 
Registry 2004), especially among younger age groups and in women which is occurring 
against a general reduction in incidence for cancer generally. These survival trends are 
seen both for head and neck cancers overall (Table 1) and for oral cavity cancer (Table 2). 
James Anthony McCaul 2004 Chapter 1,22 
There is therefore a clear need for new insights into SCCHN in order to establish new 
therapeutic strategies. Scotland is a worldwide hotspot for SCCHN with an incidence 
which has risen to 25/100,000 new case per head of population per year. (Scottish Cancer 
Registry 2004) Research into this disease carried out here is therefore both highly relevant 
to the health needs of the population and is facilitated by the population disease burden. 
Also, any therapeutic advances offered by success in this field will have relatively greater 
impact in Scotland. 
Table 1 Relative Survival at five years for head and neck cancer in Scotland for 
patients aged 15 - 99 years 
1977-1981 1992-1996 
Males 57.6% 47.7% 
Females 52.6% 52.2% 
Both sexes 56.7% 48.5% 
Table 2. Relative Survival at five years for oral cavity cancer in Scotland for patients 
aged 15 - 99 years. 
1977-81 1992-1996 
Male 35.1% 42.0% 
Female 41.6% 50.5% 
Both sexes 36.1% 43.4% 
James Anthony McCaul 2004 
1.3 Current therapy for SCCHN 
The management of SCCHN involves 
Chapter 1,23 
surgery, radiotherapy, chemotherapy and 
combinations of these modalities. Factors influencing the optimum treatment include 
features of the primary tumour such as size, site and tumour thickness and patient factors 
such as age and general medical condition. In the management of early disease, surgery 
and radiotherapy for the primary tumour show comparable effectiveness in terms of 
treatment end point (5 year survival rates). Other factors, such as site, stage and neck node 
status then become significant in decision making. Further, the complication profile of 
each of these modalities differs and so broader quality of life considerations determine the 
optimum management plan. 
In patients presenting with more advanced disease combined modality treatment is 
considered. These include larger primary lesions, i. e. T3 and T4 and those with clinically 
apparent spread of disease to the cervical nodes. These account for 66% of the SCCHN 
patients presenting in the West of Scotland (Currie, Hislop and Carton in press). 
In general for early stage disease, surgical resection or radiotherapy for the primary cancer 
with appropriate surgical management of the neck is accompanied by adjuvant 
radiotherapy where indicated. Further, where the resection margin of the primary tumour 
has been necessarily close, or where there are adverse histological features either at the 
primary site (e. g. perivascular or perineural invasion) or in the neck (e. g. nodal 
involvement at multiple levels or extracapsular spread) adjuvant radiotherapy is employed 
to treat any residual microscopic disease deposits. Clearly, recurrence of a clone of cancer 
cells is possible with the persistence of a single viable tumour cell. 
Standard radiotherapy regimen comprises a total of 60Gy of radiation delivered in fractions 
of 2Gy five days per week for six weeks. Ionising radiation has a significant side effect 
profile, including painful mucositis and skin changes, dysphagia, xerostomia, lassitude and 
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taste problems. Patients often require hospital admission to correct dehydration and 
nutritional status and there is a small but significant mortality with this treatment. 
In advanced disease, or for patients deemed unfit for surgery on medical grounds, 
combination primary chemoradiation may be utilised (cisplatin and fluorouracil with 
teletherapy radiation). Significant advances have been made using this treatment modality 
in comparison to radiotherapy alone in patients with disease considered unresectable. 
(Forastiere, Goepfert et al. 2003) Some new evidence emerging from trials involving a 
third agent are yielding promising initial data. (EORTC 2004) The role of chemotherapy 
generally in the management of this cancer at this time remains investigational. 
The overall unchanging survival in the face of enhancements in modem surgical 
management for SCCHN delineates the need for new therapeutic strategies for this disease. 
These are best identified in principle by consideration of the fundamental nature of cancer 
tissue. This can only be achieved by recognition of the genetic basis of malignancy. Cancer 
is a disease of the genome, involving changes in genes coding for cell growth, 
differentiation and apoptosis. Understanding the basis of these changes and their effect on 
cell biology is the route by which better, targeted therapeutic options will be found and 
survival rates enhanced. 
1.4 Cancer as a disease of the genome 
Steadily advancing understanding of cancer over the last 30 years has revealed this to be a 
genetic disease. (Hanahan and Weinberg 2000) Cancer is a multistep process involving 
upregulation of oncogenes with dominant gain of function and mutations of tumour 
suppressor genes with recessive loss of function. While our understanding of the 
complexity of control mechanisms for cell growth and differentiation progressively 
increases, the salient properties of the cancer cell have been proposed to be the same six 
essential features, regardless of tissue of origin (Figure 1-1) (Hanahan and Weinberg 2000) 
James Anthony McCau12004 Chapter 1,25 
Self-sufficiency for growth 
Apoptosis evasion Insensitivity to 
Antigrowth signals 
cell 
ae invasion and 
metastasis 
Unlimited Cell Replication 
Figure 1-1. Acquired features of Cancer cells (modified from Hanahan and Weinberg 
2000. ) 
Precise control mechanisms underlying these features vary between different cell types so 
that while the detail may differ the principles are the same. Organising the characteristics 
of malignant cells into these six main categories not only provides clarity of understanding 
of the processes involved in oncogenesis but also provides clear lines along which to attack 
the cancer cell therapeutically. These are the features which distinguish cancer cells from 
normal tissue and therefore provide, at least in principle, long sought for specificity in 
designing cancer treatments. Further, attacking more than one of these salient cancer 
characteristics simultaneously may produce a synergistic therapeutic benefit. 
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The concept of the holistic management of the cancer patient must remain central to 
considerations of the best strategies to adopt in finding new therapeutic approaches. In 
treating a disease which remains perhaps the biggest challenge to modem medicine in the 
developed world it is essential to maintain vision regarding appropriate outcomes. 
Attempts to "cure" cancer have been the goal of successive generations of doctors and 
scientists. However, as our understanding of the molecular processes underlying both 
normal cell growth and differentiation and the properties of cancer cells increases, it 
becomes apparent that a shift of focus toward control of the disease process, rather than 
absolute eradication, may be the most appropriate strategy. 
1.5 Unlimited cell replication 
This feature of the cancer cell is achieved by telomere maintaining mechanisms. In most 
cancers, (85-90%) telomerase is upregulated to maintain the chromosome end caps and 
renders the cell immortal (Kim, Piatyszek et al. 1994). Telomere maintenance by 
telomerase provides an attractive target in antitumour therapy and this strategic approach 
forms the basis for this thesis. The details of the telomere and telomerase function are now 
discussed. 
1.6 The Telomere 
1.6.1 Telomere composition 
Telomeres are composed of tandem repeats of DNA sequence (TTAGGG)n, repeated 
many hundreds to thousands of times located at the ends of eukaryotic chromosomes. They 
have a number of associated proteins and have many functions. These include protecting 
the chromosome from end to end fusion, recombination and recognition as damaged DNA. 
(McEachern, Krauskopf et al. 2000) They provide a means for complete replication of 
chromosomes and contribute to the functional organisation of chromosomes within the 
nucleus. Capping prevents chromosomes from fusing and their ends being misinterpreted 
as DNA double strand breaks. Telomeres also act as repositories for DNA repair enzymes 
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(Blasco, Gasser et al. 1999) and can silence genes placed close to them. (Baur, Zou et al. 
2001) While most of the telomere is double stranded, each has an overhanging, single 
stranded length of DNA on the G-rich, 3' strand. This has been implicated as a crucial 
component of the telomere which is essential for normal function. (Henderson and 
Blackburn 1989; Griffith, Comeau et al. 1999; Blackburn 2001) This may participate in the 
organisation of the telomere end into the T-loop, D-loop structure and is the substrate for 
telomerase, the cellular reverse transcriptase which can add telomeric DNA to the 
chromosome ends. Recently, this single stranded stretch of telomere DNA was shown to be 
eroded in senescent cells. Thus it seems that this is the specific molecular alteration, 
resulting in the exposure of the eroded 3' G-rich end, triggers the senescent state in 
mammalian cells. (Stewart, Ben-Porath et al. 2003) However it is still unclear whether 
erosion of the G-rich overhang itself is the cause or consequence of senescence. 
1.6.2 Telomere Structure 
The telomere structure is not yet fully understood, but appears to protect the 3' single 
stranded end from degradation and possibly from addition of repeats by telomerase. 
(Makarov, Hirose et al. 1997; Shore 1997; Wellinger and Sen 1997; Lingner and Cech 
1998; Griffith, Comeau et al. 1999; Blackburn 2000; McEachem, Krauskopf et al. 2000; 
Dubrana, Perrod et al. 2001) Large duplex loops of DNA have been shown to form at the 
telomere end (Griffith, Comeau et al. 1999; Munoz-Jordan, Cross et al. 2001) These have 
been termed T-loops and have an associated smaller D-loop. Sizes of these loops vary 
considerably in different organisms, leading to the conclusion that this structure itself may 
not form a functional unit (de Lange 2002). Indirect evidence suggests that the T-loop 
forms by invasion of the single stranded 3' G-rich overhang back into the duplex DNA of 
the telomere. While the precise structure is not clear, there is a short segment of single 
stranded DNA which represents the displaced TTAGGG strand (D-loop) at the point of 
overhang invasion. (Figure 1-2). Further recent evidence suggests that telomere length 
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homeostasis is achieved via a switch between telomerase-extendable and -nonextendable 
states. (Teixeira, Arneric et al. 2004) 
3' G-rich overhang 
5' strand 
T loop 
Figure 1-2. Schematic diagram of T-loop D-loop formation at the mammalian 
telomere modified from Griffith et al 1999 
1.6.3 Telomere associated proteins 
A number of proteins have been identified which are associated with mammalian 
telomeres. These have differing roles and many function to regulate telomere length and 
structure and to protect the telomere. (de Lange 2002) The telomere also binds proteins 
involved in DNA repair. These include the three components of the DNA dependant 
protein kinase (DNA-PK) heterotrimer (Ku 70, Ku 80 and DNA-PKcs) (Critchlow and 
Jackson 1998) and the RMN complex (Mre11, Rad50 and NBS1). Proteins involved in 
double strand break repair by non-homologous end joining are of particular interest in the 
context of cancer therapy. The double strand break is the lethal chromosomal lesion 
produced by ionising radiation and by certain chemotherapeutic agents (see on). 
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1.7 The Telomerase enzyme. 
In the germ line telomere loss is countered by the presence of telomerase (Greider and 
Blackburn 1985) which perfectly balances the loss of nucleotides during cell division by 
the direct addition of TTAGGG DNA repeats to the chromosome end (Allsopp, Vaziri et 
al. 1992). Telomerase is a RNA dependant DNA polymerase which is downregulated at 
around 20 weeks of intrauterine life in somatic cells. Since its initial discovery in 
Tetrahymena thermophila in 1985 (Greider and Blackburn 1985) it has been the subject of 
detailed research which reveals that it is composed of at least two essential components, 
the RNA template, TERC (Feng, Funk et al. 1995) and the catalytic subunit, TERT. 
(Nakamura, Morin et al. 1997) One component (hTERC) is expressed in all tissues, 
(Avilion, Piatyszek et al. 1996) but shows an approximately five-fold increase in 
expression in cancer cells. (Yi, Tesmer et al. 1999) In contrast the catalytic component 
(hTERT) is subject to close control and this is thought to be the molecular basis for control 
of enzyme activity. (Cong and Bacchetti 2000) In addition to the maintenance of telomeres 
in the germ line by telomerase there is now evidence to indicate that the final length of the 
telomere is under very sophisticated control. In particular, telomere length in the germ line 
can sometimes be reset by as yet undefined mechanisms when animals are cloned from 
senescent somatic cells. (Lanza, Cibelli et al. 2000) 
There is some evidence accumulating that telomerase may have roles beyond simple 
maintenance of telomere length. (Blasco 2002) Specifically, it is suggested that telomerase 
might promote or increase the rate of cellular proliferation, (Gonzalez-Suarez, Samper et 
al. 2001) or enhance cell survival. (Mattson, Fu et al. 2001) 
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1.8 The End Replication Problem. 
This term describes the process by which telomeric DNA is lost with every round of cell 
replication. (Watson 1972) Synthesis of DNA in the 5' lagging strand requires the use of a 
RNA primer, which is removed leaving a gap which DNA polymerase cannot fill. This 
leads to attrition of the telomere with between 50-200 nucleotides being lost at each cell 
division. Further digestion of the strand by a putative 5'-3'- exonuclease is proposed to 
increase the size of the gap (Makarov, Hirose et al. 1997), so that the double stranded DNA 
molecules have a 3' single-strand overhang. Repetition of these processes results in 
progressive attrition of the 5' ends, thus leading to a gradual shortening of the telomeres 
after many cell divisions. This is shown diagrammatically in Figure 1.3. Telomeres can 
also be shortened by oxidative damage. (von Zglinicki, Saretzki et al. 1995) 
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DNA replication 
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Figure 1-3. The end replication problem and telomeric attrition. 
From (McCaul, Gordon et al. 2002). Removal of the RNA primer (green segment) 
leaves a shortened DNA strand. Further shortening of the 5' end (Red strand) then 
occurs via putative exonuclease activity, leaving the 3' singlestranded G-rich 
overhang. Thus the human chromosome shortens at every round of cell replication. 
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1.9 The telomere hypothesis of replicative senescence 
When grown in culture, most types of normal human cells will stop proliferating after a 
predictable number of population doublings and enter senescence; a cell state where cells 
cease to proliferate but remain viable for long periods of time. This has been referred to as 
the Hayflick limit. (Hayflick 1961) After 20 weeks of intrauterine life telomerase activity 
is completely repressed in most- somatic cells (Wright, Piatyszek et al. 1996) and 
downregulated in haematopoietic stem cells. (Hastie, Dempster et al. 1990) Hence 
telomere length is not adequately maintained throughout life and progressively shortens, as 
described above. This telomeric attrition has been proposed to be the basis of a cellular 
replicometer which can both count, and remember, the number of cell divisions completed 
by a telomerase-deficient cell because cells with short telomeres enter senescence. 
(Olovnikov 1973) This idea is supported by several observations. Telomere lengths, as 
assessed by the size of telomere repeat fragments (TRFs) obtained by restriction enzyme 
digestion of the DNA are shorter in older individuals. (Hastie, Dempster et al. 1990) Cells 
grown in culture also show progressive telomere attrition with continued cell division. 
(Harley, Futcher et al. 1990) The replicative lifespan of human fibroblasts can be predicted 
on the basis of starting telomere length (Allsopp, Vaziri et al. 1992) and telomeric attrition 
both in vitro and in vitro is dependent on cell division. (Munro, Stott et al. 1999) Most 
importantly, the correction of telomere shortening should prevent senescence and this has 
been shown experimentally. Expression of the telomerase catalytic subunit, hTERT, can 
reconstitute telomerase activity (Weinrich, Pruzan et al. 1997) and extend the lifespan of 
human fibroblasts (Bodnar, Ouellette et al. 1998) without causing karyotypic changes or 
features of transformation. (Morales, Holt et al. 1999) Mouse models have provided 
valuable insight into this area. Although laboratory mice (mus sprutus) have long and 
heterogeneous telomeres, (Kipling and Cooke 1990) the cloning of the first essential 
telomerase component, TERC, (Feng, Funk et al. 1995) has made possible the creation of 
strains of telomerase-deficient mice (TERC-/-). These show telomeric attrition through 
successive generations. (Blasco, Lee et al. 1997) Breeding TERC -/- mice through four to 
James Anthony McCaul 2004 Chapter 1,33 
six generations causes compromised proliferation and loss of viability of the germ line and 
lymphocytes, (Lee, Blasco et al. 1998) sterility, (Lee, Blasco et al. 1998) poor wound 
healing (Rudolph, Chang et al. 1999) and many features of human ageing in vitro. 
(Rudolph, Chang et al. 1999). Further insights have been gained from disease states where 
telomerase and hence telomere function is adversely affected. In humans a mutation in the 
dyskeratosis congenita gene product, dyskerin, leads to an instability of the hTERC 
transcript and to a reduction in telomerase activity. (Mitchell, Wood et al. 1999) The 
fibroblasts from these patients cannot be immortalised by the expression of the hTERT 
gene because there is too little hTERC to generate the required enzyme activity. 
Interestingly, dyskeratosis congenita is characterised by early onset anaemia and bone 
marrow failure resembling the problems encountered by the telomerase null mice at later 
generations. Therefore, collectively, these studies support the concept that telomeric 
attrition prevents indefinite clonal proliferation in vitro. 
1.10 Human cellular mortality and the role of telomeres. 
Most somatic human cells, including the keratinocytes of squamous epithelium, are 
telomerase deficient and mortal in vitro. In cultured epithelial cells replicative senescence 
is thought to be controlled first by the accumulation of p16INK4A (mortality mechanism 0 
or MO). MO is not directed by telomere length (Ramirez, Morales et al. 2001) but it has 
been suggested that MO is dependent on the rate of oxidative damage, the cell type and the 
culture environment and that putative telornere-independent mechanisms of replicative 
aging might reflect inadequate growth conditions. (Ramirez, Morales et al. 2001) 
However, it should be emphasised that although there is evidence to show that oxidative 
damage drives the accumulation of p l61NK4A, or MO in vitro, the role of MO as an in vivo 
checkpoint to the development of cancer has not been firmly established. (Forsyth, Evans 
et al. 2003; Parrinello, Samper et al. 2003) After further multiple divisions and a period of 
telomere loss these cells then encounter mortality mechanism 1 (Ml) (Wright, Pereira- 
Smith et al. 1989) (see Figure 1-4). MO and MI are biologically indistinguishable 
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(Romanov, Kozakiewicz et al. 2001); both are cell cycle arrest states and referred to as 
replicative senescence. Thus loss of telomere length mediates the cessation of cell division. 
The M1 checkpoint is mediated by p53 and may be triggered by exposure of the 3' end 
following disruption of the t loop. (Blackburn 2001) In fact, t loop disruption by the 
expression of a dominant negative TRF2 induces a growth arrest with features of 
senescence. (van Steensel, Smogorzewska et al. 1998) Most recently, evidence of erosion 
of the 3' single strand DNA overhang has been demonstrated in senescent cells and this 
specific change has been suggested to be the trigger for growth arrest. (Stewart, Ben- 
Porath et al. 2003) Indeed using T-oligos to mimic exposure of the 3'- end has been shown 
to rapidly induce senescence in malignant fibroblasts. (Li, Eller et al. 2004) Following 
disruption of the cell cycle control pathways (and MO and M1) by for example, DNA 
tumour viruses, the telomeres shorten still further, until one or more becomes 
dysfunctional. At this time, as a consequence of telomeric fusions, many dicentric 
chromosomes and anaphase bridges form and result in a considerable amount of cell death. 
(Counter, Avilion et al. 1992; Counter, Hahn et al. 1998) This checkpoint on the road to 
cellular immortality is known as crisis or mortality mechanism 2 (M2) (Wright, Pereira- 
Smith et al. 1989) (see Figure 4). From these unstable cultures, rare variant cells emerge 
(1 in 107) which have acquired unlimited replicative potential. These cells have progressed 
to a state where telomeres are maintained and in 85-90% of cases this is by upregulation of 
telomerase. (Counter, Avilion et al. 1992) However, less commonly, telomerase negative 
cells survive crisis and become immortal because they use a recombination-based telomere 
elongation mechanism known as ALT (Alternative Lengthening of Telomeres). (Bryan, 
Englezou et al. 1997) While ALT has never to date been demonstrated in SCCHN, its 
possible relevance to the successful treatment by telomerase inhibitors is discussed below. 
The role of telomerase deficiency in human cellular mortality is demonstrated by the 
experiments which show that the ectopic expression of telomerase can bypass both 
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senescence (Bodnar, Ouellette et al. 1998) and crisis (Counter, Hahn et al. 1998) in these 
models. 
b) Some stem and 
progenitor cells 
Telomerose LOW i) Senescence 
a) Farm line Most somatic cells Oxidative damage? Crisis 
Telomerose ON 
Telomerose OFF (Mortality mech. 0) ii) Senescence (Mortality mech. 2) 
Telomeres maintained pl61NK4A accumulation (Mortality mech. 1) 
c) p53/ pRb dysfunction Apoptosis, Telomeres shorten (Telomeres still long) Telomeres short further telomere onaphase bridges 
attrition dicentric chromosomes 
Cell Death 
d) Telomerose Re-activation 
e) Telomerase Inhibition 
Figure 1-4. The telomere hypothesis of replicative senesence and cellular mortality. 
a) There is now considerable evidence that telomerase is active in the germ line and 
that it maintains the telomeres through successive generations. b) At some point 
during development telomerase is down-regulated, or extinguished in most somatic 
human cells from that time telomeric attrition is proposed to begin. Most carcinomas 
first encounter the telomere length-independent mortality mechanism 0 (i), which is 
bypassed by the loss of p16INK4A early in SCCHN development. Telomere 
shortening continues and culminates in replicative senescence or mortality 
mechanism 1 (ii). c) The elimination of the p53 and pRb pathways by DNA tumour 
viruses or by somatic mutations in the pathways themselves allows the cells to tolerate 
short telomeres and divide further. In the continued absence of telomerase this results 
in further telomeric attrition until the telomeres become dysfunctional and the cells 
die as a consequence of mitotic failure precipitated by dicentric chromosomes and 
anaphase bridges. d) The re-expression or up-regulation of telomerase adds 
TTAGGG repeats to the dysfunctional telomeres, renders them functional again and 
allows the cells to bypass crisis, or mortality mechanism 2. e) Conversely the 
inhibition of telomerase drives telomerase-positive cells back into crisis. 
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1.11 Telomere function and the development of cancer. 
While studies had shown that the great majority of malignant cells have upregulated 
telomerase, until recently this evidence associating telomerase with human telomere 
maintenance was only correlative. The cloning of the hTERT gene provided the ability to 
reconstitute telomerase in cultured human cells. This allowed the creation of human 
tumour cells with a small number of defined genetic changes, which is not possible in the 
absence of telomerase (Hahn, Counter et al. 1999). These studies specifically addressed the 
function of telomerase in immortalisation and oncogenesis and demonstrated a clear role in 
telomere maintenance and the avoidance of crisis. (Lingner, Hughes et al. 1997; Meyerson, 
Counter et al. 1997) Thus these observations establish telomerase activation as an 
important event in the conversion of a normal human cell into its malignant counterpart. In 
the telomerase null mouse, the development of squamous cancer (Gonzalez-Suarez, 
Samper et al. 2000), as elicited by chemical carcinogens, is strongly repressed. The 
development of other cancers is also reduced in mice additionally deficient in the 
Adenomatous Polyposis Coli (APC) (Rudolph, Millard et al. 2001) and INK4A-/- 
(Greenberg, Chin et al. 1999) tumour suppressor genes. However, when short telomeres 
are combined with p53 deficiency, an increased tumour yield is observed (Chin, Artandi et 
al. 1999) and tumours with cytogenetic features (unbalanced translocations, Robertsonian 
translocations, regional gains and losses) reminiscent of their human counterparts are 
observed (Artandi, Chang et al. 2000). The generation of genetic instability by 
dysfunctional telomeres and the acceleration of cancer development is speculated to occur 
during a short period, in which many human cancer cells will die as part of crisis (Artandi 
and DePinho 2000). Once telomeres become functional again, due to the up-regulation of 
telomerase, the genetic stability of the tumours is predicted to be restored. It is certainly 
plausible that in human tumours the genetic instability generated during crisis contributes 
to the up-regulation of telomerase. The telomerase gene is in fact located on the short arm 
of chromosome 5 and within 2Mb of the chromosome end (Chr5 p15.33). The combination 
of short dysfunctional telomeres and p53 mutation is likely to exist in the latter stages of 
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development of many human cancers. (Hastie, Dempster et al. 1990; Brachman, Graves et 
al. 1992) One caveat to the telomerase inhibition strategy is the possibility that this might 
accelerate the development of subsets of tumours that can use ALT mechanisms to 
maintain telomeres, or even uncover ALT function in cells where both mechanisms 
coexist. (Gan, Mo et al. 2002) Interestingly, however, in some cancers which are typically 
telomerase negative and telomeres are therefore maintained by the ALT mechanism, 
telomerase expression is associated with increased tumour aggressiveness. (Sanders, Drissi 
et al. 2004) these issues are discussed in more detail in section 1.13. 
1.12 SCCHN immortality and the role of telomerase. 
The immortal phenotype can arise early in SCCHN progression (McGregor, Wagner et al. 
1997; McGregor, Muntoni et al. 2002)but generally is more prevalent in the more 
advanced stages of the disease. (Edington, Loughran et al. 1995) Immortal SCCHN cells 
almost always possess dysfunctional p161NK4A, p53 and retinoic acid receptor ß genes 
(L)ughran, Clark et al. 1997; McGregor, Wagner et al. 1997) and these markers are 
associated with the bypass of M1. The bypass of M2 is most likely achieved by the up- 
regulation of telomerase which is ubiquitous in SCCHN lines and there are no reports to 
date of ALT pathway activation. (Loughran, Clark et al. 1997) These characteristics are 
found in a large subset of SCCHN in vitro (Brachman, Graves et al. 1992; Kim, Piatyszek 
et al. 1994; Reed, Califano et al. 1996) and the size of this subset matches very closely the 
fraction of SCCHN tumours that are immortal in vitro. (Edington, Loughran et al. 1995) 
Normal basal squamous keratinocytes do possess detectable in vitro telomerase activity 
(Harle-Bachor and Boukamp 1996) but there is no evidence that this telomerase is 
functional. In fact, the telomeres of normal squamous epithelium from old individuals 
(Lindsey, McGill et al. 1991), immortal SCCHN cells (Gordon, Ireland et al. 2003) and 
squamous cell carcinomas in vitro (Parris, Jezzard et al. 1999) are considerably shorter 
than normal. Also immortal SCCHN lines have cytogenetic changes, such as Robertsonian 
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translocations (K. G. Edington - unpublished data) that result from the telomeric fusion of 
two chromosomes (usually acrocentrics). SCCHN lines also have numerous chromosomal 
gains and losses, which together with Robertsonian translocations are consistent with the 
SCCHN cells having passed through crisis. (Artandi, Chang et al. 2000; Artandi and 
DePinho 2000) Finally, recently obtained direct evidence suggests that post Ml, pre M2 
SCCHN cells exist and are present in vitro. (Gordon, Ireland et al. 2003) SCCHN cells 
with mutant p53, deleted INK4A, short telomeres and low telomerase can be detected in 
vitro and these cells display features of crisis, including dicentric chromosomes and 
anaphase bridges. The ectopic expression of telomerase in these cells reduces dicentrics 
and anaphase bridges and improves growth. Furthermore, some SCCHN tumours have 
high anaphase bridge indices in vitro and comparisons of telomere function between 
primary cancers and neck metastases show tumour progression to evidence of reduced 
levels of telomere dysfunction. Taken together, this data is consistent with the idea that 
SCCHN cells re-activate telomerase following an extensive period of telomere shortening 
during multiple cell divisions. 
Thus the telomeres in SCCHN generally are very much shorter than the telomeres in 
normal somatic cells even in older patients. This should ensure that following telomerase 
inhibition, telomere dysfunction should ensue and produce cell death selectively in the 
cancer tissue before any normal tissue toxicity is observed (see below). 
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1.13 Telomerase as a therapeutic target 
A variety of different strategies targeting telomerase have been proposed and investigated. 
Telomerase is in fact unusual in that a substantial body of basic scientific research has been 
carried out prior to the development of effective drug compounds rather than the reverse 
situation. This has allowed the anticipation of many potential problems which is the 
opposite circumstance to that for most drug development (Shay and Wright 2002). 
Importantly, the ability of telomerase inhibition to kill tumour cells does not require the 
p53 (Hahn, Stewart et al. 1999) or the INK4A (Zhang, Mar et al. 1999) genes to be intact 
and this is significant, given the frequency of the inactivation of these genes in human 
tumours. 
There are some potential difficulties with the telomerase/ telomere function target for 
cancer therapy. 
First, many strategies inhibiting the enzyme will require a lag phase, during which further 
cell division and hence telomere shortening will occur prior to cell death. This lag phase 
will be proportional to the starting telomere length. (Feng, Funk et al. 1995; Hahn, Stewart 
et al. 1999; Herbert, Pitts et al. 1999; Zhang, Mar et al. 1999) Human tumours have been 
shown to have very short telomeres but some further tumour growth (and progression) 
would occur with this treatment. 
Secondly, some normal tissues express telomerase, including germ cells, haematological 
cells and basal cells of the epidermis and intestinal crypts. These normal tissues however 
only transiently express the enzyme and so any effect here would be less marked than in 
cancer cells. Clearly the planned duration of antitelomerase therapy would be significant in 
anticipating this type of toxicity. 
The inhibition of telomere maintenance by targeting telomerase will certainly produce 
selective pressure for the emergence of other mechanisms of telomere maintenance. Other 
means by which telomeres can be maintained are known to exist in cell lines which are 
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telomerase negative and have very heterogeneous telomere lengths. Termed the ALT 
pathway (Alternative Lengthening of Telomeres), the precise mechanism remains unclear 
but includes one thought to depend on homologous recombination, in both yeast and 
mammals. (Lundblad and Blackburn 1993; Bryan, Englezou et al. 1995; Bryan, Englezou 
et al. 1997; Bryan and Reddel 1997; Reddel, Bryan et al. 2001; Henson, Neumann et al. 
2002; Lundblad 2002) Recent evidence suggests that sister chromatid exchanges of the 
telomeric DNA occur at high rates in some ALT lines, which, if unequal may facilitate 
unlimited cell replication. (Bailey, Brenneman et al. 2004) This mechanism is however 
rare in human cancer and immortal tumour cell lines generally and represents only 6-7% of 
the samples analysed to date. (Reddel, Bryan et al. 2001) Furthermore there is no evidence 
that ALT is used to maintain untreated SCCHN telomeres. (Loughran, Clark et al. 1997) 
Another possible area of concern connected to the ALT mechanism is dysfunctional 
mismatch repair. In yeast this has been shown to facilitate ALT in telomerase deficient 
strains and many human tumours resistant to various chemotherapy regimens lack efficient 
mismatch repair pathways. (Rizki and Lundblad 2001) This issue has not however been 
extensively investigated in SCCHN and until recently the only published study did not find 
any significant selection for cells deficient in mismatch repair pathways after 
chemotherapy. (Blons, Cabelguenne et al. 1999) One recent report however has now 
shown that telomerase inhibition in a mismatch repair deficient colorectal carcinoma line 
can produce ALT-like telomere elongation. (Bechter, Zou et al. 2004) 
The concern has also been raised that the crisis phenotype produced by telomere 
shortening might lead to the emergence of more aggressive tumours. Although some 
evidence supports this concern, (Chin, Artandi et al. 1999) (Gonzalez-Suarez, Samper et al. 
2001) the majority of the available evidence suggests the opposite and so is reassuring in 
this regard. (Herbert, Pitts et al. 1999; Zhang, Mar et al. 1999; Kim, Rivera et at. 2001) 
(Greenberg, Chin et al. 1999; Gonzalez-Suarez, Samper et al. 2000; Boklan, Nanjangud et 
al. 2002) (de Lange and Jacks 1999; Hahn, Stewart et al. 1999; Franco, Segura et al. 2002; 
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Goytisolo and Blasco 2002) This would be averted by the use of multiple synergistic 
therapeutic interventions, such as the inclusion of an effective antiangiogenesis strategy. It 
is clear however, that the emergence of any new cancer in the face of potent telomerase 
inhibition would require the institution, in a short time frame, of an effective but different 
telomere maintenance mechanism. This has not yet been seen in SCCHN. 
Four broad areas show the most promise for clinical application and these are briefly 
considered below 
1.13.1 Telomerase specific oncolytic virus 
The high frequency of telomerase activation in cancer cells specifically allows the design 
of therapy based on the hTERT proximal promoter. Regulation of hTERT at the 
transcription level means that only telomerase positive cells activate this promoter region. 
Genes coding for pro-apoptotic pathways have been transferred using direct intratumour 
injections of plasmids or adenoviral vectors. These contain the hTERT promoter upstream 
from genes such as caspase 6 and 8 (Komata, Kondo et al. 2001), Bax (Gu, Kagawa et al. 
2000) and the FADD gene (Koga, Hirohata et al. 2001). Replication deficient adenovirus is 
however limited as a cancer therapy due to limited transduction of tumour tissue. A recent 
development has been the production of tumour-specific replication competent adenoviral 
gene therapy (hTERTp-TRAD). (Shay and Wright 2002) This adenovirus infects both 
normal and malignant cells, but only replicates in and subsequently lyses cells in which 
telomerase is expressed. Intact virions of hTERTp-TRAD would then infect adjacent 
tumour cells amplifying the effect. With this approach there is no lag phase and so 
cytotoxicity is immediate. This may mean however that cells which transiently express 
telomerase (spermatocytes, intestinal crypt cells and basal and suprabasal epidermis and 
mucosa) would also be damaged. (Holt and Shay 1999; White, Wright et at. 2001; Forsyth, 
Wright et al. 2002) 
The transcriptional regulatory sequences of hTERC and hTERT have also been used to 
activate expression of the bacterial nitroreductase enzyme. Used in combination with a 
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prodrug (CB1954) cells have been shown to be sensitized and efficiently killed. (Boyd, 
Mairs et al. 2001; Plumb, Bilsland et al. 2001; Bilsland, Anderson et al. 2003) 
1.13.2 hTERT immunotherapy. 
T cells targeted to tumour antigens have been shown to produce tumour regression. 
(Vonderheide 2002) The catalytic component of human telomerase (hTERT) is processed 
intracellularly and peptide fragments are presented as epitopes by MHC. This produces 
protective immune responses against tumours. (Minev, Hipp et al. 2000; Nair, Heiser et al. 
2000; Vonderheide 2002) Again in this approach the widespread and vast overexpression 
of telomerase in many cancers relative to normal tissue shows the potential range and 
effectiveness of the telomerase target. Here also the lag phase is avoided, but the 
possibility of an adverse effect on normal tissue transiently expressing telomerase could 
occur. Specific CTL cell kill has been elicited in prostate, lung, breast, colon and 
melanoma cells, but not in CD34+ haemopoietic stem cells. Thus the far higher and more 
persistent expression of telomerase in cancer may lend an adequate degree of specificity to 
this strategy. (Vonderheide 2002) 
1.13.3 Anti hTERC strategies. 
The RNA component of the telomerase holoenzyme complex has been targeted with 
several classes of oligonucleotides. These include phosphdiester DNA, phosphromidates, 
peptide nucleic acids, locked nucleic acids, 2'O-methyl-RNA, 2'-O-methoxyethyl RNA. 
(Norton, Piatyszek et al. 1996; Pitts and Corey 1998; Hamilton, Simmons et al. 1999; 
Corey 2000; Elayadi, Demieville et al. 2001; Gryaznov, Pongracz et al. 2001; Corey 2002; 
Herbert, Pongracz et al. 2002; Asai, Oshima et al. 2003) This approach leads to progressive 
telomere shortening in intact cells, thus incurring a lag phase in therapy. As with many 
gene therapy approaches, the above strategies are dependent on the development of 
suitable delivery systems which do not currently exist. Another anti-hTERC strategy 
described recently uses a lentiviral delivery system for efficient overexpression of mutant 
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template RNA. This approach rapidly inhibited cell growth and induced apoptosis in 
telomerase positive precancer and cancer cells. (Li, Rosenberg et al. 2004) 
1.13.4 Antitelomerase compounds 
Experiments using the expression of dominant negative telomerase mutants have clearly 
shown the ability to kill cancer cells with this approach. (Hahn, Stewart et al. 1999; Zhang, 
Mar et al. 1999) Again the problems of delivery to the tissues limits the usefulness of such 
a strategy clinically. 
Drugs that have been shown to inhibit telomerase include reverse transcriptase inhibitors 
(including AZT), nucleoside analogues, isothiazolone derivatives, a rhodocyanine and a 
catechin component of green tea (see Kelland for a review (Kelland 2001)). A further 
class of agents are those that target G quadruplex (or tetraplex) structures rather than 
duplex DNA. (Kelland 2001) Although there is no evidence to support the existence of 
quadruplex structures in mammalian telomeres, quadruplex structures are formed by the G 
strand overhang at the telomere in vitro and the aim of the G quartet-interacting drugs is to 
block the interaction between telomerase and its substrate. (Kelland 2001) 
The problem with most of the above drugs is that they affect the growth of telomerase- 
negative cells (Rha, Izbicka et al. 2000) (Naasani, Seimiya et al. 1999) suggesting that they 
may influence biological processes other than telomerase activity. However, more 
recently, a new non-nucleosidic drug, designated B1BR1532, was shown to inhibit 
telomerase, elicit telomere reduction and trigger cell cycle arrest in a highly selective 
manner, in a number of immortal human cancer cell lines (Damm, Hemmann et al. 2001). 
At the same concentration, the drug did not affect telomerase-negative normal cells or 
immortal cells using the ALT mechanism of telomere maintenance. B1BR1532 can also be 
administered orally and can inhibit the growth of human tumour xenografts in nude mice 
and as such represents the most promising anti-telomerase agent discovered to date. The 
mechanism of action of BIBR1532 has been clarified more recently (Pascolo, Wenz et at. 
2002) showing it to act non-competitively and similarly to non-nucleosidic inhibitors of 
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HIV I reverse transcriptase. Other reports about this agent have been less encouraging, 
suggesting that IC(50) values may be higher than previously reported and that further 
refinement is necessary. (Barma, Elayadi et al. 2003) 
Although cryptic damage, in the form of telomere reduction, may be sustained by normal 
telomerase positive cells, the available evidence suggests that on removal of telomerase 
inhibition, the telomeres return to their original length. (Herbert, Pitts et al. 1999) This 
result encourages the belief that normal cells may be able to reset their telomere lengths 
once anti-telomerase therapy has been curtailed. Hence, any effect of a telomerase inhibitor 
agent of shortening telomeres in either haematological or germ cells will only occur during 
the period of drug administration and it is likely that telomeres will be restored when 
therapy stops. Clearly, if long term therapy were to be considered then effects on normal 
tissue may become relevant but if a shorter duration, perhaps in combination with other 
treatment strategies were to be employed this would be less so. This opinion is also 
supported by the ability of senescent bovine cells to produce cloned animals with normal 
telomere lengths. (Lanza, Cibelli et al. 2000) 
1.14 Telomere dysfunction and radiosensitisation. 
Ionising radiation is an important component of the overall management strategy for 
treatment of SCCHN. The effectiveness of radiotherapy lies in the greater sensitivity of 
cancer tissue over normal tissues, the exact basis of which remains unclear. 
1.14.1 The biological effects of ionising radiation 
Therapeutic radiation can be either electromagnetic: x-rays or gamma rays, or particulate: 
electrons, neutrons and protons. These vary in terms of the rate of deposition of energy per 
unit length of tissue. This is termed linear energy transfer (LET) and therefore the same 
dose of radiation from sources of differing LET have different relative biological 
effectiveness (RBE). The deposition of energy in the tissues causes cell death principally 
by damaging DNA, which is the critical intracellular target. This occurs by two main 
mechanisms; direct and indirect action. 
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Direct action of radiation describes the process where the atoms of the molecular target 
(DNA) are themselves ionised, producing a biologic change. This is more marked in high 
LET radiation. 
Indirect action is where radiation interacts with other cellular constituents (principally 
water, which comprises 80% of the cell contents) causing ionisation events which produce 
free radicals. These free radicals are uncombined atoms or molecules carrying an unpaired 
electron in the outer shell and are highly chemically reactive. Interaction with nuclear 
DNA then produces molecular damage to sugar and base molecules, crosslinks between 
DNA strands and also single and double strand breaks. This mechanism predominates in 
low LET radiation (such as x-rays or gamma rays) and therefore predominates in 
therapeutic irradiation for SCCHN. 
One gray (Gy) of ionising radiation is estimated to produce approximately 150,000 
ionisation events in the nucleus. Only about 1,000 of these are DNA strand breaks. The 
double strand break (DSB) is the lethal chromosomal damage produced by ionising 
radiation. (Vamvakas, Vock et al. 1997) and these are created at a rate of approximately 
one DSB per chromosome per Gy of radiation. Thus a standard treatment fraction of 2Gy 
will produce on average two DSBs per chromosome per exposed cell. Ultimately failure to 
repair DSBs results in loss of cellular reproduction and cell death. 
1.14.2 Cellular mechanisms for DSB repair. 
The two major mechanisms involved in DSB repair in mammalian cells are 
nonhomologous end joining (NHEJ) (Jeggo 1998) and homologous recombination (HR). 
(Johnson, Liu et al. 1999) HR is an error free process and is relatively rare in mammalian 
cells. In contrast, NHEJ is relatively error prone and may well be responsible for many of 
the mutations seen in cells exposed to radiation. 
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Evidence from yeast studies shows that DSB repair proteins are stored at the telomeres and 
are mobilised from there to the site of DNA damage. (Martin, Laroche et al. 1999; Mills, 
Sinclair et al. 1999) In mammalian cells, Ku proteins are bound at the telomere (Bianchi 
and de Lange 1999; Hsu, Gilley et al. 1999) and prevent end to end fusion and guide 
localisation of the chromosome within the nucleus. (Samper, Goytisolo et at. 2000) These 
proteins also form the DNA end binding components of the DNA dependant protein kinase 
(DNA-PK) heterotrimer which is essential for NHEJ. (Smith and Eck 1999) The DNA 
repair RMN complex (Rad50/Mrell/NBS1) is also bound at the telomere (due to an 
interaction between NBS1 and TRF1 (Wu, Lee et al. 2000) and TRF2. (Zhu, Wang et al. 
1999)) 
1.14.3 The mammalian telomere in radiosensitivity 
As well as the localisation of DNA repair proteins at the telomere, further information on 
the role of the telomere in chemo- and radio-sensitivity has recently emerged. (Goytisolo, 
Samper et al. 2000; Lee, Rudolph et at. 2001; Ludwig, Saretzki et at. 2001) (Wong, Chang 
et at. 2000) When telomerase is inactivated in mice by the targeted disruption of the mouse 
TERC gene, the telomeres progressively shorten with each generation until a 
radiosensitivity syndrome is imparted, producing accelerated mortality on exposure to 
ionising radiation. (Wong, Chang et al. 2000) In these experiments it was possible to 
demonstrate that the radiosensitivity was related to telomere dysfunction rather than the 
mere absence of telomerase (Figure 4). At the cellular level, crypt stem cells in the 
gastrointestinal tract and primary thymocytes in TERC-/- mice were shown to have 
increased rates of apoptosis. Furthermore, mouse embryonic fibroblasts had a diminished 
clonogenic survival. This cellular level radio-sensitivity was shown to correlate with the 
persistence of complex chromosomal aberrations and retarded DNA repair kinetics, 
showing an intimate relationship between intact, functioning telomeres and the cellular and 
whole organism response to ionising radiation. (Wong, Chang et al. 2000) 
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The degree of radio-sensitivity of cell lines has also been correlated with telomere length. 
When mouse lymphoma cells sensitive to ionising radiation were compared to radio- 
resistant parental cells, (Mcllrath, Bouffler et al. 2001) a seven-fold difference in TRF 
length was shown between the cell types. This has been extended to human cells where a 
significant inverse correlation between telomere length and chromosomal radiosensitivity 
was shown in lymphocytes from 24 breast cancer patients and five normal individuals. 
(Mcllrath, Bouffler et al. 2001) Goytisolo et al have also shown a correlation between 
telomere length and radiation sensitivity. (Goytisolo, Samper et al. 2000) Here, fifth 
generation telomerase deficient mice, which had telomeres 40% shorter than wild type 
control animals, were hypersensitive to ionising radiation. The mice died of acute radiation 
toxicity in the gastrointestinal tract, lymphoid organs and kidneys and showed greater 
chromosomal damage and higher numbers of apoptotic cells than the similarly irradiated 
control animals. This concept is summarised in figure 1-5. 
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Figure 1-5. Telomere dysfunction radiosensitises cells to ionising radiation. 
The figure summarises how telomere length regulates the radio-sensitivity of mouse 
cells engineered to lack telomerase and possess either short or long telomeres. The 
presence of telomerase is indicated by the filled boxes and the size of the telomeres by 
the red portions of the chromosomes. The results so far indicate that cells remain 
radio-resistant even in the absence of telomerase, provided that the telomeres are 
long. 
The combination of an absence of telomerase and short telomeres, results in telomere 
dysfunction and increased radio-sensitivity. However, it is not yet clear whether the 
presence of telomerase alone is enough to protect cells from radiation, even when the 
telomeres are short. 
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While the available evidence is clear in suggesting that the shortened telomere imparts 
radiosensitivity, the exact basis of this increased cellular vulnerability is not. It may be that 
this shorter telomere cannot form a functional cap or that perhaps DSB repair proteins 
cannot be bound. Further, the 3'-G rich overhanging strand is a stretch of single stranded 
DNA. Exposure of this structure has been implicated in senescence signalling (Li, Eller et 
al. 2003) and it has been recently shown to be shortened in senescent normal cells. 
(Stewart, Ben-Porath et al. 2003) Clearly, exposure of this single stranded DNA, which 
will be more vulnerable to ionisation events than double stranded DNA, may result in a 
greater relative degree of DNA damage signalling leading to increased cell death in the 
setting of the shortened telomere. 
Experiments in the telomerase knockout mouse yield further interesting data in this regard. 
Where telomeres have shortened in successive generations to reach a point of telomeric 
dysfunction and radiosensitivity, double strand break repair is impaired. (Latre, Tusell et 
al. 2003) Chromosomes with shortened telomeres have been shown to fuse to DNA 
double stranded broken ends produced by ionising radiation. The chromosomal instability 
of the mouse genome has been shown in this model system to be due to this form of 
abnormal chromosomal fusion. The implication then is that similar fusions between 
dysfunctional telomeres and DSBs may be responsible for an increase in radiosensitivity in 
the cancer cell which might be exploitable therapeutically. (Latre, Tusell et al. 2003) 
Figure 1-6 summarises this hypothesis. 
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Figure 1-6. Telomere dysfunction and fusions with DSBs. 
This figure illustrates findings from experimental work in mice using the telomerase 
knockout model. In A. capped, functional telomeres protect the chromosome ends 
from inappropriate fusion when DSBs repair by non-homologous end joining. In B; 
the uncapped dysfunctional telomere cannot be distinguished from the DSB, resulting 
in chromosomal fusion, inhibition of accurate DNA repair and loss of cell viability. 
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All of these findings suggest that telomerase inhibitor chemotherapy, producing shortened 
telomeres in cancer cells should increase the radio-sensitivity of the tumour selectively and 
therefore enhance tumour kill. This is a very attractive proposition, not least because this 
anti-cancer therapeutic strategy makes use of the already existent treatment infrastructure. 
Further, it may be feasible to consider altering ionising radiation dosage, thus achieving 
greater selective tumour kill with reduced side effects of radiotherapy which are often 
severe. However, the fact that telomere dysfunction has been shown to elicit rapid 
apoptosis via a p53-dependent pathway in mice (see for example reference Greenberg) 
could present an obstacle to the radio-sensitisation of SCCHN by telomerase inhibition, 
since virtually all SCCHN lines with high telomerase activity have lost p53 function. 
(Loughran, Clark et al. 1997) Encouragingly, the situation is different in human cancer 
cell lines, where in many cases p53 is unnecessary for apoptosis when telomerase is 
inhibited (Parris, Jezzard et al. 1999). Furthermore, the p53 status (mutated or wild type) 
of SCCHN cultures does not influence their radiosensitivity. (Brachman, Beckett et al. 
1993) However, it is clear that the role of p53 in telomere dysfunction-related phenotypes 
needs to be examined in SCCHN. Further, the suggested gain of function phenotype of 
missense mutated p53 requires investigation. (Gasco and Crook 2003) 
1.15 Telomere dysfunction and chemotherapy. 
Recent evidence from work in oncogene-transformed telomerase-deficient mouse cells has 
shown that telomere dysfunction rather than the lack of the telomerase enzyme itself is the 
principal determinant of sensitivity of tumours to certain chemotherapeutic agents. (Lee, 
Rudolph et al. 2001) The telomerase-deficient transformed cells with short, dysfunctional 
telomeres were sensitised to killing by drugs inducing the same kind of DNA damage as 
ionising radiation. Double strand breaks are produced by the anthracyclines doxorubicin 
and daunorubicin and by actinomycin D but not by drugs working through other 
mechanisms (cisplatin, etoposide or fluorouracil). Sensitisation correlated with increased 
chromosomal fragmentation and fusion. Moreover, all the effects were reversed by the re- 
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introduction of telomerase. This evidence of specific sensitisation of tumour cells 
highlights one of the principal attractive features of the telomerase/ telomere target. 
However, the effects were somewhat muted in mouse cells without wild type p53. The 
introduction of a hammerhead ribozyme into breast tumour cells and an immortal breast 
cell line produced cleavage of hTERT mRNA and attenuation of telomerase activity, 
(Ludwig, Saretzki et al. 2001) resulting in sensitivity to doxorubicin. Further, the 
introduction of telomerase into human fibroblasts reduced sensitivity to the same drug. 
(Ludwig, Saretzki et al. 2001) As in the first study, sensitivities to other cytotoxic drugs, 
such as cisplatin were unaffected. 
A further significant development is work analysing the effect of simultaneously attacking 
the telomere and inhibiting telomerase in telomerase positive human cancer cells. (Mo, 
Gan et al. 2003) Here a synergistic effect was demonstrated using telomerase inhibition 
together with paclitaxel to shorten telomeres which was specific to telomerase positive 
cells and not seen in cells using ALT. 
These studies suggest that in certain situations the combined use of chemotherapy and 
telomerase inhibition may be effective against SCCHN. The role of p53 in telomere 
dysfunction-mediated chemosensitisation in human cancer needs to be investigated (see 
above). 
1.16 The role of p53 
1.16.1 p53 in cancer and in SCCHN 
First recognised in the 1970s, p53 is now recognised to be a crucial tumour suppressor 
protein in the mammalian cell and an enormous body of research into this area continues. 
This function is performed by its role in mediating cellular stress (e. g. hypoxia, DNA 
damage, oncogene activation) and activating a series of downstream targets which 
ultimately result in either cell cycle arrest in GI or in programmed cell death. With a half 
life in vitro of 30 minutes, p53 is modified by external stresses which result in stabilisation 
of the protein, thus allowing nuclear DNA binding by which its effects are produced. 
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It is the most commonly mutated gene in many common cancers and is estimated to be 
mutated in SCCHN in 85% of tumours. Notably, in approximately 90% of cancers, the 
mutation is missense. (Gasco and Crook 2003)This proportion is very unusually high and 
has led to speculation regarding selective pressure for this kind of mutation in human 
cancer. Thus, the suggestion is that there may be a selective advantage, over and above the 
loss of wild type p53 function, conferred by missense mutation. (Hussain, Hollstein et al. 
2000) In fact, some human cancer mutated p53 proteins have been shown to have 
properties not seen in wild type p53, including increasing resistance to drugs, increased 
tumorigenicity and the ability to transform cells in cooperation with oncogenes. (Sigal and 
Rotter 2000) The molecular basis of these effects is unclear but may involve binding of the 
missense mutant protein with either wild type p53 or other p53 family members such as 
p63 and p73 thus inhibiting their tumour suppressive effects. These proteins have been 
shown to bind to p53 DNA-binding sites in vitro and can bind to and activate p53 
downstream target genes when overexpressed in vitro. (Kaelin 1999) In contrast to p53 
these proteins are rarely mutated in human cancer although a precise role has yet to be 
clarified. 
In SCCHN the reported p53 mutation rate has varied in several studies (Gasco and Crook 
2003) Importantly, some studies may have underestimated the frequency of mutation by 
analysing only exons 5 to 8 rather than all of the coding DNA (exons 2 to 11). Where all 
coding sequences have been analysed mutation rates of between 79% to 91% have been 
found. (Kropveld, Rozemuller et al. 1999; Balz, Scheckenbach et al. 2003) 
1.16.2 p53 Codon 72 polymorphism in cancer 
In exon four at codon 72 there is a common polymorphism in the p53 protein. This results 
in the expression of either arginine (R72) or proline (P72) at this codon. This feature shows 
an intriguing gradient in human populations, with the arginine allele becoming increasingly 
prevalent with distance from the equator and there has been speculation as to the role of 
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this allele in coordinating the cellular response to UV induced damage. (Beclanan, 
Birgander et al. 1994) 
The arginine form has been shown to be more prone to HPV E6 mediated ubiquitination 
degradation than the proline form. This leads to the suggestion that individuals with this 
germline form of p53 may be more susceptible to DNA virus related cancers. (Storey, 
Thomas et al. 1998) However, studies investigating susceptibility to SCCHN with these 
polymorphisms have failed to show any increased risk of malignancy. (Hamel, Black et al. 
2000; Summersgill, Smith et al. 2000; Shen, Zheng et al. 2002) 
In established cancers in patients who are heterozygotes for Arg/Pro at codon 72 the 72P 
allele is invariably lost during carcinogenesis. (Kawaguchi, Ohno et al. 2000) This 
tendency has been confirmed in two studies in SCCHN patients, both in Europe and Japan. 
(Mann, Jost et al. 2000; Tada, Furuuchi et al. 2001) The 72R mutants have been shown to 
be more efficient in binding to and inhibiting the function of p73, thus limiting the tumour 
suppressive effect of this p53 family member. Hence the R72 p53 variant may in fact have 
a gain of function over wild type p53, providing a hypothesis for increased prevalence of 
R72 mutated p53 in human cancers. 
1.16.3 Does codon 72 status affect DNA damage response pathways? 
Intrinsic to radiosensitivity in tumour cells is the transduction of DNA damage signals 
following the formation of DSBs. In normal mammalian cells this is mediated by ATM 
and CHK2 activation of p53. Where p53 is not functional, other p53 family members may 
mediate the damage signal leading to cell cycle arrest and/ or apoptosis. If the 72R variant 
can inhibit the action of both remaining wild type p53 molecules and p63 and p73, then 
these cells may be more resistant to DNA damage signalling. Thus the effectiveness of 
radiotherapy may be influenced by the codon 72 status in SCCHN. 
1.17 Telomerase inhibitors in combination therapy. 
The principle of targeting the telomere addresses the immortality of the cancer cell, a 
feature which allows specificity of therapeutic attack. In principle any other cancer cell 
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killing therapy resulting in large scale tumour cell death, would require any residual 
tumour to then regrow from a small number of cells. All such therapies would therefore be 
expected to be synergistic with telomerase inhibitors, as more cell divisions would be 
required and therefore telomeres would be much shorter to achieve any given tumour mass. 
A specific approach in the long term might be to combine telomerase inhibitors with new 
drugs that do not damage DNA and thus do not select for potentially undesirable 
phenotypes such as deficiency of mismatch repair pathways and, as a consequence, ALT. 
One such class of drugs is the angiogenesis inhibitors. Several clinical trials of these agents 
are underway, both in combination with conventional therapy and alone. Strategies used to 
inhibit tumour angiogenesis fall broadly into three categories: interference with angiogenic 
ligands, receptors or downstream signalling; upregulation or delivery of endogenous 
inhibitors and direct targeting of the tumour vasculature. (Carmeliet and Jain 2000) Anti- 
angiogenic strategies generally are directed at targets which are features of immature blood 
vessels and this aspect lends a specificity to this anti-cancer treatment, mature native 
vessels being relatively spared. One recent study where inhibition of vascular endothelial 
growth factor-2 (VEGF-2) was investigated showed a reversal of resistance to radiotherapy 
in two radio-resistant tumour types. (Geng, Donnelly et al. 2001) There are however 
limitations of pre-clinical trials which mean that caution is needed. Subcutaneous human 
tumour xenografts in mice may be less robust than human tumours in vitro and the 
endpoint commonly used in preclinical studies is tumour regression rather elimination. 
With tumour progression a wider array of angiogenic molecules is produced. Hence any 
therapy directed against a single agent e. g. vascular endothelial growth factor (VEGF) may 
produce selection of cells expressing an alternative molecule e. g. interleukin 8. Agents 
against multiple targets used synchronously may be the most effective strategy. Further, 
current curative therapy for SCCHN involves ablative surgery to remove disease in 
combination with reconstruction of the affected part. This requires substantial wound 
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healing, which will involve the immature angiogenesis ligands targeted by 
antiangiogenesis therapies, albeit at physiological levels. This fact may necessitate a delay 
in institution of this form of therapy after surgery. It is however common clinical practice 
to delay for six weeks post-operatively prior to instituting ionising radiation and so the 
clinical impact of such delay may be small. 
The available evidence suggests that angiogenesis inhibitors can limit the expansion of 
tumours but do not kill the tumour completely (Figure 1-7b). The combined use of 
angiogenesis inhibitors and radiation is more effective than either alone in human 
xenografts (Geng, Donnelly et al. 2001) so if sufficient targeting can be applied to tumours 
greater success might be expected with angiogenesis factor inhibitors in the future. 
Telomerase inhibitors are complementary to angiogenesis inhibitors in that they kill the 
tumour very efficiently but generally would not be expected to limit its size at first (Figure 
1-7a). Thus the combined use of telomerase and angiogenesis factor inhibitors (see 
comment by Shay (Randal 2001)) may provide optimal tumour kill in both the immediate 
and then intermediate treatment phases and in the long term may help prevent the growth 
of residual tumour following therapy (Figure 1-7c). 
The use of angiogenesis and telomerase inhibitors is envisaged to be particularly useful in 
preventing the growth of occult micro metastases which is a common reason for the relapse 
of patients with solid tumours. 
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Figure 1-7. Telomerase Inhibitors in Combination therapy 
a) This figure summarises the manner in which conventional and telomerase inhibitor 
therapies might be combined in the future. The possibility of activation of the ALT 
pathway during prolonged growth under telomerase inhibition is also considered. 
Following shrinkage by radiotherapy, the tumour would grow for a variable period in 
the presence of a telomerase inhibitor until the gradual attrition of the telomeres 
provokes apoptosis and results in considerable cell death (i). It is still debatable 
whether ALT or other resistance mechanisms might contribute to relapse at this 
point (ii). 
b) Here the limitation of the use of angiogenesis inhibitors alone is illustrated. The 
inhibitors slow the growth of the tumour by denying the more central cells a blood 
supply. However, the tumour expands due to the viable outer rim. 
c) The same as in (b) but in this situation, the slow growing tumour undergoes 
telomeric attrition during the multiple divisions required to replace the cells dying in 
the necrotic centre. The tumour cells are then proposed to die as a consequence of 
telomere dysfunction. This strategy has the advantage of using two complementary 
and very specific novel approaches to cancer treatment. 
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1.18 Aims 
Evidence from mouse experiments suggests that telomere dysfunction radiosensitises 
mammalian cells. This provides a potential new therapeutic strategy, which may make use 
of synergy with conventional radiation therapy. The aim of this project was to investigate 
the effect on radiosensitivity of changing levels of telomerase expression and hence 
altering telomere function in cells derived from SCCHN. This was attempted by first using 
stable transfection of SCCHN cells with a retroviral vector carrying hTERT to enhance 
telomerase expression in order to assess any radioprotective effect. If this was the case, 
good control data would be provided and further strength given to the telomere radiation 
resistance argument. Then using a dominant negative version of the hTERT gene 
(DNhTERT), the effect of telomerase inhibition would be assessed. The reverse 
transcriptase inhibitor AZT was then investigated as a telomerase inhibiting radiosensitiser 
in SCCHN cells by assessing changes in clonogenic survival after 2Gy of radiation 
assessed. 
The precise role of the p53 protein is not clear, but evidence would suggest that wild type 
protein is not required for telomere dysfunction- or radiation-induced cell death. The R72 
variant is clearly selected for in human cancer. The role played by this variant in the setting 
of radiotherapy and any impact on cellular radiosensitivity is not clear and was assessed in 
a panel of SCCHN cell lines. Further information examining any correlation between 
telomere function (assessed by anaphase bridge index [ABI]) and SF2 and SF4 was 
obtained. 
In order to gain insight into changes in telomere function with SCCHN tumour 
progression, analysis of ABI in primary tumours and then in recurrent tumours in patients 
with SCCHN was carried out. 
If telomerase inhibition could be shown to enhance radiation induced cell kill then this 
would strengthen the argument that this may be a valid new therapeutic avenue in SCCHN. 
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The broader assessment of ABI and SF2 and SF4 may give indication as to whether this 
method of telomere function evaluation correlates with radiosensitivity. Further, any 
influence of the R72 polymorphism on SF2 and SF4 was assessed. Should ABI fall with 
tumour progression then we might predict a more limited response in late stage SCCHN in 
comparison to those cancers diagnosed and managed earlier in the disease process. 
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Chapter 2 
Materials and methods 
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2.1 Materials 
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2.1.1 Chemicals 
Solutions and buffers were prepared in and where necessary dissolved or diluted using 
dH2O from a Millipore MilliRO 15 system. 
Supplier 
Agar Scientific Ltd., 
66A Cambridge Road, 
Stanstead, 
Essex, CM24 BDA, 
UK 
Amersham International 
Little Chalfont, 
UK 
James Burrough (F. A. D. )Ltd 
70 Eastways Industrial Park, 
Witham, 
Essex, CM8 3YE, 
UK 
Fisher Scientific UK 
Bishop Meadow Road 
Leicestershire, LEI I 5RG 
Loughborough 
UK 
Hughes and Hughes 
Unit 1f Lowmoor Ind Estate, 
Tonedale, Wellington, Somerset 
Sigma Chemical Company 
Fancy road, 
Poole, Dorset, 
UK 
Chemicals 
Neutral buffered formalin 
'y32P- ATP 3000Ci/mmol, l OmCi/ml 
Ethanol 
Sodium chloride 
Sodium acetate 
isopropanol 
Histomount 
Acetone 
Bicinchoninic acid 
Bromophenol blue 
Copper sulphate 
EDTA 
Ethidium bromide 
Giemsa stain 
Glycerol 
Rhodamine B 
SDS 
TEMED (N, N, N', N'- Tetramethyl- 
ethylenediamine 
Xylene cyanol 
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Surgipath Haematoxylin 
Venture park, Stirling way, Eosin 
Bretton, Peterborough UK Histoclear 
Scott's Tap Water 
2.1.2 Enzymes 
Supplier Enzyme 
Advanced Biotechnologies, Taq polymerase 
Units B 1-B2 Longmead Business Centre, T4 polynucleotide kinase 
Blenheim road, 
Epson, Surrey UK 
Gibco BRL Life technologies, EcoR 1 
Paisley, UK Sal 1 
Nru I 
Cla 1 
Sigma Chemical Company Proteinase K 
Fancy road, 
Poole, Dorset, 
UK 
2.1.3 General plasticware 
Supplier Material 
Becton Dickinson Labware Falcon tubes 
Plymouth, UK 
Bibby-Sterilin 5ml Bijous; 20ml universals 
Stone, UK 
Elkay 
Galway, Eire 
Greiner Labortechnik 
Stonehouse, UK 
Microcentrifuge tubes 
Pipette tips 
Filter pipette tips 
2.1.4 Electrophoresis gels 
Supplier Material 
Gibco BRL Life technologies, Agarose, electrophoresis grade 
Paisley, UK 
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Severn Biotech Ltd Acrylamide 40% w/v 
Unit 2, Park Lane, 
Kidderminster, 
Worcester, UK 
2.1.5 Paper and X-ray film 
Supplier Material 
Whatman International 3MM paper 
Maidston, UK 
HA West, Fuji Super RX medical X-ray film 
Clydebank, Glasgow, UK 
2.1.6. Microbial host, media and supplies 
Supplier 
Bibby - Sterilin, Stone, UK 
Difco, Becton Dickinson 
Plymouth, UK 
Gibco BRL Life technologies 
Paisley, UK 
Sigma Chemical Company 
Poole, Dorset, UK 
Material 
Tryptone 
Yeast extract 
Petri dishes 
Competent E. Coli DH5a cells 
Ampicillin 
2.1.7. Drug resistance plasmids 
pBabe puro (Hahn, Stewart et al. 1999) was obtained from Dr EK Parkinson at the CRUK 
Beatson Institute for Cancer Research. The map for this plasmid is shown in figure 2.1 
pBabe puro TERT and pBabe puro DNTERT (Hahn, Stewart et al. 1999)were a gift from 
Professor R. A. Weinberg, Whitehead Institute for Biomedical Research and Department 
of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 
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Figure 2-1. Diagram illustrating components of the pBabepuro plasmid 
James Anthony McCaul 2004 
2.1.8 Cell culture media 
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Su lier Material 
A/S Nunc i ml cryotubes 
Botolph Claydon, 
UK 
Autogen Bioclear Fetal Bovine Serum 
Holly Ditch Farm, 
Mile Elm, Calne, 
Wiltshire, UK 
Becton Dickinson Labware Falcon tissue culture dishes; 
Plymouth, 
UK 
Fisher Scientific UK Dimethylsulfoxide 
Bishop Meadow Road 
Leicestershire, LEI 15RG 
Loughborough 
UK 
Gibco BRL Life Technologies DMEM 
Paisley Hepes buffer 
UK L-Glutamine 
Sigma Chemical Company Benzylpenicillin 
Fancy road, Streptomycin 
Poole, Dorset, Hydrocortisone 
UK Bovine donor calf serum 
Worthington Chemical Corporation Trypsin 
Reading, 
UK 
2.1.9. Supplies for specialised cell culture techniques 
( Supplier Material 
Gibco BRL Life Technologies Lipofectamine 
Paisley 
UK 
A/S Nunc Chamber slides 
Botolph Claydon, UK 
Sigma Chemical Company Polybrene 
Fancy road, Optimem 
Poole, Dorset, Lipofectamine 
UK 
Merck (WDR International) Acrodisc syringe filters; 0.2µm, 0.45µm 
Poole, Dorset, UK 
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2.1.10. Cell lines 
The following cells are SCCHN lines derived from in vivo tumours. (Edington, Loughran 
et al. 1995) These were obtained from Dr EK Parkinson at the CRUK Beatson Institute for 
Cancer Research; 
Table 3. Keratinocytes supplied by Dr EK Parkinson. 
Keratinocy te line Site of origin Tumour TNM stage Proliferative fate 
BICR 3 Alveolus T2NOMo immortal 
BICR 6 Hypopharynx T4N1Mo immortal 
BICR 7 Tongue T4N2cMa Mortal; Crisis 
(PDL=42) 
BICR 10 Buccal Mucosa Recurrent immortal 
BICR 16 Tongue Recurrent immortal 
BICR 31 Tongue T4N2BM0 immortal 
BICR 56 Tongue T4N1Mo immortal 
BICR 63 Tongue T2N2BMo immortal 
BICR 68 Tongue T4NoMo immortal 
BICR 78 Alveolus T4N1Mo immortal 
BICR 82 Maxilla Recurrent immortal 
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The following cell lines were also utilized in this thesis. 
Table 4. Other cell lines. 
Cell line Cell type Source 
Swiss 3T3 Mouse embryonic ATCC 
fibroblasts 12301 Parklawn Drive 
Rockville 
Maryland, 20852 
USA 
NIH 3T3 Mouse embryonic ATCC 
fibroblasts 12301 Parklawn Drive 
Rockville 
Maryland, 20852 
USA 
HFF Human foreskin fibroblasts Dr EK Parkinson, BICR 
(Method described in 
(Bums, Baird et al. 1993)) 
Phoenix A Retroviral producer line Dr GP Nolan, 
Stanford University Medical 
Centre, 
San Francisco, California 
USA 
DHSa Modified E. Coli bacteria Gibco BRL Life 
Technologies 
Paisley, UK 
GM847 SV40 immortalised human Dr Olivia Pereira-Smith 
fibroblasts (ALT cell line) Baylor College of Medicine, 
Waco, Texas, USA. 
SCC 4 Squamous cell carcinoma ATCC 
SCC 9 (all of lingual mucosa 12301 Parklawn Drive 
SCC 15 origin) Rockville 
SCC 25 Maryland, 20852 
USA 
2.1.11. Radiation source 
An Alcyon 2 radiotherapy machine, located in the CRUK Beatson Institute for Cancer 
Research was used as the ionising radiation source in experiments detailed in this thesis. 
This is a 'Co source, providing gamma irradiation. 
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2.1.12. Molecular Biology kits. 
Table 5. Molecular Biology Kits 
Supplier Kit 
Qiagen Ltd 
Crawley, West Sussex 
UK 
Intergen Company 
Oxford 
QIAGEN plasmid midi kit 
TRAPEZE Telomerase detection kit 
UK 
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2.2 Methods. 
2.2.1 Cell culture techniques 
2.2.1.1. Culture of cell lines 
All keratinocyte cell lines and clones were cultured in DMEM supplemented with 10% 
(v/v) FBS, 2mM L-glutamine, 20mM HEPES buffer, 50U/ml penicillin, 20ng/ml 
streptomycin, and 0.4µg/µ1 hydrocortisone (I OH medium). 
Human foreskin fibroblasts and GM847 fibroblasts were cultured in DMEM supplemented 
with 10% FBS, 2mM L-glutamine, 20mM HEPES buffer, 50U/ml penicillin and 20ng/ml 
streptomycin (1OC medium). When experiments were carried out comparing both HFFs 
and GM847 cells to malignant keratinocytes, all cells were grown in keratinocyte medium 
as described above. Phoenix A cells, Swiss 3T3 cells and NIH 3T3 cells were grown in 
DMEM supplemented with 10% DCS, 2mM L-glutamine, 20mM HEPES buffer, 50U/ml 
penicillin and 20ng/ml streptomycin (1OC medium). All cell lines were maintained in a 
humid 37°C, 5% CO2 incubator. 
Prior to trypsinising keratinocyte for experiments or for replating or storing in liquid 
nitrogen, feeder cells were removed by exposure of the cell layer to 0.02% EDTA in PBS 
for 30 seconds, followed by vigorous pipetting. Remaining keratinocytes were washed 
with PBS and then trypsinised in a humid 37°C, 5% CO2 incubator for 15 minutes using 
equal volumes of 0.02% EDTA in PBS and 0.1% trypsin. 
Cryopreserved cell stocks were prepared from early passage cell lines and clones as 
follows. Cells were maintained in culture until they reached approximately 75% 
confluence. They were then trypsinised, neutralised with normal growth medium and 
pelleted. The cell pellet was resuspended in freezing medium (10% DMSO in normal 
growth medium) to a density of 1x 106cells/ml, and the suspension transferred to 
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cryotubes (Iml per vial). The cryotubes were wrapped in cotton wool and placed in a- 
70°C freezer overnight to slow freeze and the following day were immersed in liquid 
nitrogen for long term storage. Cryotubes were recovered from liquid nitrogen by 
immediate immersion in a large volume of water at 37°C. The cell suspension was then 
made up to a volume of 10ml with normal growth medium and the cells pelleted. Cells 
were resuspended and plated at a density of 0.5-1.0 x 106 cells per 10cm dish. 
2.2.1.2. Transfection of Phoenix A cells 
Cells were cultured in 9cm plates until approximately 50-80% confluent. Two solutions 
were prepared; one containing 20µg of plasmid DNA in 650µ1 of Optimem serum free 
medium and one containing 34µg of lipofectamine reagent and 642µl of Optimem. These 
were then combined and allowed to stand at room temperature for 30 minutes to allow 
liposomal complexes to form. The Phoenix A cells were washed once in PBS. Optimem 
was added to each of the transfection solutions to a volume of 5mls. These solutions were 
pipetted onto the producer cells and incubated at 37°C in humid 5%CO2 for 5 hours. A 
control plate of cells was treated with lipofectamine reagent and Optimem serum free 
medium only. Following incubation 7mis of growth medium containing twice normal 
concentration of serum was added, without removing the transfection mixture. The plates 
were incubated overnight (approximately 18 hours) at 37°C before the transfection mixture 
was removed and replaced with complete growth medium. The cells were incubated for a 
further 24 hours at which point retrovirus containing supernatant was harvested. 
2.2.1.3. Selection determination 
Kill curves were used to determine the appropriate level of antibiotic selection to use in 
transfections. Cells were plated at 105 per 6 cm plate and placed under selection media 
after 48 hours. Thereafter selection media was changed twice weekly. Complete cell death 
after two weeks was taken to be the appropriate antibiotic selection. Appropriate cell line 
selection determination values are shown in table 2.1 
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Table 6. Puromycin concentration for selection in feeder cells and keratinocytes 
Cell line Puromycin concentration 
NIH3T3 2µg/m1 
Swiss 3T3 2µg/m1 
BICR 6 'µg/m1 
2.2.1.4 Viral titre assessment 
NIH 3T3 cells were seeded at a density of 105 cells per 6 cm dish and cultured at 37°C in 
humid 5% C02 for 24 hours. Serial dilutions of virus were produced by adding l0011 of 
virus containing supernatant to growth medium with 41tg/ml polybrene added to a volume 
of 4mis. This was diluted to produce concentrations of 10"2,10-3,10-4 and 10-5. Plates were 
infected with 1.5mis of appropriate dilutions and incubated for four hours. Growth medium 
was added to a final volume of 5ml and the plates incubated overnight. Plates were then 
medium changed and after a further 24 hours in culture selection commenced by the 
addition of 2µg/ ml puromycin. Selection was performed for ten days followed by staining 
with Giemsa and the viral titre calculated. 
2.2.1.5. Viral Infection of Swiss 3T3 cells, HFFs and GM847 cells. 
Puromycin resistant Swiss 3T3 feeder cells were generated by infecting with retrovirus 
produced in Phoenix A amphotropic producer cells. This virus included the pBabe puro 
plasmid and hence conferred puromycin resistance. Swiss 3T3 cells were plated at a 
density of 5x 105 cells per 9cm plate and cultured in humid 5%C02 at 37°C for 72 hours. 
At this point 2mls of neat retrovirus containing supernatant was applied to the cell layer 
with 8mg/ml of Polybrene and incubated for four hours. Duplicate mock plates had 
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Polybrene containing medium only added during the incubation period. Following 
incubation growth medium was changed for fresh 1OC and the cells allowed to recover 
overnight. Cells were then split by trypsinisation and seeded at a density of 3x 105 on 9cm 
plates. After a further 72 hours cells were placed under selection with medium containing 
21tg/ml puromycin. Puromycin resistant colonies were then pooled and replated onto 9cm 
plates. Further pools of colonies were stored in liquid nitrogen for further use. The same 
method was used to generate HFFs and GM847 fibroblasts infected with virus carrying 
pBabe puro, pBabepurohTert and pBabepuroDNhTert. 
2.2.1.6. Viral Infection of keratinocytes. 
Cells to be infected were seeded in duplicate at a density of 5x 10s cells per 6cm plate 
with 3x 105 lethally irradiated puromycin resistant feeder cells 72 hours prior to infection. 
Viral supernatant was added with 8mg/ml Polybrene and incubated for four hours. 
Duplicate mock plates had Polybrene containing medium only added during the incubation 
period. Following incubation growth medium was changed for fresh 1OH and the cells 
allowed to recover overnight. Cells were then split by trypsinisation and seeded at a 
density of 3x 105 on 9cm plates with 9x 105 puromycin resistant irradiated Swiss 3T3 
cells. After a further 72 hours cells were placed under selection with medium containing 
2µg/ml puromycin. Puromycin resistant colonies were then ring cloned into individual 6cm 
plates and pools of colonies stored in liquid nitrogen for further use. 
2.2.1.7. Determination of AZT dosage. 
BICR 6 cells were cultured in 9 well plates in duplicate wells on a feeder layer of lethally 
irradiated 3T3 cells. 105 cells per well were allowed to grow in culture for 48 hours prior to 
the introduction of AZT at the following concentrations; control, 5014M, 100µM, 200{iM, 
400µM, 8001M, 1 mM, 1.4mM and 2mM. 
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The maximum dosage which still allowed cells to reach confluence was 100µM AZT. The 
range for telomerase inhibition and radiosensitivity testing was therefore selected as 
control, 50µM AZT and 100µM AZT. 
2.2.1.8. Rhodamine Stain for Keratinocytes 
Medium was aspirated from plates containing adherent cells and these were washed with 
PBS. 10% formaldehyde was then overlaid for 15 mins. This was aspirated and the cells 
then washed again with PBS. Rhodamine B stain (1%) was then overlaid for 30mins. Cells 
were then rinsed in tap water until all excess stain was removed, air dried and then 
observed under a low power microscope and colonies counted. 
2.2.1.9. Giemsa Stain for 3T3, HFF and GM847 cells. 
Medium was aspirated from plates containing adherent cells and these were washed with 
PBS. 10% formaldehyde was then overlaid for 15 mins. This was aspirated and the cells 
then washed again with PBS. Giemsa stain (10%) was then overlaid for 30mins. Cells were 
then rinsed in tap water until all excess stain was removed, air dried and then observed 
under a low power microscope and colonies counted. 
2.2.1.10 Determination of population doublings. 
The number of population doublings achieved in the dominant negative hTERT clones was 
calculated at each passage according to the formula of Paul et al., 1975; 
PD = (log N- log No) x 3.32 
Where No = initial cell number 
N= final cell number 
Equation 1. Formula for calculation of population doublings in cultured cells 
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2.2.1.11. Culture of cells for Anaphase Bridge Scoring. 
Keratinocytes were plated on single well chamber slides at a density of 8x 104 with X 
lethally irradiated Swiss 3T3 cells. These were culture at 37°C in 5% humid CO2 until 
reaching 50 - 70% confluence. Growth medium was aspirated, cells washed with PBS and 
placed in acetone at 0°C for 15 minutes. These were then post-fixed in neutral buffered 
formalin for 5 mins, washed in water and stained with haematoxylin for one minute. After 
a further rinse in water the slides were placed in Scott's tap water for one minute. Slides 
were immersed in eosin for 20 seconds, rinsed once more in water and dehydrated in 
graded alcohols before placing in Histoclear for one minute. These were then mounted 
using silicon glass cover slips and histomount. 
2.2.2 Microbiological techniques. 
2.2.2.1. Transformation of bacteria with plasmid DNA 
Competent E. Coli (DH5a) were thawed on ice and aliquots transferred to prechilled 1.5m1 
screw cap microcentrifuge tubes. Approximately lOng of plasmid DNA was added and 
gently mixed with the cells by stirring with a pipette tip. After incubation on ice for 30 
mins, cells were heat shocked at 42°C for 45s and then placed on ice for a further 2 mins. 
400µl of SOC medium (2% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 20mM 
glucose, 10mM NaCl and 10 mM MgCl2) was then added to the mixture and the cells were 
incubated at 37°C for one hour in an orbital shaker at 240 rpm. After this time cells were 
pelleted by pulsing in a microcentrifuge. 450µ1 of supernatant was discarded and the cells 
resuspended in the remaining 50µl. Cells were then spread on LB medium plates 
containing 1.5% (w/v) agar supplemented with the appropriate antibiotic (ampicillin). 
Plates were incubated in the inverted position at 37°C, and colonies transferred into LB 
medium the following day. 
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For the preservation of bacterial stocks, a 0.5m1 aliquot of overnight culture in LB 
medium (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract and 1% (w/v) NaCI, pH 
7.0) was mixed with an equivalent volume of 50% (w/v) glycerol, chilled on ice and then 
stored at -70°C in plastic cryotubes. 
2.2.2.2. Plasmid DNA Extraction 
Plasmid DNA was extracted using the QIAGEN Midi kit. A single colony was picked from 
a selective plate (see section 2.2.2.1) and used to inoculate a Sml starter culture of LB 
medium containing 100gg/ml ampicillin. The culture was incubated for 8 hours at 37°C in 
an orbital shaker at 240 rpm , 
diluted 1/1000 into selective LB medium and incubated for a 
further 16 hours at 37°C in an orbital shaker at 240 rpm. The bacterial cells were harvested 
by centrifugation at 6000 xg for 15 mins followed by removal of supernatant. These were 
then resuspended in 10ml of P1 buffer. An equal volume of P2 buffer was added and these 
gently mixed by inversion, followed by incubation at room temperature for 5 mins. 10mis 
of buffer P3 was added and the solution then incubated for a further 20 mins. This was then 
centrifuged at 20,000 xg for 30 mins at 4°C to separate plasmid DNA from cell debris. 
The supernatant from this spin was removed and promptly respun at 20,000 xg for 15 
mins at 4°C. A QIAGEN 500 tip was equilibrated by running 10mis of QBT buffer 
through it by gravity flow. The supernatant was passed through the equilibrated tip under 
gravity flow, passing through plasmid DNA retaining resin. The QIAGEN tip was washed 
twice with 30m1 of QC buffer. DNA was eluted from the resin using 15m1 of QF buffer 
and collected in a 30m1 tube. This was then precipitated by adding 0.7 volumes of 
isopropanol to the eluted DNA. This mixture was then centrifuged at 15,000 xg for 30 
mins at 4°C and the supernatant decanted leaving the DNA pellet in the tube. This was 
washed with 5mis of 70% ethanol and centrifuged at 15,000 xg for 10 mins at 4°C 
followed by careful decanting of supernatant, leaving the pellet undisturbed. This was then 
air-dried for 10 mins and then redissolved in TE buffer, pH 8.0. Plasmid DNA 
concentration was determined as described for genomic DNA. 
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2.2.3. Irradiation of cells in culture. 
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2.2.3.1. Irradiation of feeder layer Swiss 3T3 cells. 
Cells were trypsinised into suspension, centrifuged and neutralised in normal medium. Cell 
density was calculated using a haemocytometer. Universals containing these cells were 
maintained on ice and transported to the radiation suite. Universals were placed in the 
radiation source at a distance of 0 cm under an intensifying screen. Flasks containing water 
were placed around the specimen universals in order to achieve uniform scatter of ionising 
radiation throughout the field. Exposure to 60Gy provides feeder 3T3 cells which support 
keratinocyte growth without 3T3 cell replication. 
2.2.3.2. Irradiation of keratinocytes. 
Feeder layer cells were removed by as described above and keratinocytes trypsinised, 
neutralised in normal medium, centrifuged at 1000 rpm at 4°C for 5 minutes and then 
resuspended in fresh medium. Cell density was calculated using a haemocytometer and 
appropriate dilutions prepared to obtain 2x 105 cells in 5mls of growth medium. These 
were maintained on ice in universal tubes and transported to the radiation suite. Universals 
were placed in the radiation source at a distance of 100cm under an intensifying screen. 
Flasks containing water were placed around the specimen universals in order to achieve 
uniform scatter of ionising radiation throughout the field. Cells were then plated at an 
appropriate density to obtain between 50-200 colonies per plate, this density having been 
calculated from earlier experimental data for each cell line studied. 
2.2.4. Extraction, quantification and sequencing of genomic DNA. 
2.2.4.1. Extraction of genomic DNA from human keratinocytes. 
Genomic DNA was prepared from malignant human keratinocytes using the method of 
(Laird, Zijderveld et al. 1991). Feeder layer fibroblasts were removed as described above 
and cells harvested by trypsinisation and pelleted by centrifugation (5 mins at 4°C at 1000 
rpm) in a universal tube. Cells were resuspended in PBS and transferred to a 
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microcentrifuge tube before brief centrifuging . These were then resuspended and 
simultaneously lysed in lysis buffer (100mM Tris. HCl pH 8.5,5mM EDTA, 0.2% (w/v) 
SDS, 200mM NaCl and 100µg/ml proteinase K) and incubated at 37°C with constant 
agitation. DNA was precipitated by addition of an equal volume of isopropanol, with 
gentle mixing until all viscosity was gone. The aggregated precipitate was removed by 
lifting from the solution with a sterile custom made loop (made by heating a glass Pasteur 
pipette tip in a Bunsen flame). Excess liquid was dabbed off and the DNA rinsed in 70% 
(v/v) ethanol. After being briefly allowed to air-dry, the DNA was dispersed into at least 
0.5 ml of TE (10mM Tris. HCL and 1mM EDTA pH 8.0) and maintained at 37°Cwith 
agitation until completely dissolved. 
2.2.4.2. Quantification of DNA. 
DNA was quantified by spectrophotometric determination of it UV light absorbancy. 5µl 
of sample was added to 495µ1 of deionised water and the absorbency of the solution 
measured at 260nm and 280nm in a disposable plastic cuvette, using dH2O as a blank. The 
concentration of the solution was calculated using de Beer's law on the basis that an 
optical density of 1.0 at 260nm corresponds to a concentration of 50Ag1ml for double 
stranded DNA and 33µg/ml for single stranded oligonucleotides. Pure preparations of 
DNA and RNA have a ratio of A2o/A28o readings between 1.8 and 2.0. 
2.2.4.3. Sequencing of p53 codon 72. 
Extracted and quantified genomic DNA was analysed for codon 72 argenine or proline 
status by the CRUK BICR DNA sequencing service. 
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2.2.5. Assessment of Anaphase Bridge Indices. 
2.2.5.1. Anaphase bridge scoring for culture slides. 
Mitotic figures in late anaphase were located at x200 magnification and then scored at 
x400 under an Axioskop microscope in the CRUK BICR. At least 30 anaphase mitoses 
were scored for each cell line assessed by the author and also independently by Dr EK 
Parkinson, the vernier number for each being recorded manually. An anaphase bridge 
figure is defined as a mitosis in late anaphase where trailing chromatin from daughter 
chromosomes extends more than 2/3 of the distance across between anaphase plates. There 
must be sufficient distance between the plates to allow assessment and no evidence of a 
cleavage furrow heralding the onset of telophase present. 
2.2.5.2. Anaphase bridge scoring for archival primary and recurrent 
SCCHN tumours and BCCa tumours. 
The archive of oral squamous cell carcinoma specimens held in the Oral Pathology 
department of Glasgow Dental Hospital and School was analysed by Professor DG 
MacDonald in order to locate primary and recurrent tumour specimens from the same site 
in the same individual patients. Specimens were coded and the observer blinded as to the 
identity of each slide. For each patient a disease free interval of at least six months 
following treatment and prior to the clinical emergence of recurrent carcinoma was 
required for inclusion in the study. For each tumour specimen at least 30 appropriate 
anaphase mitotic figures were scored. Where an insufficient number of anaphases were 
found in the archival tumour slides, fresh sections were prepared from archival tumour 
blocks. 
H&E stained slides were analysed on an Olympus BX40 light microscope in the Oral 
Pathology department of Glasgow Dental Hospital and School. Anaphases were recorded 
as either normal or bridged and the vernier number manually recorded. 
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2.2.6 Telomere Repeat Amplification Protocol. 
2.2.6.1. Preparation of cell extracts. 
Cells to be assayed had the feeder layer removed and were trypsinised and counted as 
detailed above. Centrifuging for five minutes at 1000rpm was followed by washing once 
with PBS. Cells were then pelleted again by spinning at 12,000 xg in a microfuge at 4°C 
for five minutes and the PBS carefully removed. Cells were then resuspended (105 - 106 
cells) in 200µl of 1x CHAPS lysis buffer. These were incubated on ice for 30 minutes and 
the supernatant then retained (as 2x 1O1i1 aliquots), frozen on dry ice and then stored at - 
80°C. Extracts can be stored for up to one year. 
2.2.6.2. Bicinchoninic acid (BCA) protein assay. 
Bovine serum albumin solution was prepared in dH2O to produce a stock of 2mg/ml 
solution. From this, stocks of BSA solution in CHAPS lysis buffer were prepared in a 
range of concentrations from 0.08mg/ml up to 2mg/ml. These were placed in wells in a 
microreader plate and 200µ1 of bicinchoninic acid solution (9.8m1 of BCA combined with 
2O0µ1 of CuSO4) added to each well. 101i1 aliquots of each whole cell protein extract were 
placed in duplicate wells and BCA added as previously. The plate was then incubated at 
37°C in a hot room for 45 minutes. Light absorbencies were read at 570nm using a 
Dynatech MR7000 spectrophotometer to produce a standard curve for protein and a 
reading for each protein sample was estimated from this. 
2.2.6.3. Preparation of controls. 
Heat inactivated controls were generated for each cell line tested by treating 41il of protein 
extract for 10 minutes in a hot block at 85°C. Two microlitres of this heat inactivated 
extract were subsequently used in the assay. Primer/ dimer/ PCR contamination control 
was provided by use of 211 of 1x CHAPS lysis buffer in one lane. A telomerase positive 
quantitation control template (TSR8) provided in the TRAP kit was run in another lane. 
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2.2.6.4. Radioactive end labelling of TS primer. 
For twelve assays, 'y32 P-ATP (4µl) was combined with TS primer (l6µ1), l Ox kinase buffer 
(3.2µl) and T4 PNKinase (10unit/ Al; 1µl) and 7.8µl of dH2O. These were incubated for 
20mins at 37°C and then the enzyme heat inactivated at 85°C for five minutes. Two 
microlitres were used per TRAP assay reaction. 
2.2.6.5. Preparation of master mix and reaction tubes. 
In a separate room in the laboratory, the following components were combined using 
Gilson pipettes kept solely for PCR experiments; 10xTRAP reaction buffer (70µl), 
50xdNTP mix (14µl), TRAP primer mix (14µl), dH2O (540.4µl) and Taq polymerase 
(5units/µl; 5.6µl). Radiolabelled TS primer was then added (21Al per assay). This mastermix 
was then added to thin-walled reaction tubes to a final volume of 50µ1 per tube. 
2.2.6.6. PCR amplification. 
This was carried out using an Applied Biosystems Gene Amp PCR System 9600 machine 
in two steps. The first was 30°C for 30 mins during which time telomerase mediated 
formation of radio end labelled DNA repeats occurred and the second was 30 cycles of 
95°C for 30s and 59°C for 30s during which taq polymerase mediated amplification of 
reaction products occurred. 
2.2.6.7. Polyacrylamide gel electrophoresis and data analysis. 
Loading dye was added to each reaction tube and 25 µl of the sample run on a 10% non- 
denaturing PAGE gel with 0.5x TBE running buffer. Heat treated and non-heat treated 
samples were loaded in alternate lanes. The negative control lane was added first and the 
positive control lane last to avoid carry-over contamination. This was run at 400 volts for 
1.5 hours until the Xylene cyanol was 70-75% down the gel and the Bromophenol blue had 
just run off the bottom of the gel. The gel was then fixed for 20 minutes in a solution of 
methanol, sodium acetate and sodium chloride and then dried on a gel drier. Reaction 
products were then visualised on the BioRad molecular Phosphoimager and the telomerase 
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products generated calculated by comparing the ladder of products to the 36bp internal 
standard using Quant One imaging software. An autoradiograph was also generated by 
exposing the dried gel to x-ray film and developing this in a Kodak developer. 
2.2.6.8. Semi-Quantification of Telomerase activity. 
The signal generated from the area of the gel corresponding to TRAP products was 
measured in all samples including the non-heat treated (X) and heat treated lanes (X0) and 
from the CHAPS lysis buffer control (R0) and the TSR8 quantitation control (R). The 
signal was measured from the 36bp internal standard in the non-heat treated samples (C) 
and the TSR8 quantitation control (CR). The telomerase products generated were calculated 
from the following formula; 
TPG (units) = -Xo /Cx 100 (where 0.1 mole =1µ1 of TSR8) 
(R-Ro)/ Cr 
TPG = telomerase products generated. 
Equation 2. Formula for calculation of telomerase DNA products generated in the 
TRAP assay. 
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Chapter 3 
Results. 
Radioprotection of SCCHN cells in vitro with 
increased expression of telomerase. 
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3.1 Introduction 
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A body of evidence now suggests that the telomere is a crucial structure in determining the 
cellular response to ionising radiation. Yeast evidence shows that double strand break 
repair proteins (yKu80 and Sir3p) are bound at the telomere and are mobilised from there 
to the site of DNA damage during cellular repair processes. (Boulton and Jackson 1996; 
Martin, Laroche et al. 1999; Mills, Sinclair et al. 1999) Telomere length in yeast has been 
shown to influence response to ionising radiation. Mutations in yeast DNA repair proteins 
(yKu80, yKu70, Mrel1, Rad50, Xrs2, Sir2 and Sir3) alters both telomere length and 
sensitivity to irradiation. (Haber 1998) In the nematode Caenorhabditis elegans mutation of 
DNA repair mtr-2 causes shortening of the telomeres and enhanced cell kill in response to 
irradiation. (Ahmed and Hodgkin 2000) In studies of the human genetic disorders Ataxia 
telangiectasia (AT) and the Nimjegen breakage syndrome (NBS) further relevant evidence 
has arisen. Patients with AT are highly radiosensitive and are cancer prone. (Taylor, 
Hamden et al. 1975) The NBS protein is found at telomeres and cells from NBS patients 
are also radiosensitive. (Lombard and Guarente 2000)In mammalian cells the telomere is a 
site of DNA DSB repair protein binding and an association has been shown between 
telomere shortening and ionising radiation sensitivity both in human tissue (Mcllrath, 
Bouffler et al. 2001) and in mice. (Goytisolo, Samper et al. 2000; Wong, Chang et al. 
2000). Further relevance of the telomere as a DSB repair protein binding site is shown by 
the high incidence of telomeric fusions observed in Ku- deficient mice, which are 
radiosensitive. (Bailey, Meyne et al. 1999) 
The upregulation of the telomerase enzyme maintains the telomere at shortened length in 
human malignant cells. Based on the evidence above, the inhibition of this enzyme, 
producing further shortening of the telomere in human cancer cells may therefore enhance 
radiosensitivity. We initially examined the converse, by assessing the effect of increasing 
telomerase expression in a rare, telomerase deficient cancer cell line and comparing this 
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effect to that seen in cancer cells already with high telomerase levels. Each of two cell 
lines had been stably transfected with a retroviral vector carrying either the empty vector 
pBabeNeo or the hTERT expression vector pBabest2 by Dr KE Gordon, (Gordon, Ireland 
et al. 2003)who kindly donated these cells. These are detailed below. 
3.2 BICR 7 shows a crisis phenotype. 
Cell lines derived from in vivo SCCHN tumours at the CRUK BICR by Dr EK Parkinson 
(Edington, Loughran et al. 1995)and the R9 research group show a variety of different 
telomere lengths and levels of telomerase upregulation. (Gordon, Ireland et al. 2003) The 
BICR 7 cell line has short telomere restriction fragments (TRFs) on Southern blotting 
(3Kb) and a relatively low level of telomerase. This is reflected in a high anaphase bridge 
index (0.55) and a low cloning efficiency (3%) when compared to other similarly derived 
lines (<0.2 ABI and cloning efficiency of >25%). BICR 7 is in fact mortal, despite having 
bypassed MO and M1 as shown by p16 and p53 immunostaining (Gordon, Ireland et al. 
2003) The BICR7Tert cells however have a much enhanced expression of telomerase 
(increased 80 fold) and increased TRF lengths (10Kb). This is in fact a telomere length in 
excess of that seen in pre-MO keratinocytes. (Dickson, Hahn et al. 2000) The cloning 
efficiency of these cells is increased to 28% and the anaphase bridge index falls to 0.07. 
This evidence therefore shows the reversal of telomere dysfunction with increased 
telomerase. 
3.3 B/CR 6 
In contrast, the BICR 6 line shows longer TRFs (6.5kb) and higher endogenous levels of 
telomerase. This cell line grows well in tissue culture and is immortal, with few anaphase 
bridge figures and a cloning efficiency of 33%. When supraphysiological levels of 
telomerase are expressed in the BICR6Tert cells, the cloning efficiency, which is already 
high, is unaffected. Telomere length, however is increased to >10kb, again longer than 
normal, pre-MO keratinocytes. 
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Comparisons between levels of enzyme expression and the effect on telomere length and 
function is given in table 3.1 
Table 7. Telomerase activity and telomere function in BICR6Neo, BICR6Tert, 
BICR7Neo and BICR7Tert. (Gordon, Ireland et al. 2003) 
Cell line Telomerase Cloning TRF length Anaphase 
catalytic efficiency bridge index 
activity (TPG) 
BICR6Neo 145.8 33% 6.5kb 0.09 
BICR6Tert 320.5 37% >10kb 0.02 
BICR7Neo 1.7 3% 3kb 0.55 
BICR7Tert 192 28% >10kb 0.07 
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3.4 Radiation survival curves for BICR6Neo, BICR6Tert, 
BICR7Neo and BICR7Tert. 
These cells were used experimentally to examine the influence of the telomerase enzyme 
on radiosensitivity, affording a contrast between cells with low telomerase expression and 
many features of the crisis phenotype (BICR 7) and a cell line with stable telomere 
function and higher telomerase levels (BICR6). The effect of supraphysiological 
expression of telomerase on radiation survival could then be assessed. 
Each cell line was grown in tissue culture as described in materials and methods. Cells in 
suspension were irradiated with 0,1,2,3,4,5 and 10 Grays of radiation for BICR 6Neo and 
BICR6Tert and with 0,2 and 4 Grays for BICR 7. Each assay was calculated with two 
replicate plates. Survival at these levels of ionising radiation exposure was then assessed 
by calculating cloning efficiency as described in materials and methods. Each experiment 
was completed three times and the data pooled. 
3.4.1. Radiation survival at 0 -10 Grays for B1CR6Neo vs. BICR6Tert. 
Data for BICR6 Neo and for BICR6 Tert is presented graphically in figures 3-1. The scale 
here is logarithmic. The comparison of data from these two cell lines demonstrates no 
appreciable effect on radiosensitivity in BICR6 cells when telomerase expression is 
increased to supraphysiological levels with corresponding changes in TRF length over 
BICR 6 cells expressing drug resistance vector only. 
James Anthony McCaul, 2004 Chapter 3,87 
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Figure 3-1. Radiation survival curve for BICR6Neo vs. BICR6Tert. 
Values represent means of experiments in triplicate. Each individual experimental 
value is the mean of two results. Differences are not statistically significant between 
these cell lines for any ionising radiation dose (Mann-Whitney U-test). 
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3.4.2. Radiation survival at 0-4 Grays for BICR7Neo vs. BICR7Tert. 
Early experiments with BICR7Neo indicated very low radiation survival with ionising 
radiation doses greater than 4 Gy. For this cell line, in order to achieve analysable data, 
radiation doses of 0,2 and 4Gy were therefore selected. Two replicate plates were set up 
for each data point. Additionally, ten fold increases in plating of irradiated suspended cells 
was found to be appropriate in order to allow the growth, staining and counting of colonies 
for cloning efficiency calculation. This data is demonstrated graphically in figure 3.2. The 
scale here is again logarithmic. The combination of data from these two cell lines shows a 
clear difference in radiosensitivity. There is improved radioresistance when BICR 7 
ectopically expresses telomerase, lengthens the TRF restriction fragments and restores 
telomere function. 
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Radiation survival curve for BICR7Neo vs 
BICR7Tert 
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Figure 3-2. Radiation survival for BICR7Neo and BICR7Tert. 
Radiation survival for BICR7Neo and BICR7Tert at 0,2 and 4Gy expressed as 
survival fraction (%). Values represent means of experiments in triplicate. Each 
individual experimental value is the mean of two results. Difference in SF2 and SF4 
between drug resistance vector only and hTERT expressing cells are statistically 
significant (p<0.01 in both cases; Mann-Whitney U test). 
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3.5. Radiosensitivity in HFFs with ectopic expression of 
telomerase. 
Early pass HFF cells were grown in culture as described in chapter 2. These were then 
transfected with Phoenix A retrovirus carrying the hTERT gene. Clones were selected and 
pools subjected to 2 Gy of ionising radiation as described. As control cells transfected with 
DNhTERT and drug resistance vector only virus (pBabeDNhTERT and pBabepuro 
respectively) failed to undergo cell division for an adequate number of cell divisions, it 
was not possible to compare these cells to hTERT HFFs. Comparison was therefore made 
with early pass wild type HFF cells and two separate pools of hTERT HFFs (HFF Ti and 
HFF T2) and SF2 calculated. Expression of telomerase was confirmed using the TRAP 
assay and this is shown in figure 3-3. hTERT HFF clones clearly replicated at a higher rate 
in tissue culture. Experiments were carried out using two replicate plates and repeated 
three times. Results were then pooled and are shown in figure 3.3. 
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TRAP Assay for HFF WT and HFF Tert clones 
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Figure 3-3. TRAP assay for HFF TERT clones and HFF WT cells 
Telomere repeat amplification protocol assay for HFF TERT clones and HFF WT 
early pass cells. (H. I.; heat inactivation). Lanes are labelled and show positive control 
(TSR8), negative control (CHAPS lysis buffer) and heat inactivation control lanes as 
indicated. HFFTI and HFFT2 protein extracts show telomerase products while HFF 
wild type produce none. 
James Anthony McCaul, 2004 
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Figure 3-4. Telomerase activity in HFF Tert clones 
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Telomerase activity in HFF cells expressing puromycin resistance gene and hTERT 
gene. This is expressed as telomerase products generated as amplified in the TRAP 
assay PCR method as described in chapter 2. Wild type HFFs show no telomerase 
catalytic activity 
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Figure 3-5. SF2 for HFF WT and HFF Tert 1 and HFF Tert 2 
Survival fraction at 2 Gy for early pass wild type HFFs vs two pools of hTERT HFF 
clones. Values represent means of experiments in triplicate. Each individual 
experimental value is the mean of two results. There is no statistically significant 
difference for SF2 HFF1 and HFFT2 compared to wild type controls (Mann Whitney 
U test). 
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3.6. Radiosensitivity of GM847cells with ectopic expression of 
telomerase. 
The immortal ALT cell line GM847 was then used to investigate the specificity of the 
observed effects of telomerase on telomere function. Using the described method, clones of 
GM847 fibroblasts were generated by transfection with retrovirus carrying hTERT, 
DNhTERT and drug resistance plasmid only. Multiple clones of each were then ring 
cloned and cultured under puromycin selection. Two clones each of antiobiotic resistance 
vector only, DNhTERT and hTERT expressing cells were then selected and cultured for 
radiation survival calculation. Expression of telomerase was confirmed using the TRAP 
assay and this is shown in figures 3-5 and 3-6. 
Telomerase 
products 
<ý7=36bp 
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H. I. +-+-+- 
Sample TSR8 CHAPS GM847T1 GM847P1 GM847DNhT1 
Figure 3-6. TRAP assay for GM847 clones. 
Telomere repeat amplification protocol assay for GM847 fibroblast clones. (H. I.; heat 
inactivation). Lanes are labelled and show positive control (TSR8), negative control 
(CHAPS lysis buffer) and heat inactivation control lanes as indicated. GM847TERT 
clone (GM847T1) shows telomerase products, whereas GM847puro (GM847P1) and 
GM847DNhTERT (GM847DNhTI) clones do not. 
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Figure 3-7. TRAP assay for GM847 clones 
Telomere repeat amplification protocol assay for GM847 fibroblast clones. (H. I.; heat 
inactivation). Lanes are labelled and show positive control (TSR8), negative control 
(CHAPS lysis buffer) and heat inactivation control lanes as indicated. GM847TERT 
clone (GM847T2) shows telomerase products, whereas GM847puro (GM847P2) and 
GM847DNhTERT (GM847DNhT2) clones do not. 
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Figure 3-8. Telomerase activity in GM847 cells 
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Telomerase activity in GM847 cells expressing puromycin resistance gene and 
hTERT gene. This is expressed as telomerase products generated as amplified in the 
TRAP assay PCR method as described in chapter 2. GM847 cells expressing drug 
resistance vector only (GM847Puro) and those expressing dominant negative hTERT 
(GM847DNhT) show no telomerase catalytic activity. 
Figure 3-7 shows the level of telomerase products generated in the ectopic telomerase 
expressing cells shown in the assays illustrated in figures 3-5 and 3-6. Survival fraction at 
2Gy was then calculated and is illustrated in figure 3-8. No significant differences were 
observed in SF2 between clones expressing empty vector only, hTERT or DNhTERT. 
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Figure 3-9. SF2 for GM847 fibroblast clones. 
Survival fraction at 2 Gy for GM847 fibroblasts expressing antibiotic resistance gene 
only (GM847puro), hTERT (GM847T) and dominant negative hTERT 
(GM847DNhTERT). Values represent means of experiments in triplicate. Each 
individual experimental value is the mean of two results. Differences in SF2 are not 
statistically significant for comparisons between any of the clones (P>0.05 in all 
comparisons; Mann Whitney U test). 
3.7. Discussion: 
This data shows a clear reduction in radiosensitivity of a SCCHN cancer cell line (BICR 7) 
when the endogenous level of telomerase is increased by ectopic expression of the hTERT 
gene product; the telomerase enzyme. This has been shown to restore telomere function in 
these cells as evidenced by increased TRF length, reduced anaphase bridge index and 
improved cloning efficiency. (Gordon, Ireland et al. 2003) Control cells (BICR 7Neo) were 
not rendered radioresistant by the stable transfection and clonal selection process. Using 
BICR 6 in this experiment demonstrates the absence of a radioprotective benefit with 
supraphysiological levels of telomerase in a cancer cell line which already expresses 
adequate levels of telomerase for telomere maintenance. This is the first evidence of the 
effect of manipulating telomerase in eukaryotic cancer cells with regard to the cellular 
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response to ionising radiation. Building on previous data suggesting that the telomere is a 
crucial structure in determining radioresponsiveness of the cell, this provides proof of 
function for the telomerase enzyme in maintaining the telomere for response to double 
strand break DNA damage. While it is likely that overall radiosensitivity is a multifactorial 
feature of mammalian cells, in these in vivo derived SCCHN cells a clear effect is 
demonstrated in enhancing radiosensitivity in BICR 7 to what is in fact a relatively high 
radioresistance phenotype. (Brachman, Beckett et al. 1993) BICR 6 is among the more 
radioresistant SCCHN cell lines recorded in the literature and in these experiments BICR 7 
was found to achieve an SF2 even higher than this cell line. 
In order to assess the specificity of this effect on cancer cells only, early pass HFFs were 
compared to HFFs stably transfected with the hTERT expression vector. Here in fact SF2 
was shown to be reduced in the hTERT cells, although differences for the two clones used 
were not statistically different from wild type cells. Thus the telomerase protective effect is 
not seen in normal cells with long (10-15kb) telomeres and no in vitro evidence of 
telomere dysfunction. 
The specificity of the effect on telomere dysfunction in telomerase dependant SCCHN 
cells was investigated by transfecting ALT cells (GM847) with hTERT. The effect of 
ectopic expression of hTERT in these cells has been recently reported. (Perrem et al) The 
ALT mechanism has been shown to be suppressed in telomerase expressing variants, 
although the telomerase enzyme per se was shown not to be the repressing factor. While 
GM847 cells have long and heterogeneous telomeres, expression of telomerase lengthens 
the shortest telomeres. Despite this effect these experiments using clones of GM847 cells 
expressing hTERT and the dominant negative hTERT genes showed no significant 
variation from those expressing the puromycin resistance vector only. Thus the 
radioprotective effect of telomerase is shown to be specific to cancer cells maintaining the 
shortened, post-senescent telomere with the telomerase enzyme complex and not to operate 
in ALT cells. 
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The key aim of this research is to investigate the translational value of manipulation of 
telomerase in producing a cell killing effect that is specific to cancer tissue. The next 
question to attempt to answer is the effect of inhibition of the telomerase enzyme in 
SCCHN cells on radiosensitivity. Should this provide an increase in cell death with 
ionising radiation then there may be a potential therapeutic benefit for SCCHN patients 
with a telomerase inhibition strategy. 
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Chapter 4. 
Results. 
Modulation of SCCHN radiosensitivity by 
telomerase inhibition. 
James Anthony McCaul, 2004 
4.1 Introduction 
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In this phase of investigation we aimed to assess the effect of telomerase inhibition on 
radiosensitivity of SCCHN. Our aim was to achieve inhibition of the catalytic activity of 
the telomerase enzyme complex, to assess the impact of that inhibition on telomere 
function and to then assay changes in radiation survival. 
4.1.1 Telomerase inhibition with dominant negative hTERT. 
A number of investigators have successfully achieved telomerase inhibition in 
experimental systems. Among the methods used, dominant negative mutants which inhibit 
endogenous telomerase function have been among the most effective. (Hahn, Stewart et al. 
1999; Zhang, Mar et al. 1999) Several point mutants in the telomerase catalytic subunit 
hTERT which substantially reduce telomerase activity have been previously identified. 
(Harrington, Zhou et al. 1997; Nakamura, Morin et al. 1997; Weinrich, Pruzan et al. 1997) 
This information allowed the development of experimental systems where such mutants 
were shown to reliably inhibit telomerase. One group used a muristerone inducible system 
to produce expression of the mutant telomerase (Zhang, Mar et al. 1999) while in another, 
an amphotrophic retroviral vector transferred either DNhTERT or a drug resistance marker 
only into cells and produced stable expression of the mutant protein. (Hahn, Stewart et al. 
1999) Both of these experimental systems have been shown to successfully inhibit 
telomerase, eliminating tumorigenicity and producing tumour cell death. The DNhTERT 
method of telomerase inhibition was selected for investigation with SCCHN in this study. 
James Anthony McCaul, 2004 Chapter 4,101 
4.1.2. Dominant negative hTERT 
The dominant negative hTERT used in these experiments contains two amino acid 
substitutions in the third reverse transcriptase motif. Residues 710 (aspartate) and 711 
(valine) are replaced with alanine and isoleucine respectively. This catalytically inactive 
protein has been shown to successfully inhibit endogenous telomerase activity in cancer 
cells producing a reduction in telomere length and ultimately loss of tumour cell invasion 
in animal models and tumour cell death. (Hahn, Stewart et al. 1999) 
4.1.3. DNhTERT in SCCHN 
For this part of the investigation we infected several SCCHN cell lines with a retrovirus 
encoding either the empty pBabe puro vector, or the same vector containing pBabehTERT 
or pBabeDNhTERT. Infection was successful in BICR 6 and a number of clones were 
isolated as described in chapter 2. This cell line has robust growth characteristics and 
radiation survival at the high end of the range for SCCHN cell lines (SF2 = 71.4%, SF4 = 
24.3%; see chapter 5). These cells express high levels of telomerase in comparison to other 
SCCHN and have correspondingly low levels of telomere dysfunction. (Gordon, Ireland et 
al. 2003) Initial experiments using the DNhTERT construct in the pBabepuro plasmid with 
the phoenix A retroviral vector system produced a number of clones of the BICR 6 line as 
described in detail in chapter 2. Early data obtained from cloning efficiency experiments 
did show some evidence of radiosensitisation of DNhTERT clones in comparison to 
controls (empty vector BICR6 Puro and high level telomerase expressing BICR6 Tert). 
Unfortunately however, after a number of population doublings, while puromycin 
resistance was retained by all 12 DNhTERT clones, telomerase enzyme activity was 
retained in the surviving cell populations in all cases, although to differing levels of 
catalytic activity. (Fig 4-1- 4-3) 
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Figure 4-1. TRAP assay for BICR6 DNhTERT clones 1-5 
Telomere repeat amplification protocol assay showing DNA products generated by 
telomerase activity in BICR 6 DNhTERT clones I-5 
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Figure 4-2. TRAP assay for BICR6 DNhTERT clones 6- 10 
Telomere repeat amplification protocol assay showing DNA products generated by 
telomerase activity in BICR 6 DNhTERT clones 6- 10. 
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TRAP Assay for BICR6 DNhTERT clones 11,12 
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Figure 4-3. TRAP assay for BICR6 DNhTERT clones 11 and 12 and Puro 1, Puro 2 
and Tert I 
Telomere repeat amplification protocol assay showing DNA products generated by 
telomerase activity in BICR 6 DNhTERT clones 11 and 12 and BICR 6 Puro 1 and 2 
and BICR 6 TERT. 
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At this stage we therefore turned our attention to other methods of telomerase inhibition. 
Specifically, we investigated the small molecule inhibitor 3'-azido, 3'-deoxythymidine, or 
AZT. 
4.2 3 -azido, 3 -deoxythymidine (AZT) 
4.2.1. AZT historical background. 
Initially developed as a cancer chemotherapeutic agent, AZT was not considered to be a 
potentially useful agent after initial laboratory experiments. Early work with lab animals 
showed high levels of toxicity when AZT was administered in the drinking water. (Olivem 
and Poirier 1993) When administered as a bolus however, toxicity levels were found to be 
much lower. In the mid 1980s researchers tackling the human immune deficiency virus 
associated AIDS epidemic found that AZT inhibited viral reverse transcriptase. A 
subsequent phase II trial on the effectiveness of AZT in HIV associated disease was 
stopped early because of the effectiveness of the drug and the drug entered clinical practice 
in 1987. 
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Figure 4-4. Chemical structure of AZT. 
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The chemical structure of AZT is shown in figure 4.1. The drug represents a false 
nucleotide which resembles thymidine; the 3'-hydroxy group being replaced with an azido 
(N3) group. On entry to the cell it is phosphorylated by thymidine kinase to AZT 5'- 
triphosphate which is the active metabolite of the drug. This is incorporated into growing 
DNA strands instead of thymidine triphosphate and causes premature chain termination. 
The drug is known to have a low affinity for DNA polymerases ay, ß, and y and also 
mitochondrial polymerase 'y but a high affinity for HIV-1 reverse transcriptase and 
therefore has a high degree of specificity of action. (Melana, Holland et al. 1998) 
4.2.2 AZT in current clinical practice. 
When first introduced into clinical practice in 1987 it was thought that the optimum dosage 
regimen would be 100mg every four hours with no overnight break. This was modified in 
light of the side effect profile of the drug in clinical practice. Currently AZT is utilised to 
avert foetal maternal transmission of HIV infection and as one component of combination 
therapy to treat HIV related disease. 
4.2.3 AZT in cancer 
The early development of AZT as a cancer therapeutic agent was followed by some work 
in gastrointestinal cancers and some tumour regression in colorectal cancers has been 
reported. (Posner, Darnowski et at. 1990; Posner, Darnowski et at. 1992; Beitz, Damowski 
et al. 1995; Falcone, Lencioni et al. 1997) In these studies, the effect of AZT on telomerase 
was not investigated. 
The catalytic component of the telomerase enzyme complex has been shown to be closely 
related to other reverse transcriptases. (Lingner, Hughes et al. 1997) (Nakayama, Tahara et 
al. 1998) During the course of the investigation of the role of telomerase in cancer cells, 
numerous known reverse transcriptase inhibitors have been studied. Among these, AZT 
has been used to successfully inhibit telomerase in B-cell and T-cell lines (Strahl and 
Blackburn 1996) (Melana, Holland et al. 1998), breast cancer cell lines (Melana, Holland 
James Anthony McCaul, 2004 Chapter 4,106 
et al. 1998) and uterine endometrial cancer lines (Murakami, Nagai et al. 1999). Further 
studies have examined the effect of AZT inhibiting telomerase with other telomere 
interacting agents (Rha, Izbicka et al. 2000) (Mo, Gan et al. 2003). 
We investigated the effect of AZT on telomerase catalytic activity in BICR 6 SCCHN 
cells. As controls, cells transfected with hTERT and stably expressing supraphysiological 
levels of the telomerase enzyme were used. We then assayed the effect of this inhibition on 
telomere function by assessment of anaphase bridge scoring. Finally, radiation survival 
after 2 Grays of ionising radiation was assessed for cells treated with AZT. 
4.3. Telomerase inhibition in SCCHN with AZT 
4.3.1. TRAP assay data for BICR6 wild type and BICR6Tert with AZT. 
Appropriate AZT dosages for these experiments were obtained by culturing cells in the 
drug at a variety of dose levels. Doses selected were the highest which still allowed cells to 
reach confluence in twelve-well plates, as described in detail in chapter 2. The levels of 
telomerase inhibition were established by TRAP assay of protein extract from cultured 
cells. The Telomere repeat amplification protocol used, for these experiments (TRAPese, 
Intergen Co. ) is a PCR based, semiquantitative assay of telomerase activity in whole 
protein extract from cells. In order to establish the linear range for the BICR cell lines, 
preliminary work was carried out on prepared cellular extracts within the R9 research 
group by Dr EK Gordon. These experiments showed linearity with protein inputs of 
between 0.2-2 µg. (Gordon, Ireland et al. 2003) 
The protein input for the BICR6 cell line used in the telomerase inhibition experiments was 
at the lower end of the pilot range (0.2-2µg). Pilot experimental data showed that inputs of 
0.2µg for BICR6 and BICR6Tert produced telomerase products inside the stated linear 
range for the TRAP assay (1 - 300TPGs). These data are shown in figures 4.5 to 4.7. Clear 
evidence of inhibition of telomerase is shown in BICR 6 cells cultured for seven days in 
50µM and 100µM AZT. 
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Figure 4-5. TRAP assay of BICR 6 cells cultured in AZT 
DNA products generated by telomerase activity in protein extract from BICR 6 cell 
cultured in AZT for seven days. The intensity of the control 36bp band can be seen to 
increase with higher doses of AZT, reflecting reduced telomerase catalytic activity 
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Figure 4-6. Telomerase activity in BICR6 wild type cells cultured in AZT for seven 
days. Values are the average of duplicates. Error bars represent individual values. 
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Figure 4-7. Telomerase activity in BICR6Tert cultured in AZT for seven days. Values 
are the average of duplicates. Error bars represent individual values. 
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4.3.2. Telomere function in BICR 6 cells cultured in AZT. 
Using culture slides, we cultured BICR 6 wild type and BICR 6 Tert cells from the same 
plates as those under investigation for radiation survival in the three AZT doses (control, 
50µM and 100µM) in identical conditions. These were fixed and stained and examined by 
light microscopy by two observers (the author and Dr EK Parkinson). Thus the ratio of 
bridged anaphase mitoses to normal anaphase mitoses was calculated. These results are 
shown in figure 4-8. Figure 4-9 shows three bridged anaphase mitoses from a culture slide 
of BICR 6 wild type growing in medium containing 501AM AZT. 
Anaphase Bridge Index (ABI) for BICR6 wild type 
and BICR6TERT with AZT 
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Figure 4-08. ABI of BICR 6 wild type and BICR6Tert cultured in control medium 
and in medium containing 50µM and 100µM AZT. Values are the average of 
duplicates. Error bars represent individual values. 
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Figure 4-9. BICR 6 wild type cells cultured in medium containing 50µM AZT. Three 
bridged anaphase mitotic figures are indicated (green arrows) 
While telomere dysfunction appeared to increase with AZT mediated telomerase inhibition 
in BICR 6 wild type cells, there was also an apparent increase in telomere dysfunction in 
control BICR6Tert cells. 
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4.3.3. Growth effects of AZT on SCCHN cells. 
Culturing tumour cells in AZT has been shown previously to affect in vitro rates of cell 
division and also colony formation. (Strahl and Blackburn 1996; Melana, Holland et al. 
1998; Murakami, Nagai et al. 1999; Brown, Sigurdson et al. 2003) These effects have been 
shown to be more marked in cancer cell lines than in normal tissue. (Strahl and Blackburn 
1996; Murakami, Nagai et al. 1999) In the experiments described here colony forming 
efficiency of both BICR6 wild type cells and BICR6Tert cells was affected by AZT. This 
is depicted in figure 4.6. The reduction in cloning efficiency is similar for both wild type 
BICR 6 and BICR6Tert cells. Notably only a minimal effect on colony forming efficiency 
is seen in GM847 fibroblasts cultured in AZT. These cells maintain telomeres via the ALT 
mechanism and do not express telomerase (E K Parkinson, personal communication). 
AZT effect on cloning efficiency of BICR6 and 
BICR6Tert SCCHN cells 
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Figure 4-10. The effect of AZT on colony forming efficiency in BICR6 and 
BICR6Tert. Values represent means of experiments in triplicate. Each individual 
experimental value is the mean of two results Different values for each dose and each 
cell line are not significant statistically (p>0.05 in all cases). 
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4.3.4. Radiosensitivity of BICR 6 cells cultured in AZT. 
Having established that telomerase catalytic activity was indeed reduced in a dose 
dependent fashion by AZT and that this was affecting telomere function, we then 
investigated any change in radiation survival in these cells. This data is depicted in figure 
4-11. which combines SF2 data for BICR6 wild type and BICR6TERT cells for control 
cells and for each of the AZT doses examined. All experiments were repeated in triplicate, 
with a total of six replicates for each value. 
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Figure 4-11. SF2 for BICR6 and BICR6 Tert cells treated with AZT 
Radiation survival after 2Gy for BICR 6 wild type and BICR6Tert cells cultured in 
control (normal) medium and medium containing 50µM and 100µM AZT. Values 
represent means of experiments in triplicate. Each of three individual experimental 
values is the mean of two results Statistically significant differences were found 
between control and 100µM AZT for BICR 6 wild type cells (p<0.01) and between 
BICR6 wild type and BICR6Tert cells both treated with 100µM AZT (p<0.01); 
Mann-Whitney U Test. 
This bar chart shows the clear reduction in SF2 for wild type BICR6 cells with AZT. This 
reaches statistical significance in these experiments at 100µM AZT (p<0.01). Note that 
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surviving cells are expressed as a percentage compared to non-irradiated controls. Actual 
cell survival with combined AZT and irradiation is much less in BICR 6 (mean 8.6% 
survival in 1001M AZT at 2 Gy). In experiments carried out using the same method with 
GM847 cells no change in radiosensitivity at 2Gy was seen with AZT in a range of 
concentrations up to 100µM (E K Parkinson, personal communication). 
4.4. Discussion. 
Initial work with DNhTERT mutant expressing cells proved unsuccessful due to continued 
expression of telomerase in the populations of puromycin resistant cells obtained by ring 
cloning cells transfected as described in chapter 2. Other groups have found similar 
difficulties in adopting this strategy. (Delhommeau, Thierry et al. 2002) Reducing 
telomerase expression in cancer cell lines with already short telomeres has been shown to 
result in drastic telomere shortening and cytogenetic instability. In one study 50% of clones 
successfully transfected escaped from crisis by 15-35 days of culture and recovered a 
proliferation rate similar to control cells. This was investigated and found to be due to 
telomerase reactivation, mainly by loss of the DNhTERT transcript, with maintenance of 
other components of the transfected plasmid, but also by transcriptional upregulation of 
endogenous hTERT. (Delhommeau, Thierry et al. 2002) Such findings emphasise the level 
of selective pressure produced by the crisis phenotype and the facility with which some 
cancer cells can upregulate telomerase. This is of course a concern regarding the use of 
telomerase inhibition therapeutically and a further driver toward combination therapies 
which will reduce the opportunity for emergence of resistant clones of cells. (Hanahan and 
Weinberg 2000) 
In this series of experiments, we chose not to investigate in detail the means by which 
telomerase expression had been re-established or maintained, but rather to press forward 
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inhibiting telomerase by other means in order to address the question of reduced 
telomerase expression and the effect on telomere function and radiation survival in 
SCCHN. 
The growth inhibitory effect of AZT on cancer cells has been described by a number of 
authors in a variety of different cancer cells lines. (Strahl and Blackburn 1996; Melana, 
Holland et al. 1998; Murakami, Nagai et al. 1999; Rha, lzbicka et al. 2000; Gan, Mo et al. 
2002; Brown, Sigurdson et al. 2003) Notably, this effect on cell replication has been 
described as much less marked in normal cells. (Melana, Holland et al. 1998) In our 
experiments, AZT at 50µM and 100µM concentrations caused significant reduction in 
colony forming efficiency in wild type SCCHN tumour cells. A lesser but similar effect 
was observed in cells expressing ectopic hTERT. While some of this effect may be due to 
non-specific toxicity, there is only a small effect on colony forming efficiency in ALT cells 
at the highest AZT dose used here (Dr EK Parkinson, personal communication). Thus 
ectopic hTERT is not able to significantly block the growth inhibitory effects of AZT over 
the short time frame of exposure in these experiments. Interestingly, in longer term 
experiments examining the effect of AZT on colon cancer cells, the most marked effect is 
seen early and reduces with time. (Brown, Sigurdson et al. 2003) 
Telomerase catalytic activity, as assessed by the PCR based TRAP assay was shown to be 
reduced in the presence of the small molecule inhibitor AZT. These experiments have 
therefore shown that telomerase inhibition is achievable using this reverse transcriptase 
inhibitor in BICR6, an in vivo derived SCCHN cell line. The data obtained here are 
comparable to the levels of telomerase inhibition seen in work carried out on other lines 
with AZT. (Brown, Sigurdson et al. 2003) 
Telomere function appeared to reduce with telomerase inhibition due to AZT contained in 
culture medium. This occurred in a dose dependent fashion with wild type BICR6 cells and 
in a short time frame. BICR 6 are known to have telomeres of between 4-6kbp (Gordon, 
Ireland et al. 2003) and so reduction of telomere length alone (losing 150-250 base pairs 
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per cell division) would not be predicted to have occurred sufficiently in such a short 
interval (seven days) to produce the level of telomere dysfunction observed. There was 
also a reduction in telomere function in control BICR6Tert cells. These cells have very 
high levels of telomerase expression and there was no detectable change in telomerase 
activity by TRAP assay when they were exposed to AZT. This is an interesting, if 
unpredictable finding, which perhaps reflects the complex nature of telomere capping. The 
data obtained are however not adequate to draw any firm conclusions regarding AZT 
induced changes in telomere function. AZT inhibits reverse transcriptase function by 
competing for the catalytic site of the enzyme and is relatively specific for enzymes of this 
type. (Melana, Holland et al. 1998) Again, where telomerase is inhibited effectively, a 
reduction in capping may reflect the further role(s) of the telomerase enzyme complex in 
maintaining cytogenetic stability in the context of the shortened telomeres of the cancer 
cell. There is however a further function of AZT in its incorporation into growing DNA 
chains, causing chain termination. It is possible that this function is contributing to the 
observed increase in ABI. A further consideration here is whether the incorporation of 
AZT into telomeric sequences could produce mutant telomeres and therefore account for 
change in ABI and reduction in cloning efficiency. Recent work has shown that the 
formation of such mutant telomeres in tumour cells inhibits tumour cell proliferation. 
(Kim, Rivera et at. 2001) Some more recent evidence has provided a mechanism for this 
and suggests that mutated telomeres in fact cause impaired chromosome separation and 
lead to a unique checkpoint response. (Lin, Smith et al. 2004) Here mutation of the RNA 
template of the telomerase enzyme complex caused incorporation of mutant telomeric 
DNA sequences in yeast. Although both growth rates and telomere profiles were variable, 
chromosome separation was consistently abnormal. These mutants displayed aberrant 
separation of sister chromatids at the centromere as well as the telomere, implying cell 
cycle checkpoint activation. Taking this evidence into account, it may well be the case that 
incorporation of AZT into the telomeres of telomerase proficient cells produces mutant, 
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dysfunctional telomeres. Thus we would anticipate that both wild type and ectopic hTERT 
expressing cells would be affected by mutated telomere DNA. This may therefore account, 
at least in part for the observed increase in ABI in BICR6Tert cells seen at 50µM AZT 
concentration. 
Most interestingly in this part of our work, a clear increase in radiation induced cell death 
was observed when telomerase was inhibited in BICR6 wild type cells. This effect was not 
observed in BICR6Tert cells, where no telomerase inhibition could be detected. This 
finding is consistent with the intact functioning telomere having a critical role in 
radioresistance and complements the reverse fording of enhanced radioresistance in BICR7 
with increased expression of telomerase complements in chapter 3. 
The means by which this radiosensitisation is occurring is not entirely clear. Previous 
corroborative evidence in cell lines showed radiosensitivity increasing with telomere 
shortening. (McIlrath, Bouffler et al. 2001) Further, in the telomerase null mouse a 
radiosensitivity syndrome only developed after four to six generations, when telomeres had 
sufficiently shortened. (Goytisolo, Samper et al. 2000) Further work has shown that the 
shortened telomeres in these animals associate with double strand breaks induced by 
ionising radiation, interfering with correct rejoining of the broken ends. (Latre, Tusell et al. 
2003) There had not been sufficient time for critical telomere shortening caused by cell 
division and the end replication problem in the experiments described in this chapter. 
Telomere function had certainly reduced in the AZT treated cells and reduced 
progressively with increasing AZT dosage. It is possible then that it is the intact, 
functioning telomere that is essential for radiation resistance. Telomere dysfunction can 
clearly be induced by shortening, but perhaps also by disruption of the mechanisms of 
maintenance of the short, post-senescence length telomere in the cancer cell. This 
maintenance may well involve the telomerase enzyme complex by means other than 
lengthening as has been suggested by other investigators. (Blasco 2002) 
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The exact mechanism by which telomere dysfunction induces radiosensitisation is not 
clear. Speculatively, the binding of DSB repair proteins (Mrell/Rad50/NBSI and the 
DNAPK complex) may be hampered by the loss of telomere function. The T-loop, D-loop 
structure provides a means for the localisation of the 3' single-stranded DNA overhang. 
This may also be disrupted in the context of telomerase deficient telomere dysfunction in 
cancer cells and be implicated in radiosensitivity. The uncapped, post-senescent telomere 
may also be capable of combining with double strand break sites, as described by Latre et 
al. (Latre, Tusell et al. 2003) It is also possible that telomerase has a role to play in DSB 
repair occurring elsewhere in the genome and that telomerase inhibition impairs this. 
Interestingly, while in these experiments we are examining the effect of ionising radiation 
in combination with telomerase inhibitor therapy, other workers have assessed the effect of 
other chemotherapeutic agents in the context of AZT telomerase inhibition. (Mo, Gan et at. 
2003) Targeting telomeres with paclitaxel, in combination with AZT, confirms that in 
combination this approach is effective in specifically inducing cell death in telomerase 
positive cancer cells. Telomerase negative osteosarcoma cells were unaffected by AZT. 
The clearest implication of ionising radiation work in the context of chemotherapy would 
be for the use of double strand break inducing agents. These include doxorubicin, 
daunorubicin and actinomycin D. 
We selected BICR 6 for AZT experiments as a typical SCCHN line derived as part of a 
series of cell lines at the Beatson Institute for Cancer Research. In terms of p53 and p16 
status (both mutated) and upregulation of telomerase (expression toward the high end of 
the range found, with low levels of telomere dysfunction (Gordon, Ireland et al. 2003)) 
BICR 6 is a representative and relatively robust SCCHN cell line for experimentation. 
BICR 6 is also one of the most radioresistant lines we have studied. While proof of concept 
is provided by the experiments detailed in this chapter, testing the effect of AZT on 
telomerase expression across a wider panel of cell lines would give useful further data. 
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Animal experiments would also provide desirable further information. Implanting tumour 
cells in nude mice and assessing the effect of AZT in combination with ionising radiation 
in this context would help to further elaborate the usefulness of this approach. 
In clinical practice, AZT is used to avert vertical transmission of HIV infection and also as 
a component of combivir® with other antiretroviral agents. Doses used in practice are 
between 500mg - 1500mg and are described as equivalent to 20 - 60µM. While previous 
phase II experiments using AZT in combination with other chemotherapeutic agents (5- 
FU) have been terminated due to toxicity, the targeted nature of ionising radiation therapy 
makes this a more attractive modality to combine with AZT mediated telomerase 
inhibition. 
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5.1 Introduction 
In this chapter experiments are described which examine two further parameters in relation 
to radiation survival in SCCHN. These are; codon 72 polymorphism and primary versus 
recurrent tumour of origin. Additionally the influence of observed telomere function in 
SCCHN cell lines. The first two of these recognise the complex nature of the cellular 
response to ionising radiation which may be affected by multiple factors while the third 
returns once again to telomere function across a panel of in vivo derived SCCHN lines 
5.1.1. p53 codon 72 polymorphism in SCCHN. 
Epidemiological studies have shown a statistically significant linear correlation between 
the frequency of the p53 Pro72 allele and latitude in several populations. (Beclanan, 
Birgander et al. 1994; Sjalander, Birgander et al. 1995) Epidemiological data from 
Scotland does verify a higher incidence than the rest of the UK which cannot be entirely 
accounted for by the higher rates of tobacco use and alcohol consumption. (Scottish Cancer 
Registry 2004) This therefore implies some other genetic or environmental predisposing 
feature, the nature of which remains obscure at this time. Interestingly, data relating to the 
p53 codon 72 status in SCCHN occurring in the Scottish population is currently lacking. 
5.1.2. p53 Arginine codon 72 Is more effective in producing apoptotic 
cell death. 
Recent in vitro studies have demonstrated the increased capability or the arginine 
polymorphic variant of p53 to induce apoptotic cell death. (Dumont, Leu et al. 2003) 
Codon 72 in fact lies in the proline rich domain which has been demonstrated to be 
essential for p53 to fully induce apoptosis. At least part of this increased apoptotic effect of 
the arginine variant is its superior localisation to the mitochondria accompanied by release 
of cytochrome C into the cytosol. This has been proposed to account, at least in part, for 
the reduced Arg72 incidence in regions with greater UV in the environment. 
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5.1.3. Mutated p53 Arg72 can bind to and inactivate both wild type p53 
and p63 and p73 proteins. 
Other p53 family members have been shown, at least when over expressed to bind to 
canonical p53 binding sites in vitro (Marin, Jost et al. 2000). These can also 
transcriptionally activate p53 target genes in vivo, therefore exerting the p53 associated 
tumour suppressive effects. (Kaelin 1999) Previous experimental work has demonstrated 
an increase in carcinogenicity when cells null for p53 are transfected with mutated p53. 
(Halevy, Michalovitz et al. 1990; Dittmer, Pati et al. 1993)Accumulation of mutated p53 in 
cancer cells can function in a dominant negative role by forming heterooligomers with 
wild-type p53 expressed by the second allele. Evidence presented recently shows that 
mutated p53 Arg 72 can both physically interact with and form complexes with p73 under 
physiological conditions and hence can inactivate it. (Marin, Jost et al. 2000) The p73 
protein itself is only rarely mutated in cancer. Further, the cellular response to 
chemotherapeutic agents has been shown to be significantly affected by p53 codon 72 
polymorphism. (Bergamaschi, Gasco et al. 2003)Cancers expressing the mutated Arg 72 
variant have been demonstrated to have lower response rates to cisplatin than those 
expressing the mutated pro 72 variant. 
5.1.4. p53 in the cellular response to DNA double strand breaks 
The cellular reponse to stress induced by ionising radiation damage is mediated via DSBs 
which interact with kinases (ATM and CHK2) to phophorylate p53 at serine residues 15 
and 20 respectively. This alteration then induces the p53 mediated transcription of a 
number of other mediators to induce either cell cycle arrest or apoptosis. Where p53 is 
mutated, this effect is lost and hence the cellular response to radiation is altered. This 
pathway is summarised in figure 5-1 
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Figure 5-1. Cellular response to ionising radiation mediated by phosphorylation of 
p53 protein family members 
The clear implication from work on this polymorphism is that the while in the absence of 
wild type p53 the other p53 family members can continue to exert p53-like tumour 
suppressive effects, the mutated Arg 72 p53 protein may be capable of interfering with 
these protective pathways. We therefore set out to establish the codon 72 status in our cell 
lines and whether the oncogenic effect of mutated p53 Arg 72 could be demonstrated in the 
context of the cellular response to ionising radiation by examining radiation survival at 
2Gy and 4Gy in a number of SCCHN in vivo derived cell lines. 
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5.2.1. Establishing the codon 72 status of SCCHN cell lines. 
In total 15 cells lines were analysed for codon 72 status and radiation survival at 2Gy and 
4Gy. Eleven of these were derived from in vivo SCCHN from Scottish patients and four 
others were obtained from the American tissue Culture Collection. Genomic DNA was 
harvested from cells grown in tissue culture as described in chapter 2. This was quantified 
and then amplified using a PCR method to provide exon 4 DNA. This was sequenced in 
the BICR and codon 72 status established. This information is summarised in table 5.1. 
The Scottish derived cells comprised 73% Arginine at codon 72 and 27% proline. This is 
shown in figure 5.2. All cells obtained from ATCC are arginine at codon 72. 
p53 codon 72 status 
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Figure 5-2. codon 72 status in SCCHN cell lines 
p53 codon 72 status in SCCHN cell lines derived from in vivo SCCHN tumours in 
Scottish patients at the Beatson Institute for Cancer Research 
I "y......, ..... 
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Table 8. Codon 72 status, p53 mutation and primary or recurrent status of SCCHN 
cell lines 
p53 mutation status and codon 72 status in cells assessed for radiation survival and 
anaphase bridge scoring. Information was acquired from Burns et at (Burns, Baird et 
al. 1993) and experimentally as described in chapter 2 
SCCHN Cell line P53 status Codon 72 status Tumour of origin 
status (primary or 
recurrent) 
BICR 3 arg- pro (282) Arg Primary 
BICR 6 glu-+ stop Arg Primary 
(192) 
BICR 10 No protein Pro Recurrent 
BICR 16 trp--' stop Pro Recurrent 
(146) 
BICR 31 3bp del Arg Primary 
BICR 56 21bp del Arg Primary 
BICR 63 iso-º phe Arg Primary 
(255) 
BICR 68 Elevated p53 Arg Primary 
BICR 78 cys-º phe Arg Primary 
(176) 
BICR 82 unknown Arg Recurrent 
DOK unknown Pro Primary 
SCC 4 pro- ser 151 Arg Recurrent 
SCC 9 32bp deletion; Arg Primary 
285+ out of frame 
SCC 15 deletion Arg Primary 
SCC 25 2bp deletion; 209+ Arg Primary 
out of frame 
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5.2.2. Radiation survival data for SCCHN lines at 2Gy and 4Gy. 
Each of the 15 cell lines was grown in tissue culture, split into suspension, irradiated, 
replated and cultured to obtain countable colonies as described in chapter two. All 
,, experiments were once again repeated in triplicate to obtain the data shown in figure 5-3. 
This data demonstrates a range of radiation survival across the cell lines tested at 2 Gy and 
4 Gy. The figure also shows the range for SF2 for normal keratinocytes. It is clear that 
SCCHN lines are generally more radioresistant than non malignant cells. The single 
exception here is BICR7 which, as described in detail in chapter 3 is an unusual cell line in 
terms of both its telomere function and radioresistance. 
5.2.3. Radiation survival data with codon 72 Arg/ Pro status. 
For the hypothesis that mutated p53 Arg72 to be true, clearly cells require to have p53 
protein translation occurring. We therefore have divided the data into those lines with gain 
of function and those with loss of function mutations of p53. For each of these groups 
these are further divided according to codon 72 status. 
Figure 5-4. shows radiation survival at 2 Gy for cell lines with gain of function p53 
mutation comparing Arg 72 with Pro 72. Only a single gain of function Pro 72 cell line 
was available (DOK) and this is compared with six gain of function Arg 72 lines, the mean 
SF2 for which is shown. While there is a range of SF2 for Arg 72 the mean value is similar 
to SF2 for DOK. 
In figure 5-5. the same SCCHN cell lines are depicted, this time with the surviving fraction 
at 4 Gy of radiation. Again a range of values is seen in the Arg 72 lines, the mean value 
being in fact similar to that for DOK. 
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Loss of function cell lines are depicted in figures 5-6. and 5-7. In this case two of the lines 
were pro 72 and as anticipated given the absence of p53 protein there is no significant 
difference in radiation survival at either 2Gy or 4Gy for either coded polymorphism. 
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Figure 5-3. SF2 and SF4 for SCCHN cell lines 
Surviving fraction at 2Gy and 4Gy is shown for SCCHN cell lines together with range 
of SF2 for wild type human keratinocytes. Values represent means of experiments in 
triplicate. Each individual experimental value is the mean of two results. Error bars 
are Standard errors of means. 
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Figure 5-4. SF2 for SCCHN cells with gain of function p53 mutation; Arg 72 vs Pro 
72. Values represent means of experiments in triplicate. Each individual experimental 
value is the mean of two results. Error bars are Standard errors of means. 
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Figure 5-5. SF4 Gy for SCCHN cell lines with gain of function p53 mutation Arg 72 
vs Pro 72. Values represent means of experiments in triplicate. Each individual 
experimental value is the mean of two results. Error bars are Standard errors of 
means. 
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Figure 5-6. SF2 for SCCHN cell lines with loss of function p53 mutation Arg 72 vs 
Pro 72. Values represent means of experiments in triplicate. Each individual 
experimental value is the mean of two results. Error bars are Standard errors of 
means. 
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Figure 5-7. SF4 for SCCHN cell lines with loss of function p53 mutation Arg 72 
versus Pro 72 Values represent means of experiments in triplicate. Each individual 
experimental value is the mean of two results. Error bars are Standard errors of 
means. 
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5.3. Discussion. 
The data obtained from these experiments show that SCCHN cells are more radioresistant 
than normal keratinocytes at 2Gy of radiation. Mean SF2 for SCCHN was 67.3%, where 
the accepted range of SF2 for non-malignant keratinocytes is 25-45%. The single 
exception to this was BICR 7 (SF2=33.3%), a cell line which shows many features of crisis 
and expresses low levels of telomerase. (Gordon, Ireland et al. 2003) The basis of this 
increased radiosensitivity may lie at least in part in the understood key role of p53 in the 
cellular response to ionising radiation. Notably p53 is mutated in 15 of the 16 lines tested. 
The single exception here is BICR 68 (wild type p53), which also is unusual in having wild 
type p16. This cell line also has a low colony forming efficiency and differentiated 
phenotype. 
The data obtained from the sample analysed show an excess of Arg 72 in mutated p53 in 
cancer in the SCCHN cells. This does conform to the hypothesis of excess of this 
polymorphism in the population, but is at a higher than expected proportion (73% Arg 72) 
thus perhaps reflecting preferential loss of the Pro 72 allele in heterozygotes (Brooks, Tidy 
et al. 2000). It is important however to interpret such observational data carefully. It must 
be considered that this is a small sample and so firm conclusions based on observational 
data cannot be drawn. 
Several of the lines analysed had loss of function p53 mutations and so this short series is 
not consistent with the hypothesis of Crook et al which suggests that 90% of p53 mutations 
in SCCHN are gain of function. (Gasco and Crook 2003) Only seven of the lines tested 
were gain of function mutations and were therefore appropriate for analysis in assessing 
any potential oncogenic effect of mutated p53 Arg 72 versus Pro 72. The data obtained do 
not show any difference in radiosensitivity between these groups. Loss of function p53 
mutations were also analysed as control data and these too show, as expected, no 
difference in radiosensitivity between either polymorphism. 
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In conclusion, the data presented are unable to show any significant difference in the 
response to ionising radiation of SCCHN cells based on p53 codon72 arginine or proline 
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Chapter 6 
Telomere function and radiation survival in SCCHN 
cell lines. 
James Anthony McCaul, 2004 
6.1. Introduction. 
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6.1.1. Telomere function. 
Telomere function requires adequate length of telomeric DNA repeats and other telomere 
components to allow appropriate capping. (Blackburn 2001) Where these are lacking and 
telomeres are dysfunctional, chromosome ends fuse and these can be identified within the 
dividing cell. The resulting breakage-fusion-bridge events are considered to be a major 
contributor to the high levels of rearrangement of genetic material observed in the 
malignant cell. Additionally, shortened telomeres have been shown to impart 
radiosensitivity syndrome in telomerase null mice and increased radiosensitivity is 
observed in tumour cell lines with shorter telomeres. 
6.1.2. Assessment of Telomere Function. 
Telomere function can be assessed by analysis of phenotypic features. Mitotic figures can 
be examined for evidence of telomere dysfunction and some of the phases of mitosis are 
demonstrated in figure 6-1. Evidence of fusion of the ends of daughter chromosomes 
presents as bridged anaphase mitoses (Figure 6-2. ) An anaphase bridge is defined as an 
anaphase mitosis where 2/3 of the distance between the separating poles is spanned by a 
bridge of two fused chromosomes. (Rudolph, Millard et al. 2001; Gordon, Ireland et al. 
2003) The proportion of anaphase mitoses which are bridged due to this fusion of daughter 
chromosomes with inadequate telomere function can be expressed as a ratio of the total 
number of anaphase mitoses seen in a tumour cell population. This is termed the anaphase 
bridge index (AB» (Gordon, Ireland et al. 2003). 
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Figure 6-1. Mitotic figures seen in a H&E stained slide culture of BICR 10 
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Figure 6-2. Normal and abnormal anaphase mitoses in SCCHN cell lines 
H&E stained culture slides showing anaphase mitoses and a tripolar mitosis; a. A 
normal anaphase mitosis in SCC9. b. A bridged anaphase mitosis from BICR3. c. A 
bridged anaphase mitosis from BICR 56 and d. a tripolar mitosis seen in BICR78 
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Previous studies imply that where telomere dysfunction is observed this may reflect either 
insufficient length of telomeric DNA or other structural defect. (Blackburn 2000)Given the 
localisation of DNA double strand break repair proteins bound at the telomere reduced 
telomere function could be speculated to be associated with reduced radiation survival. We 
investigated this question by recording the ABI for each cell line and comparing this to the 
SF2 and SF4 established and demonstrated in figures 5.4.1. to 5.4.4. ABI data is shown in 
figure 6.3. Scores obtained by the two investigators (JMcC and EKP) were averaged and 
standard deviations are demonstrated. Note that for cell lines BICR6, BICR7, BICR 31 and 
BICR 63 ABI data had been established and published previously. (Gordon, Ireland et al. 
2003) The combined data is represented as scatter plots in figures 6.4 and 6.5. No 
statistically significant linear regression (ABI =a+0x SF[2 or 4]) was found for either 
radiation survival point. 
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Figure 6-3. Anaphase bridge indices for the 16 SCCHN cell lines examined. Values 
are averages, bars represent individual values from the two observers. 
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Scatter plot of ABI vs SF2 (%) In SCCHN 
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Figure 6-4. ABI vs SF2 for SCCHN cell lines 
This scatter plot demonstrates the lack of any linear relationship between ABI and 
surviving fraction after 2Gy of ionising radiation for SCCHN. A trend line has been 
added. Regression analysis shows Pearson correlation R= -0.38, p=0.146. 
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Figure 6-5. Scatter plot of ABI vs SF4 for SCCHN cell lines 
This scatter plot demonstrates the relationship of ABI and surviving fraction after 
4Gy of ionising radiation for SCCHN. and shows the lack of any linear relationship. A 
trend line has been added. Linear regression analysis (ABI= a+ßx 4Gy) shows 
Pearson correlation = -0.47, p=0.067. 
SF4 (%) 
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In further analysing a possible model for the relationship between ABI and the SF2 and 
SF4 values, non-linear regression was assessed. While for the variable 2Gy non significant 
results where found, the inverse transformation of 4Gy without constant term, seems to 
provide a better fit as can be seen in the scatter plot below (figure 6.6). The model has the 
following equation: 
ABI = 5.107/4Gy 
(p value < 0.001; R square =0.82) 
Equation 3. Formula describing the non-linear relationship between SF4 and 
telomere function assessed by ABI. 
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Figure 6-6. Scatter plot of ABI vs SF4 for SCCHN cell lines; non-linear relationship. 
This scatter plot describes ABI versus surviving fraction after 4Gy of ionising 
radiation for SCCHN. Non-linear regression analysis provides the equation 
ABI=5.107/SF4(%). R square = 0.82, p<0.001. 
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U. Discussion. 
Attempts to establish a correlation between telomere function by anaphase bridge score 
and radiation survival produced interesting results. No correlation of significance was 
found between ABI and SF2. For ABI and SF4 a clear, non-linear correlation was 
demonstrated (p<0.0001, R square = 0.82). This provides further support for the role of the 
telomere in radiosensitivity; deteriorating telomere function produces increased cell death 
on exposure to ionizing radiation in a predictable manner. The lack of correlation at 2Gy is 
an interesting finding. This radiation dose corresponds to a single fraction used 
therapeutically and would be anticipated to induce around 300,000 ionisation events in the 
nucleus and a wide range of DNA damage but only approximately two DSBs per 
chromosome. Most DNA damage would be repaired within two hours of exposure. An 
approximate doubling of each of these values is expected after 4Gy exposure and at this 
dose we see a tight correlation with radiation survival. Tumour response to radiotherapy is 
known to be a multifactorial phenomenon involving such factors as cellular oxygenation, 
tumour doubling time and bystander effects. These experiments control for oxygenation 
with constant incubator conditions and for bystander effect by the use of single cell 
suspensions. It may simply be the case that for SCCHN a single 2Gy fraction is insufficient 
to elaborate the true radiosensitivity of the cancer cell. 
Further work is now needed to establish whether this finding translates into clinical 
responses to radiotherapy. Analysis of ABI at tumour diagnosis and analysis of any 
correlation with survival will be not only of interest but of relevance in determining 
prognosis. Should this also prove to be useful information then any changes in ABI 
following therapeutic use of an antitelomerase agent may provide an index of likely 
success of radiotherapy or other double strand break inducing agent. The data obtained 
suggest that increasing ABI from 0.2 to 0.4 could reduce SF4 from -25% to less than 10%. 
Clearly, the biological nature of the systems involved in all these processes produce 
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variation and so as with almost all prognostic parameters ABI will predict across a 
population rather than for the individual. 
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Chapter 7. 
Results. 
Telomere function and radiation survival in Primary 
and Recurrent SCCHN; Analysis of SCCHN Cell 
lines and archival SCCHN tumour sections. 
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7.1. Introduction. 
Tumour progression refers to the selection process which occurs within the tumour cell 
population during the lifespan of a cancer. This selective pressure continues to produce 
clones of cells which are more suited to the environmental stresses placed upon them. 
These stresses include the cytotoxic effects of therapeutic agents, including chemotherapy 
and radiotherapy. 
This concept is particularly relevant in the context of recurrent malignancy. Clearly tumour 
progression has been ongoing in this circumstance and the tumour population which 
persists has escaped therapeutic attempts at cure, which in the context of SCCHN will 
often have included radiotherapy. 
We therefore sought to establish whether the radioresistance of recurrent SCCHN differed 
from that of primary tumours by assessing radiation survival at 2Gy and 4Gy in cell lines 
derived from tumours in these two categories. 
Tumour progression might also be predicted to select for enhanced telomere function, 
which is mediated by telomerase upregulation in SCCHN. If this occurs, then an 
antitelomerase therapeutic strategy may be less effective in the recurrent disease scenario. 
Since any new therapeutic agent will inevitably go through phase I and II testing in the 
context of advanced cancer, it may be that antitumour effects are less marked here than 
would be the case for early disease. We therefore assessed telomere function in primary 
and recurrent disease by ABI scoring of archival sections of primary SCCHN tumours and 
recurrences in the same patients. 
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7.2. Primary versus recurrent status and radiation survival in 
SCCHN cell lines. 
Using the panel of cell lines assessed in this investigation we were able to compare cells 
derived from primary lesions with those from recurrent SCCHN. Each of the recurrent 
SCCHN assessed had been previously treated and this information is contained in table 
7.1. Here we attempt to provide initial data regarding any change in radiosensitivity in 
recurrent tumours which have failed standard therapy. 
Table 9. Therapeutic modalities previously utilised in management of four recurrent 
SCCHN cell lines 
Recurrent cell line Surgery Radiotherapy Chemotherapy 
BICR 10 Yes Yes Yes 
BICR 16 Yes Yes Yes 
BICR 82 Yes Yes Yes 
SCC 4 Yes Yes Yes 
Radiation survival data is shown in figure 7.1. Here the mean values for SF2 are very 
similar for primary versus recurrent malignancy (primary 62.5%, recurrent 63.3%). For 
survival after 4Gy similarly there is little difference (primary 21.7%, recurrent 24.4%). 
Although the survival values are consistently greater for recurrent disease, the differences 
are not statistically significant (SF2; p=0.9, SF4; p=0.6 ). 
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Figure 7-1. Radiation survival at 2Gy and 4Gy comparing primary and recurrent 
SCCHN cell lines. Values represent means of experiments carried out in triplicate, 
each experiment carries duplicate plates. SF2 and SF4 are demonstrated for SCCHN 
derived from primary (BICR63 to BICR7) and recurrent (BICRIO to SCC4) tumours 
with mean values for each group. Mean differences are not statistically significant 
(SF2 p= 0.9, SF4 p=0.6) 
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7.3. ABI in primary versus recurrent tumour derived SCCHN cell 
lines. 
Data obtained during analysis if the ABI for all cell lines studied during the course of this 
investigation was assessed regarding the primary or recurrent status of the tumour of 
origin. This information is shown in figure 7-2. Telomere function assessed by ABI is 
superior in the recurrent group, but the number of cell lines in this group is small. The 
difference does not reach statistical significance (p = 0.21). 
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Figure 7-2. ABI for primary and recurrent SCCHN cell lines. ABI is demonstrated 
for SCCHN cell lines derived from primary (BICR 68 to BICR 31) and recurrent 
(BICR 16 to SCC4) with mean values. Each value is the mean of two observer scores indicated by the error bars. Differences do not reach statistical significance (p = 0.21) 
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7.4. Telomere function in archival primary and recurrent SCCHN 
sections. 
In this part of the investigation, tissue sections from primary and recurrent SCCHN were 
selected from the archive of the Oral Pathology department of Glasgow Dental Hospital 
and School. These tumours were all of oral cavity origin and were selected from the 
database of more than 2,500 tissue blocks. Tissue sections were selected by Professor DG 
MacDonald and then coded. Sections from five primary SCCHN with corresponding 
recurrent tumours were analysed by the author. For each section, we aimed to score as 
many anaphasc mitotic figures as possible, aiming for 20. While in some sections a much 
greater number were found which were of adequate quality for scoring, for two of the 
recurrent tumours a total of five new sections had to be cut in order to provide enough 
tissue for analysis. In many cases the recurrent tissue was only a small block which had 
been obtained to confirm recurrence, rather than a larger piece of material obtained during 
surgical resection for cure as was the case for each primary cancer. Figure 7-1 shows two 
anaphase mitoses photographed in archival H&E stained SCCHN tissue. On completion of 
scoring the code was broken and matched primary and recurrent tumours compared. This 
data is contained in table 7-2. and 7-3. 
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Figure 7-3. H&E stained tissue sections from SCCHN tumours 
This figure illustrates a. bridged anaphase mitotic figure. b. normal anaphase mitosis 
in an invading cord of tumour cells. 
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Table 10. ABI for five cases of primary and corresponding recurrent SCCHN scored 
under light microscopy 
anaphases scored ABI Time to recurrence. 
Case 1 23 Primary 0.44 28 months 
29 Recurrent 0.32 
Case 2 67 Primary 0.6 12 months 
15 Recurrent 0.4 
Case 3 30 Primary 0.6 45 months 
37 Recurrent 0.28 
Case 4 72 Primary 0.3 14 months 
32 Recurrent 0.34 
Case 5 106 Primary 0.33 12 months 
130 Recurrent 0.33 
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Figure 7-4. ABI of matched SCCHN primary and recurrent tumours 
In each case either ABI starts low (mean value 0.31) or drops to a lower value in 
recurrent disease (mean value 0.33), indicating improved telomere function in 
recurrent disease. 
7.5. Discussion 
In tumour tissue where disease recurs after therapeutic intervention, the tumour 
progression process has continued for many months. If management is surgery only, 
recurrence from microscopic residual tumour deposits represents a cell population which 
has undergone clonal evolution for some time. Where chemotherapy and or radiotherapy 
have been used additionally, there has clearly been additional selective pressure in the 
tumour microenvironment. All three recurrent SCCHN cell lines studied here were derived 
from tumours where chemotherapy and radiotherapy had been used therapeutically and so 
had been subject to exactly this pressure. 
Cells derived from recurrent SCCHN tumours were not significantly different in 
radioresistance than those derived from primary cancers. This may indicate that for 
SCCHN derived from the Scottish population, ionising radiation may still be of value in 
the context of disease recurrence and so this novel information may be of value in 
ABI of matched primary SCCHN and n 
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therapeutic planning. Ionising radiation doses were calculated historically on the basis of 
the average tolerance of normal human tissues and maximum tolerable tissue exposures 
therefore used (e. g. 60Gy for the neck in 30 fractions of 2Gy). Subsequently, therapeutic 
regimes have been the subject of much research and have been and continue to be modified 
in the light of such data. (Dische, Saunders et al. 1997; Fu, Pajak et al. 2000; Poulsen, 
Denham et al. 2001; Overgaard, Hansen et al. 2003). Reirradition describes the use of 
radiation for a second time following disease recurrence. (Spencer, Harris et al. 2001; 
Spencer, Wheeler et al. 2003) The limiting factor in use of ionizing radiation is toxicity to 
the normal tissues and a range of radiosensitivity is known to exist in normal human 
tissues (Haikonen, Rantanen et al. 2003) A tumour specific radiosensitiser is an attractive 
prospect in this context in particular. If telomerase inhibition could selectively 
radiosensitise SCCHN this would offer the prospect of effective cancer therapy, while 
limiting host toxicity. 
The evidence presented here showing no increase in radioresistance in recurrent SCCHN 
may provide some support for this strategy. The data series is however small (four 
recurrent cancers) and so should be interpreted with care. 
Telomere function in the recurrent lines shows a difference from that in cell lines derived 
from primary tumours. While this may point toward improved telomere function in 
recurrent disease the small numbers of recurrent lines are small and the data does not reach 
statistical significance. 
Tumour tissue sections examined for ABI show some interesting data. Difficulties with 
this approach include the relative lack of available tissue from recurrent disease. Surgical 
resection of disease in this context is rarely a viable option and so such tumour specimens 
are relatively rare and generally of small volume. Further, in some specimens there is a 
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paucity of mitotic figures, reflecting the replicative state of the constituent clones of 
tumour cells at the time of fixing of the tumour tissue. 
Recurrent disease was identified as further malignant tissue occurring at the site of 
previously resected tumour tissue at least six months post treatment (see table 7.1 for time 
to recurrence in each case). In the context of SCCHN there is clear evidence of mucosal 
field change and so the possibility of second primary cancers emerging in the same patient 
rather than a true recurrence of disease cannot be entirely excluded. (Jefferies, Edwards et 
al. 2001) 
The data presented conform to the hypothesis that telomere function enhances with tumour 
progression unless ABI is already at a low threshold value of around 0.3. This reflects 
similar findings in the study of cervical metastases from SCCHN oral cavity primary 
tumours. Here the ABI was shown to drop in cells which had successfully spread to the 
neck. (Gordon, Ireland et al. 2003) This series is however too small to test for statistical 
significance. 
While the data described in this chapter provide for interesting discussion in the context of 
telomere function and SCCHN disease recurrence, it is not possible to draw firm 
conclusions due to the small numbers of cases involved. Further examination of more cases 
in a similarly designed study would enhance the data presented here. An assessment of 
ABI in tissue samples and correlation with survival would also be valuable data to assess 
the significance of telomere function in determining disease outcome. This may be useful 
both in establishing prognosis and also in quantifying any survival advantage conveyed by 
antitelomerase therapy induced telomere dysfunction. 
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Chapter 8. 
Discussion. 
James Anthony McCaul, 2004 Chapter 8,156 
8.1. Summary of experimental results. 
The experimental evidence accumulated in this thesis provides some insight into 
telomerase manipulation and its effect on telomere function and the impact of this effect on 
the radiosensitivity of SCCHN. Restoration of high levels of telomerase expression by 
stable transfection of the hTERT gene in the BICR7 cell line produced increased 
radioresistance. This was not seen in BICR6 which has already high levels of telomerase 
and robust telomere function, nor in normal human fibroblasts or the GM847 ALT line. 
When telomerase catalytic activity was successfully inhibited by AZT, a deterioration in 
telomere function was observed. This was accompanied by a dose dependent reduction in 
radiation survival after exposure to ionising radiation. This effect was ablated by high level 
telomerase expression in BICR6Tert cells and was not seen in GM847 ALT cells, thus 
confirming both ablation of the effect with excess telomerase and telomerase specificity of 
effect. 
Radiosensitivity of SCCHN tumours is likely to be a multifactorial phenomenon. Studies 
on p53 codon 72 polymorphism had indicated that this variation produced differing 
responses to cisplatin chemotherapy, mediated via effects on p73. Recognising this we 
considered the possible impact of p53 codon 72 polymorphism on the response to ionising 
radiation. The data obtained do not allow us to draw any firm conclusions and a larger 
series of tumours would be necessary to establish any meaningful correlation. 
We discovered a significant non-linear correlation between observed telomere and 
radiation survival. This further supports the telomere function and radiation survival 
hypothesis and may indicate that observed telomere function could be used to predict 
tumour response to radiotherapy. This would be particularly useful in the context of 
clinical trials of telomerase inhibitor agents. Further data examining telomere function in 
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recurrent SCCHN tissue and comparing with primary disease implied that telomere 
function improves with disease progression. These data did not reach significance. 
8.2. Final Discussion 
In interpreting the experimental data contained in this thesis a number of issues are 
relevant in consideration of the possible mechanisms involved and in planning further 
work moving toward telomere function manipulation as a potential therapeutic strategy. 
8.2.1. The role of Telomerase in the malignant cell. 
The wider issue of the role of telomerase in mammalian cells beyond telomere lengthening 
and maintenance has received considerable attention. Forced expression of telomerase in 
both cells and mice with normal length telomeres has shown growth and survival effects of 
telomerase which are distinct from net telomere lengthening. (Blasco 2002) In the context 
of exposure to ionising radiation, recent reports have examined the effect of telomerase on 
normal human fibroblasts. There was no change in SF2 for HFFs ectopically expressing 
hTERT in the experiments included in this thesis and this has now been confirmed by other 
investigators. (Ojima, Hamano et al. 2004) 
Human fibroblasts immortalised by ectopic telomerase expression have also been shown to 
have increased spontaneous and post irradiation chromosomal stability. (Pirzio, Freulet- 
Marriere et al. 2004) This data refers to chromosomal fragmentation seen both in first 
generation metaphases after irradiation and also some time after irradiation therefore 
showing that telomerase at these levels in this context confers resistance to both the 
immediate and late effects of ionising radiation exposure. Further clarity on the role of 
telomerase in these human cells was provided by experiments showing that the protective 
role of telomerase was only evident in human fibroblasts with short, presumably near 
dysfunctional telomeres. Resistance was dependent on the ability of telomerase to elongate 
short telomeres and was not evident in cells with long telomeres. (Rubio, Davalos et al. 
2004) 
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Ojima et al also concluded that ionising radiation tended not to damage telomeres directly, 
but rather the telomere damage signals were a delayed event after exposure, occurring after 
multiple cell divisions in the progeny of exposed cells. Of note in all these studies is the 
level of telomerase expression produced by ectopic expression of the enzyme. This is 
certainly in excess of that seen in the context of human malignancy and so while this may 
provide some insight into the interaction of damage mechanisms occurring in normal cells 
and the overexpressed telomerase enzyme, the relevance of these finding to the post-crisis 
cancer cell is not clear and firm conclusions cannot, as yet, be drawn. (Gordon, Ireland et 
al. 2003; Ojima, Hamano et al. 2004; Pirzio, Freulet-Marriere et al. 2004). 
Further studies using the mouse model and mouse cells have tended to imply that the 
telomerase role in radiosensitivity may not be in healing broken chromosome ends, at least 
not by the addition of telomere repeats. (Latre, Genesca et al. 2004) Telomerase proficient 
mouse embryonic fibroblasts (MEFs) were compared to telomerase knockout MEFs in 
response to DSBs induced by exposure to ionising radiation. Telomerase did not affect the 
efficiency of chromosome rejoining after radiation induced DSBs. Earlier studies by the 
same group have indicated that telomeric functions and DNA repair pathways are closely 
linked. In the context of the shortened telomere in late generation mTERC-/- mice, correct 
repair of double strand breaks is impaired. (Latre, Tusell et al. 2003) Chromosomes with 
shortened telomeres fused to DSB chromosome ends, interfering with correct repair (see 
figure 1.6. ). This concept is appealing in attempting to explain the increased 
radiosensitivity seen with age (and accompanying telomere shortening) in humans and may 
help explain the enhanced radiosensitivity seen in the context of telomerase inhibition 
(chapter 4) and increased radioresistance in hTERT expressing BICR7Tert cells (chapter 
3). The human immortal malignant keratinocyte, however, has a post-senescent and post- 
crisis telomere equilibrium which relies on telomerase for its maintenance. It is most likely 
therefore that advances in our understanding of the role of telomerase in radiosensitivity of 
human cancer cells will come from experiments using in vitro human cancer cell models or 
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indeed correlative information gleaned by scrutiny at the cellular, chromosomal and 
molecular level during trials of anti-telomerase therapy in cancer. Clearly access to tumour 
tissue is highly relevant in this context and so SCCHN is an appealing cancer in which to 
study the potential therapeutic benefits of this approach. This again emphasises one of the 
intriguing aspects of targeted cancer therapy based on our increasing understanding of the 
normal and malignant human cell molecular biology. Historically many therapeutic agents 
were discovered to be useful and the precise basis of this effectiveness established 
somewhat later, if indeed at all. It is relevant to recall throughout considerations of the 
potential relevance of these experiments that the exact basis by which ionising radiation is 
effective in treating malignant disease is unclear. This therapeutic modality shows great 
variation across tumour types and indeed even within tumour subtypes and even in the 
same patient. 
8.2.2. Telomere binding proteins and teiomere function 
The topics of telomere binding proteins and their various roles in chromosomal 
homeostasis are now considered to be extensive and diverse. (de Lange 2002) How these 
components contribute to telomere functional capping is of relevance to our discussions of 
the therapeutic application of functional telomere manipulation in cancer and to assays of 
telomere dysfunction. Regarding the first of these, clearly all normal human cell 
chromosomes have telomeres and telomere componenets which are normal for that cell 
type. This means that targeting a telomere binding proteins with capping maintenance 
function might risk losing the specificity offered by the telomerase targeting strategy. 
Where telomere function assays are concerned, recent evidence has shown the existence of 
a novel telomere cohesion molecule which is cleaved by tankyrase 1. (Dynek and Smith 
2004) This acts in the normal cell during mitosis to maintain apposition of the telomere 
and is cleaved in early anaphase to allow separation of daughter chromosomes. Should this 
molecule play a role in cancer cell telomere maintenance then this might at least affect 
anaphase bridging and hence cellular viability and certainly this novel protein merits 
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further investigation in the cancer cell. In the context of telomerase inhibitor therapy, 
quantifiable indices of telomere dysfunction are necessary in order to assess the 
effectiveness of any given agent. The anaphase bridge index is such an assay, but 
necessarily requires enough mitotic figures visible in any given tumour section to allow 
quantification. Clearly telomere dysfunction will occur in other cell cycle phases and 
methods of detecting this would be an improvement on the current situation. Recent reports 
have described DNA damage foci at dysfunctional telomeres created via inhibition of 
TRF2. These are associated with response factors such as 53BP1, 'y-H2AX, Rad 17, ATM 
and Mrell. These have been termed Telomere Dysfunction-Induced Foci (TIF) and 
provide the needed means of evaluation of telomere status in cells suspected of harbouring 
telomere dysfunction. (Takai, Smogorzewska et al. 2003) This method could also be used 
to corroborate our finding of a non-linear correlation of ABI with radiation survival. 
8.2.3. Agents for teiomerase Inhibition. 
While a variety of approaches has been shown to effect inhibition of the telomerase 
enzyme complex, very few small molecule agents suitable for oral administration have 
been described. The most novel is BJBR1532 which has shown promise but may be less 
effective than originally thought. (Barma, Elayadi et at. 2003) Experiments using this agent 
at higher concentrations in leukaemia cells have produced new information which is of 
relevance to consideration of how telomerase inhibition might affect the cancer cell. Dose 
dependant cytotoxitiy was demonstrated in AML and CLL culture assays but not in normal 
CD34(+) cells. Importantly, cell death did not depend on telomerase catalytic activity, but 
rather a time dependent telomere erosion effect was seen, cell death being delayed with 
longer telomeres and associated with loss of TRF2 and p53 phosphorylation. Thus there 
seemed to be a direct structural damage to the individual telomeres rather than telomerase 
suppressed telomere shortening, hinting at a loss of some maintenance function of the 
telomerase enzyme complex at the telomere. (El-Daly, Kull et al. 2004) 
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In the experiments in chapter 4 we successfully affected telomere function by telomerase 
inhibition using AZT; one of a number of small molecule reverse transcriptase inhibitor 
with good bioavailability and well established pharmacological parameters. 
Notably, in the context of HIV disease, Kaposis sarcoma is a frequent AIDS related 
malignancy which is particularly radioresponsive in the context of antiretroviral therapy. 
An appealing aspect of these experiments is the effectiveness of AZT which is an agent 
which is already in clinical practice. In these experiments doses of AZT were close to the 
plasma concentration of drug aimed for in HIV therapy. AZT has been shown to act by 
competitive inhibition binding to the active site of reverse transcriptase enzymes. It also 
may be incorporated into growing DNA chains causing either premature chain termination 
or a mutated telomere which cannot functionally cap. Certainly the short time course 
(seven days) of our experiments in BICR6 would not allow simple replicative telomere 
attrition to account for the reduced telomere function and radiosensitivity observed. 
Incorporation of mutant telomeric DNA has been shown to be an effective uncapping 
strategy (Kim, Rivera et al. 2001; Lin, Smith et al. 2004) and a synergistic effect was seen 
when this was combined with expression of hairpin short-interfering RNA against hTERC 
RNA. (Li, Rosenberg et al. 2004) 
Current estimates for new drug development approximate 15 years in trials and a cost of 
around $500 million. (NCI 2002) If a drug with fully understood pharmacokinetic and 
pharmacodynamic properties is effective in the context of targeted therapy then clearly 
there will be a substantial reduction in time to clinical trials. Thus while targeted therapy 
addresses the very fundamental specific differences of the cancer cell at the genomic level, 
agents to produce effect need not be entirely novel and complex in nature. 
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8.2.4. Radiosensitisation of malignant cells. 
Ionising radiation has proved to be an effective anticancer therapy in the context of 
SCCHN. Interestingly, the mode of radiation induced cell death and the true basis of the 
increased radiosensitivity of the malignant versus the normal keratinocyte remains obscure. 
There is substantial toxicity with standard therapies and many patients require hospital 
admission for supportive therapy during the course of standard schedules. There is also a 
mortality rate in patients undergoing radiotherapy. Radiation sensitivity also varies both 
between and within tumour types. 
Both of these factors have driven the search for radiosensitising agents which might 
enhance therapeutic effectiveness and limit toxicity to normal tissues. Over time two main 
classes of drugs have emerged; halogenated pyrimidines and hypoxic cell sensitisers. 
These are now discussed in turn. 
Halogenated pyrimidines are incorporated into the growing DNA strand in place of the 
normal thymidine precursor. These molecules have a halogen (chlorine, bromine or iodine) 
incorporated instead of the methyl group. The theoretical basis upon which experiments 
with these agents was based is that these agents are incorporated to a greater extent in to 
the DNA in malignant tissue due to faster cell cycle time in the tumour population versus 
normal tissue. The DNA strand is then thought to be more susceptible to DSBs induced by 
ionising radiation and hence radiosensitise the tumour. Importantly, these substances were 
found to be effective only if they were incorporated into DNA over successive generations, 
thus increasing the amount of analogue included and hence maximally weakening the 
DNA strand. This contrasts with the early effect of AZT shown in our experiments. The 
effectiveness of such drugs (bromodeoxyuridine and iododeoxyuridine) was shown both in 
vitro and in vivo and shown to be similar for both agents with x-rays. (Mitchell, Morstyn et 
al. 1984) Initial trials in head and neck cancer patients proved however to have 
unacceptable levels of normal tissue damage. Some reports of use of these agents in other 
cancers have proved more promising (e. g. high grade gliomas which comprise rapidly 
growing tumour tissue with very slowly growing, or non-growing surrounding tissue) 
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(Sullivan, Herscher et al. 1994) More recently, newer agents in this class of molecule have 
been investigated. Gemcitabine (2'2'-difluoro-2'-deoxycytidine) is another pyrimidine 
analogue which has shown promise in a number of preclinical models including head and 
neck cancer. (Shewach and Lawrence 1996; Mason, Milas et al. 1999; Robinson and 
Shewach 2001; Sangar, Cowan et al. 2004) (Fields, Eisbruch et al. 2000) Importantly, 
incorporation of the analogue into cellular DNA seems to depend on a high growth fraction 
and labelling index. (Begg, Haustermans et al. 1999) It may be therefore that this approach 
would be more helpful if targeted to such tumours. 
Hypoxic cell sensitisation has been attempted using both hyperbaric oxygen and hypoxic 
radiosensitising agents. Increasing oxygen tension within hypoxic tumour tissue facilitates 
the production of free radicals which produce indirect DNA damage (estimated to 
comprise approximately 70% of total X-Ray and -t-Ray ionising radiation induced DNA 
damage). 
The possible benefit of hyperbaric oxygen therapy in improving tumour oxygenation and 
hence radiation cell kill was first investigated in the middle of the last century by 
Churchill-Davidson. (Churchill-Davidson, Sanger et al. 1955) The clinical trials which 
followed involved small numbers of patients and generally were hampered by the logistics 
of use of the hyperbaric chamber. As a consequence, unconventional fractionation regimes 
tended to be employed (fewer larger fractions). Overall, hyperbaric radiotherapy was 
shown to be superior to radiotherapy in air, producing a 6.6% improvement in local 
control. (Overgaard 1995) The use of this therapy has however now diminished markedly 
with some authors suggesting increased morbidity as a factor in this. (Overgaard 1995) 
Enhancing oxygen delivery to the tissues generally is facilitated by an appropriate 
circulating haemoglobin (Hb) concentration. This has been shown to be of significance in 
the context of SCCHN (Overgaard, Hansen et al. 1989), where local control is favoured by 
higher Hb levels. This data is not straightforward to interpret as patients with aggressive, 
rapidly advancing disease which responds poorly to any treatment modality are most likely 
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to also be anaemic as part of their systemic disease process. (Dische 1991) Further, the 
immunosuppressive effect of red cell transfusion producing increased recurrence rates 
must be considered. Trials using erythropoietin to enhance haemoglobin with radiotherapy 
in SCCHN patients have proved disappointing. (Henke, Laszig et al. 2003) 
Hypoxic cell radiosensitisers are chemical agents which are aimed to mimic oxygen in 
sensitising tumour cells. Importantly, such agents require to be highly lipid and water 
soluble and not be metabolised rapidly by the cell. These features will therefore allow 
continued diffusion through cancer tissue to reach those cells most distant from the 
capillary bed, which are normally relatively radioprotected by their hypoxic state. The 
nitroimidazoles are a group of related compounds which have been extensively 
investigated in this regard. The first to be analysed was metronidazole, an antibiotic agent 
active against anaerobic organisms. In order to effectively radiosensitise, ten-fold higher 
doses were required to be used and induced severe nausea and vomiting (Urtasun, Band et 
al. 1976) Misonidazole was used widely in trials, but doses used clinically were limited by 
peripheral neuropathy which extended to central nervous system involvement if therapy 
was not stopped. (Saunders, Dische et al. 1978) Etanidazole, pimonidazole and nimorazole 
were the next generation of nitroimidazoles to be examined. Etanidazole showed no 
advantage in two large head and neck trials carried out, one in Europe and one in the USA. 
(Chassagne, Charreau et al. 1992; Lee, Cosmatos et al. 1995) Subsequent studies in early 
disease have confirmed this outcome. (Eschwege, Sancho-Garnier et al. 1997) 
Pimonidazole in fact showed adverse outcome in the treatment arm of one study, thought 
to be attributable to the vasoconstrictive effect of the compound actually exacerbating 
radioresistance by further increasing hypoxia within tumour tissue. (Dische, Bennett et al. 
1989) Significantly, nimorazole was shown to confer a therapeutic advantage in a Danish 
study. (Overgaard, Sand Hansen et al. 1991) This effect was only seen in subgroup 
analysis, and was restricted to supraglottic and pharyngeal tumours only. A further finding 
from this research was that Hb level also made a significant difference in both control and 
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nimorazole treated groups. (Overgaard, Sand Hansen et al. 1991) A further randomised, 
double-blind trial from the same group has confirmed this finding, focusing in this study 
on supraglottic and pharyngeal SCCHN only. Here the nimorazole treated group had 49% 
local control versus 33% in the control group. (Overgaard, Hansen et al. 1998) In 
summary, the nitroimidazoles have been shown to produce an effect which is only modest 
and only in certain cancer subtypes. 
8.2.5. Targeted radiosensitisation. 
While the radiosensitisation principal aims to be selective for tumour cells, this specificity 
of action will be most effective if targeted at pathways and molecules specific to the 
tumour cell. Some recent preclinical work in radioresistant tumour models has targeted 
tumour angiogenesis. In both glioblastoma multiforme and malignant melanoma tumours, 
anti-VEGF2 antibodies have been shown to modify tumour vasculature and reverse 
radioresistance. (Geng, Donnelly et at. 2001) This is an interesting outcome, since reduced 
vascularity and resulting cellular hypoxia could be expected to reduce radiosensitivity, but 
in fact the opposite was observed. 
8.2.6. Telomerase inhibition and radiosensitisation; 
In the telomerase inhibition experiments in this work reduction of telomerase activity had 
three main effects in the malignant cells studied. Cloning efficiency was reduced in 
keeping with the findings of other authors (Blasco 2002). This has been shown to be a far 
more marked effect in cancer cells versus normal cells. (Murakami, Nagai et al. 1999) 
Secondly telomere function was reduced and this was accompanied by a third effect; 
radiosensitisation. The focus of this work was to assess the effect of changing telomere 
function on radiation survival. The means by which this observed sensitisation is occurring 
is intriguing and central to considerations of how any novel agent might act and therefore 
be discovered. 
Work by the Weinberg group described the post senescent telomere as having an eroded 
3'-single stranded end. (Stewart, Ben-Porath et al. 2003) It is possible and has been 
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suggested that in this circumstance the shortened telomere relies on the telomerase enzyme 
for capping, in a fashion distinct from the maintenance of repeats. (Blackburn 2001) 
Certainly, AZT is rapidly effective in producing telomere dysfunction in BICR 6, 
suggesting an effect distinct from telomere erosion accompanying cell division which 
would take some time. This rapid onset telomere dysfunction may be simply producing 
failure to bind signalling or assessing gene products which are then more freely available 
to signal cell damage and induce cell death. Perhaps the most appealing answer currently 
offered by experimental evidence for the radiosensitising effect of impaired telomere 
function with telomerase inhibition is that described by Latre et al where uncapping of the 
short telomere simply allows inappropriate chromosomal fusion and hence loss of cellular 
viability. (Latre, Tusell et al. 2003) 
A different and perhaps contributing explanation might be that the induced telomere 
dysfunction simply causes cell cycle arrest in mitosis by anaphase bridging. This is a 
particularly radiosensitive cell state regardless of other parameters. This type of cell cycle 
synchronisation effect has been shown to occur using docetaxel in colon cancer cells where 
a G2/M arrest was noted. (Dunne, Mothersill et al. 2004) Intriguingly taxanes like 
docetaxel and paclitaxel have been used experimentally and shown to target telomeres for 
degradation and so could conceivably be radiosensitising, at least in part, by induction of 
telomere dysfunction. (Mo, Gan et al. 2003) The addition of docetaxel to standard 
chemoradiation for SCCHN has also resulted in increased tumour response rates in clinical 
trials currently underway. (EORTC 2004) Assessment of telomere function in cancer cells 
in this context could certainly yield valuable information. 
Studies using BIBR 1532 have shown a progressive telomere shortening resulting 
ultimately in proliferation arrest with hallmarks of senescence (Damm, Hemmann et al. 
2001) and cell death. (El-Daly, Kull et al. 2004) Notably in leukaemia studies, telomere 
length was significant in predicting time to cell death which was not dependent on 
telomerase catalytic activity levels. Work in telomerase knockout mice showed that 
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telomere shortening after successive generations of progeny produced radiosensitisation in 
the normal mouse cell. (Goytisolo, Samper et al. 2000; Wong, Chang et al. 2000) 
Assessing the effect of BIBR1532 on radiation survival might therefore help in dissecting 
whether induced telomere dysfunction per se or telomere length reduction is the more 
significant change. Again, however, although the murine model may provide some insight 
and give direction for future research, any effect in human cancer could only be evaluated 
in human cancer cell systems and ultimately in clinical trials. 
BICR6 is a SCCHN cell line with high levels of telomerase expression. Although this was 
successfully inhibited in our experiments, we were also able to demonstrate that with 
tumour progression to recurrence both in cell lines and in vivo specimens telomere function 
improved. This implies further upregulation of telomerase with clonal evolution in the 
cancer population. Clearly the inhibition of the telomerase enzyme complex will be most 
effectively achieved clinically where endogenous levels of expression are lower. Thus we 
would predict that telomerase inhibitor chemotherapy would be most effective in early 
disease, or even as a chemopreventive agent in the context of management of dysplastic 
epithelium. This may have relevance in clinical research with any novel antitelomerase 
therapeutic in early studies in patients with late stage disease, where a reduced 
effectiveness might be expected. 
The finding that SF4 correlated in a non-linear fashion with telomere function further 
corroborates that radioresponsiveness and telomere function may be linked. If borne out by 
further studies this could become a component of individualisation of therapy for cancer 
patients in the future, when telomerase inhibitor agents become available clinically 
8.4 Further Research plans 
In taking these research findings further, establishing the impact of AZT in other SCCHN 
lines would be a priority. We selected BICR6 as a cell line with typical p16, p53 and pRb 
status, with high endogenous telomerase expression and low level anaphase bridging. 
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Assessing the telomerase inhibition, telomere function and radiation survival effects on 
other SCCHN lines would further enhance our confidence in this therapeutic approach. 
Novel agents like BJBR1532 which have been shown to inhibit telomerase effectively 
would also be of relevance in experiments with malignant keratinocytes and might enhance 
our understanding of the radiosensitisation mechanism. 
Experiments in nude mice with subcutaneous SCCHN xenografts could provide 
comparison of control animals with those fed AZT in an in vivo animal model. Tumour 
responsiveness would be assessed and histologic assessment of ABI and TIF assays would 
provide data regarding induced telomere dysfunction. The pharmacologic properties of 
AZT are already well established and so should the above research provide further data 
supporting the telomerase inhibition radiosensitisation hypothesis then progress to clinical 
trials could be rapid. 
Current accepted management of SCCHN involves surgery and radiotherapy, implemented 
according to clinical criteria. All patients who have unfavourable clinical parameters after 
primary surgery will progress to external beam teletherapy. This affords us an excellent 
opportunity to assess the impact of a telomerase inhibitor agent in this population. A 
randomised, doubleblinded prospective trial of telomerase inhibitor (perhaps AZT) versus 
placebo could run within the existing treatment infrastructure. This approach would be 
immediately selecting out patients in the poorest prognosis post surgery group, who are 
most likely to develop recurrent disease. This means that any reduction in recurrence 
would be best demonstrated in these patients and that correspondingly the best clinical 
impact would be seen here. Further, most patients who will have recurrence would be 
expected to have this relatively soon in disease course (approximately 85% within 2 years 
of primary therapy) and so initial survival data differences would be accumulated relatively 
quickly. Adopting this strategy would also mean that the telomerase inhibitor agent would 
be administered perhaps only during the six weeks of radiotherapy. Therefore should an 
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agent like AZT be used drug toxicity would be expected to be lower than in patients on 
long term therapy (e. g. in HIV disease). 
8.5 Conclusion. 
We are now in the dawn of the era of truly targeted cancer therapy based on our 
understanding of novel molecular targets. In sight of these targets, we now require the 
"magic bullets" first described by Ehrlich in the context of sepsis. Our advanced 
understanding means that we realise that rather than bullets, we require missiles with both 
a delivery system and the anticancer payload. Novel agents like BIBR1532 show early 
promise and will surely be followed by others. Importantly, scrutiny of mechanism may 
allow the use of agents already employed in other therapeutic contexts and AZT is a good 
example of this. 
The telomere and its maintenance by telomerase are a good example of an issue in human 
medicine which has been described some time ago and has its full therapeutic potential 
realised many years after first description. In the 40 years since Barbara McClintock and 
Leonard Hayflick first published on the subject there has been a lull followed by a build to 
a worldwide momentum behind this therapeutic approach. (Mc 1951; Hayflick 1961) 
There will surely be developments in this field in the near future. In the face of a cancer 
which is relatively easy to diagnose and monitor, SCCHN remains stubbornly resistent in 
terms of prognosis. The need for new targeted therapy to improve outcome with minimal 
toxicity in this disease is clear. The West of Scotland is a world-wide disease focus for 
SCCHN and so the need here is great. The corollary of this is that further laboratory 
investigation followed by well designed and run clinical trials will be facilitated by the 
Scottish population disease burden and positive outcomes can have the maximum benefit 
in these patients. Telomerase represents one of the most promising cancer molecular 
targets under study today. Further lab investigation must be followed promptly by 
James Anthony McCaul, 2004 Chapter 8,170 
translational research in order to maximise its potential for our cancer patients in the 
shortest possible timeframe. 
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2"d European Conference on Head and Neck Cancer; Lille 2003 
Golden Award for Best Research Poster; Telomerase Inhibition with 
AZT radiosensitises head and neck cancer cells 
The search for new and more specific cancer therapies continues. Due to the end 
replication problem, telomeres at the chromosome ends shorten with each replication of the 
cell. The immortalisation of human cancer cells requires maintenance of these telomeres 
through many rounds of replication. In more than 90% of all human tumours this is 
achieved by the upregulation of the telomerase enzyme; a RNA dependent reverse 
transcriptase. In epithelial cancers, including squamous carcinoma of the head and neck, 
the percentage of tumours utilising this mechanism may be even higher. This distinction 
between normal tissue and malignant cells represents an attractive target for new, more 
specific anticancer therapies. 
The telomere has many functions and many associated proteins. These include proteins 
involved in repair of DNA double strand breaks (DSB). The DSB is the lethal cellular 
injury produced by therapeutic ionising radiation. Telomerase inhibition, producing 
telomere shortening and/ or dysfunction may therefore affect the radiosensitivity of cancer 
cells 
Here we describe experiments where we have increased telomerase levels in cancer cell 
lines derived from in vivo human squamous cancers by stable transfection of the hTERT 
gene. In cells with low endogenous telomerase this intervention produced radioprotection. 
We further describe experimental data from work using the reverse transcriptase inhibitor 
AZT (3'-azido-deoxythymidine) to inhibit the telomerase enzyme in human oral squamous 
carcinoma cells. Levels of telomerase suppression achieved (assayed using the TRAP PCR 
method) and corresponding SF2 (surviving fraction after two Grays of radiation) are 
discussed. 
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p53 codon 72 polymorphism, telomere function and radiation 
survival in SCCHN lines 
J. A. McCaul', E. Parkinson2 
1West of Scotland Maxillofacial Service, Glasgow United Kingdom; 2Beatson 
Institute for Cancer Research, Glasgow United Kingdom 
Introduction 
p53 is the most widely mutated tumour suppressor gene in human cancer. An 
important polymorphism occurs in exon four at codon 72 which may be either an 
arginine (Arg 72) or praline (Pro 72) residue. A gradient exists within the human 
population, with the arginine variant becoming more prevalent with distance from 
the equator. This is thought to be linked to the ability of the Arg 72 variant to 
induce apoptosis in response UV induced DNA damage. In human cancer the 
arginine form of the protein is selected for and may in fact, when mutated, act as 
an oncogene(s), by interfering with the tumour suppressive effects of both residual 
wild type p53 and other p53 family members (p63 and p73). Recent evidence 
suggests that cancers with mutated p53 Arg 72 have reduced response rates to 
chemotherapy, seen as reduced rates of apoptotic cell death. We aimed to assess 
any effect of Arg72 mutated p53 on radioresistance. 
We have shown previously that manipulation of the telomerase enzyme, which is 
functionally specific to cancer cells, results in altered radiation survival in SCCHN. 
The anaphase bridge index (ABI) provides a functional assessment of the 
telomeres, which depend on telomerase for maintenance in cancer cells. In this 
study we analysed all SCCHN lines for telomere function in order to assess for 
correlation with radiation survival. 
Methods 
We examined the codon 72 status of a group of 16 in vivo derived SCCHN cell 
lines by sequencing p53 exon four in genomic DNA harvested from growing 
cultures. The influence of this status on radiation survival was assessed after 2Gy 
and 4Gy of radiation delivered in an Alcyon II 60Co radiation source. Cells were 
replated and cultured and cloning efficiency was calculated. All experiments were 
repeated in triplicate. 
Further information on the correlation of telomere function with radiation survival 
was investigated by assessment of anaphase bridge indices (ABI) for each cell 
line. 
Results 
An excess of Arg 72 polymorphisms was found in the mutated p53 in this series. 
No significant differences in radiation survival between Arg72 and Pro72 p53 
mutations could be demonstrated. Telomere function analysed together with 
radiation survival assess for correlation showed no link at 2Gy. However the 4Gy 
survival fraction for SCCHN was shown to correlate with the level of telomere 
dysfunction (p<0.001, R square =0.82). This non-linear correlation is given by the 
model ABI = 5.107/SF4. 
Conclusions 
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The Arg72 polymorphism is more prevalent in SCCHN derived from Scottish 
patients, in keeping with other latitude based studies. There was no demonstrable 
radioresistant effect of gain of function p53 mutation for either polymorphism. 
We have shown a direct correlation between telomere function in SCCHN and 
radiation survival for these tumours. ABI may therefore be a useful tool firstly to 
predict the effectiveness of radiotherapy for any given tumour and also to predict 
any enhance radiotherapy effect produced by a telomerase inhibitor agent. 
6thlntHN 2004 131000 
Telomerase Inhibition with AZT radiosensitises head and neck 
cancer cells 
J. A. McCaull, E. Parkinson2 
West of Scotland Maxillofacial Service, Glasgow United Kingdom; 2Beatson 
Institute for Cancer Research, Glasgow United Kingdom. 
Introduction. 
Telomerase is a new, potentially highly selective cancer therapeutic target. 
Telomeres at the chromosome ends shorten with cell replication. The 
immortalisation of human cancer cells requires maintenance of these telomeres 
through many rounds of replication. In more than 90% of all human tumours this is 
achieved by the upregulation of the telomerase enzyme; a RNA dependent 
reverse transcriptase. In epithelial cancers, including squamous carcinoma of the 
head and neck (SCCHN), the percentage of tumours utilising this mechanism may 
be even higher. This distinction between normal and malignant cells represents an 
attractive target for new, more specific anticancer therapies. 
The telomere has many functions and associated proteins including those involved 
in repair of DNA double strand breaks (DSB). The DSB is the lethal cellular injury 
produced by ionising radiation. 
To investigate whether telomerase inhibition, producing telomere shortening and/ 
or dysfunction affects the radiosensitivity of cancer cells we increased telomerase 
levels in cancer cell lines derived from in vivo human squamous cancers by stable 
transfection of the hTERT gene and assessed radiation survival. We further 
describe experimental data from work using the reverse transcriptase inhibitor AZT 
(3'-azido-deoxythymidine) to inhibit the telomerase enzyme in human oral 
squamous carcinoma cells. 
Methods. 
SCCHN cells were stably transfected with hTERT using phoenixA retrovirus 
carrying the pBabepuro plasmid with an hTERT construct inserted. Thus large 
increases in cellular level telomerase expression were produced. Cells derived 
from tumours with low endogenous telomerase expression (BICR 7) were 
compared with those from tumours with high telomerase expression (BICR 6). 
Both empty vector treated cells and hTERT expressing cells were then irradiated. 
Survival curves were calculated by replating and culturing colonies and comparing 
irradiated with non-irradiated cells. As controls we assessed non malignant human 
cells (HFFs) and also the rare ALT cell line GM847. These latter cells are immortal 
fibroblasts which do not use telomerase. These controls underwent the same 
genetic manipulations. 
The effect of telomerase inhibition was then assayed by culturing wild type tumour 
cells with high telomerase expression (BICR 6) for seven days in medium 
containing the small molecule reverse transcriptase inhibitor 3'azido-, 3'deoxy- 
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thymidine (AZT) in a previously calculated dose range. The PCR based telomere 
repeat amplification protocol (TRAP) assay was used to measure telomerase 
inhibition. These were irradiated with 2Gy of ionising radiation, recultured and 
survivals curves calculated. 
As controls we used the same tumour cells transfected with hTERT in which AZT 
would be predicted not to be capable of producing telomerase inhibition and also 
GM847 ALT cells. 
Results 
In cells with low endogenous telomerase increasing expression produced 
statistically significant increases in radiation survival. Where telomerase inhibition 
was achieved with AZT (assayed using the TRAP PCR method) corresponding 
SF2 (surviving fraction after two Grays of radiation) was reduced. 
Conclusions 
Manipulating telomerase expression cell lines affects radiation survival specifically 
in in vivo derived SCCHN. AZT can effectively inhibit telomerase in these cells. 
These data provide proof of concept for the therapeutic potential of telomerase 
inhibition as a targeted strategy in SCCHN management. 
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Surgeons Conference, Killarney, Ireland, 2002 
Abstract accepted for presentation 
Telomerase Inhibition and the Radiosensitisation of Head and Neck Cancer 
McCaul J A, Parkinson, E. K. 
Chromosome integrity depends on the function of telomeres at the chromosome ends. 
These repeats of DNA (TTAGGG)n and associated proteins shorten with cell division until 
the cell cannot replicate. The germ line avoids this with telomerase, which maintains the 
telomere. Telomerase is not active in normal cells, but tumours must maintain telomere 
length and function and do this in most cases by reactivating telomerase. Telomerase 
inhibition shortens telomeres and causes apoptosis. Furthermore, as tumour cells have 
short telomeres, they have increased susceptibility over normal cells. Telomerase is 
therefore an attractive, highly selective target. The telomere also functions in DNA double 
strand break repair and dysfunction provokes radio-sensitivity in mice. Thus inhibiting 
telomerase may enhance the effectiveness of radiotherapy. 
Two cancer cell lines derived from oral cancers with functional (BICR6) and dysfunctional 
(BICR7) telomeres were selected for study. Each had the hTERT gene inserted to increase 
telomerase expression. In BICR6 where high levels of telomerase are expressed 
constitutively there is little evidence of telomere dysfunction. Overexpression of 
telomerase had no survival effect. However BICR7 expresses low levels of telomerase and 
displays telomere dysfunction. Here target cells became radioresistant . 
Experiments radiosensitising head and neck carcinoma by inhibiting telomerase are in 
progress. 
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British Association of Oral and Maxillofacial Surgeons 
Conference, Glasgow, 2003 
Abstract accepted for presentation. 
Due to the end replication problem, telomeres at the chromosome ends shorten with each 
replication of the cell. Immortalisation of human cancer cells requires maintenance of 
telomeres through many rounds of replication. In more than 90% of all human tumours this 
is achieved by upregulation of telomerase; a RNA dependent reverse transcriptase. In 
epithelial cancers, including squamous carcinoma of the head and neck, the percentage of 
tumours utilising this mechanism may be even higher. This distinction between normal 
tissue and malignant cells represents an attractive target for new, more specific anticancer 
therapies. 
The telomere has many functions and associated proteins. These include proteins involved 
in repair of DNA double strand breaks (DSB). The DSB is the lethal cellular injury 
produced by ionising radiation. Telomerase inhibition, producing telomere shortening and/ 
or dysfunction may therefore radiosensitise cancer cells 
We describe experiments where we have increased telomerase levels in cancer cell lines 
derived from in vivo human squamous cancers by stable transfection of the hTERT gene. 
In cells with low endogenous telomerase this intervention produced radioprotection. We 
further describe experimental data where the reverse transcriptase inhibitor AZT (3'-azido- 
deoxythymidine) inhibited the telomerase enzyme in SCCHN cells. Levels of telomerase 
suppression achieved (assayed using the TRAP PCR method) and corresponding SF2 
(surviving fraction after two Grays of radiation) are discussed. 
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Scottish Oral and Maxillofacial Surgery Meeting Abstracts 
Prize for Best Research Paper; Crosshouse, Kilmarnock 2001. 
Telomerase inhibition and the future management of SCCHN. 
The telomerase enzyme complex represents a specific target for future cancer therapy. 
Correlative evidence suggests that the short dysfunctional telomere radiosensitises the cell. 
We investigated the role of telomerase in radiosensitivity in two SCCHN cell lines; BICR6 
and BICR7. Our data show that in the presence of poor telomere function, ectopic 
expression of telomerase radioprotects the cancer cell. This provides evidence for the role 
of the telomerase enzyme complex in radiation survival for SCCHN tumours. 
Prize for Best Research Paper; Perth 2003; P53 codon 72 
polymorphism and radiation survival in SCCHN lines. 
P53 is the most widely mutated tumour suppressor gene in human cancer. An important 
polymorphism occurs in exon four at codon 72 which may be either arginine or proline. In 
human cancer the arginine form of the protein is selected for and may in fact, when 
mutated, act as an oncogene. 
This study examines the codon 72 status of a group of in vivo derived SCCHN cell lines 
and assesses the influence of this status on radiation survival. 
T. C. White Prize Lecture. The Royal College of Physicians and 
Surgeons of Glasgow. Awarded February 2003 
Abstract for T. C. White Prize Lecture 
Telomerase Inhibition in Sauamous Carcinoma of the Head and Neck 
The overall five year survival rates for squamous Cancer of the Head and Neck have remained 
unchanged for 30 years. An exciting new therapeutic possibility is inhibition of the enzyme 
telomerase. This project examines the effectiveness of telomerase inhibition on tumour growth and 
in particular targets the radiosensitivity of this tumour type when telomerase is inhibited and the 
chromosome telomeres shorten. 
Telomeres are structures forming caps at the ends of eukaryotic chromosomes which maintain their 
integrity. These are comprised of repeats of DNA (TTAGGG)n and associated proteins. Because of 
the end replication problem, the telomere is known to shorten with every cell division. Eventually, 
the telomere is so short that the cell can no longer replicate. In germ line cells this problem is 
avoided by the enzyme telomerase which maintains the telomere repeats and therefore cell division 
can continue. Telomerase is not active in normal somatic cells, which can only carry out a finite 
number of cell divisions. Human tumours, including squamous cell carcinoma of the head and neck 
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(SCC-HN), need to maintain telomere length and function. They do this in most cases (85-90%) by 
reactivating telomerase. Inhibiting telomerase has been shown to lead to apoptosis. Furthermore, 
as most tumour cells have very short telomeres, they are more likely to succumb to telomerase 
inhibition than normal cells. Telomerase is therefore an attractive, potential, highly selective anti- 
cancer target. The telomere also has a role in the repair of DNA double strand breaks and telomere 
dysfunction provokes radio-sensitivity in mice. Thus inhibiting telomerase may produce enhanced 
effectiveness of radiotherapy for cancer by selectively radiosensitising telomerase positive cancer 
cells. 
Cells derived from human oral squamous carcinomas are being used to investigate this hypothesis. 
The existence of dicentric chromosomes and/ or anaphase bridges are a good correlate of telomere 
dysfunction and two cell lines with functional (BICR6) and dysfunctional (BICR7) telomeres were 
selected for study. In BICR6, where the tumour constitutively expresses high levels of telomerase 
already and shows little evidence of telomere dysfunction there was no effect on radiosensitivity. 
However BICR7 expresses low levels of telomerase and displays telomere dysfunction and in this 
case, the overexpression of telomerase rendered the target cells radioresistant. 
Experiments designed to radiosensitise head and neck carcinoma by inhibiting telomerase are in 
progress. Additionally, tumours specimens are being collected from patients undergoing surgery 
for oral cancer in order to fully assess the telomere lengths and telomerase levels in these cancers in 
the Scottish population. 
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j if J, Jý il NEW TELOMERASE, TELOMERE LENGTHS AND RADIOSENSITISATION WITH TELOMERASE INHIBITION IN HEAD AND NECK CANCER 
Researc hers 
Dr ;A McCail, Dr EK Par<, nson. 
Aim 
1. To determine whether mar! p. lation of the 
to or-erase enzyme i scuamo, is cell carciroma of 
the head anc reck (SCCHN ) affects raciosensitivity 
of Is cancer type. 
2. To assess the effect of different forms of the 
mutated o53 prote-i on racicresponsiveress of 
SCCHN. 
Project Outline/Methodology 
This was a lab-basec irvestigaticn involving the 
cult, re of SCCHF derved cells in a cell culture 
system which -eprccuces closely the corditons seen 
in patients. The telomerase erzyme 's a very new 
target in cancer anc is a protein which mairtains the 
ch-omoscme enocaps. These are called the 
telorreres. Using cell Lnes with cefined levels of 
te, orrerase protein and known 'evels of telorrere 
dysrjncticn, we were able to mar, plate telomerase 
5y both transfer- ns human genes into cells and by 
. is ng small molcile dr, igs. Tb s allowed us to assess the response to icnis ng rac aticn delivered to the 
carter cells na machire used for carter treatment 
anc comoare radiation surd, val. As controls we 
assessed cancer cells without the adced genes, 
nermai cells, and cells immortalised by a rare 
mechanism termec ALT. These last cells are immortal 
but do not .. se the telornerase enzyme. We aimec o 
assess the usefLlress of sta ping w th antibocies n 
estmatng telcrnerase levels in SCCHN. We 
nvest gated the fLnction of the telcmeres in primary 
ant recurrent SCCHN, to : )rev de evidence or 
Jpreg. lation of telcrnerase w, 111 tLmoJr progression 
as th s mght infLerce the success of treatment in 
late stage cance-. Fu-ther we-K nckLdec the 
sequencing of mn., tated p53 jr a -iLrroer cý7 SCCHN 
fires 
Key Results 
We demonstrated clear radioprotectior produced by 
nc"eas rig telornerase levels jr carter cells with lcw 
levels of this oretein (P<0.0: ). Ti s effect was 
spec fic to cancer cells us ng telcmerase to maintain 
t'iei- mn~iortal ty, being absent n rorrral cells and n 
ALT cells. We then were able tc demonstrate that 
AZT, ar antiretroviral dGw defy jsed to treat HIV 
c sease co-lc nhib, t telornerase, oroduce cysfjrct on 
of the telomeres and erhance the effectiveness of 
raciation in prccuc, ng cell death (p<0.0: ). Our 
investigation of recurrent tJmours showec that with 
tumour progression telornere function improves. 
SCCHN lires derived from recurrent cancer were rot 
sigrifcantly more radioresistant. 
Conclusions 
Telomerase irhibiticn can be used to enhance the 
efectiveness of rad: otheraDy for SCCH'V. With more 
acvarced disease, teioroerase levels are IiKely 'c be 
highe- anc so ts potential theraDeAc benefit may 
be -ore diV`icA to ach eve. 
What does this study add to the field? 
Previous work has shown a co''-elation between 
telornere length and radioresistance n other carters. 
Ir lice, nhihiticn of telomerase aric the result nc 
snertened telomeres ever successive generations 
I'ave -leer shown to become racicsensitive. We have 
proviced the first evicence in ei aryotic malignant 
cells for the radiosersitis ng of hu-an cancer cells öy 
inhibiting telomerase. 
Implications for Practice or Policy 
Irh bition cF telomerase in patents wit -ieac and 
reck sgcamous carter may prey de Jse`ul 
therapejtic acvantage when combirec with 
radiotherapy. This effect car be orod, iced with AZT. 
This new strategy fits well with the current NHS 
treatment infrastructure already in place for these 
patents. This approach is also most li<ely to be 
e4'ective in early stage disease. 
Where to next? 
Clir: cal trials . js ng : his strategy will provice insight into 7cw effective : elomerase irh oition with radlat or 
will 5e jr enharcirg survival in SCCHN. Determining 
the effect in other tumour types will allow the likely 
eFfect of this strategy n ether cancer's to oe 
assessed. 
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Sojthern Gereral Hosp tal 
Govar Rcad 
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Chef Scientist Office, St Andrews House, Regent Road, Edinburgh, EH1 3DG Tel: 0131 244 2248 
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merase inhibition in head and neck cancer 
Telomerase inhibition and the future 
management of head-and-neck cancer 
James A McCaul. Katrina E Gordon. Louise J Clark. and E Kenneth Parkinson 
Telomeres are tandem repeats of DNA associated with 
specific proteins. These structures cap eukaryotic 
chromosomes and maintain the integrity of the 
chromosome ends. In the germline, tolomoros are 
maintained by the enzyme telomorase. but in normal 
somatic coils the enzyme's activity is low or undetectable. 
Human tumours. including squamous-cell carcinoma of 
the head and neck (SCCHN). need tolomeraso to maintain 
tolomere function: inhibition of the enzyme can lead to 
apoptosis. Furthermore. because most tumour cols have 
vary short tolomeres, they are more likely to succumb to 
tolomerasa inhibition than normal coils. Tolomoraso is 
therefore a potential selective anticancer target. The 
tolomere is also involved in the repair of DNA double 
strand breaks. and telomore dysfunction provokes 
radiosensitivity. In this review we consider whether 
manipulation of tolomere function may selectively 
sensitise SCCHN to radiotherapy and discuss the 
possible pitfalls. We also assess how some conventional 
treatments may affect the subsequent use of telomeraso 
inhibitors. 
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The overall 5-sear survival for squamous-sell car%ituma of 
the head and neck !u(. HN o has not . hanged during the 
past 20 years. I)espite advances in surgical management and 
radiation oncology, the ; -year survival proportion of 
45_50o remains static. ' A promising target for new 
approaches to cancer therapy has recently emerged, in the 
form of the enzyme tekm erase Possible strategies directed 
against trbmerase have been reviewed mans times " Here 
we focus on the recent developments in the field, in the 
context of ut, HN, because about 0'>i of these cancers 
show detectable telomerase activity ! figure Ii In 
particular. we discuss the Possible use of telumerase 
inhibitors to selectively radiosensitise HN cells and the 
possible limitations ofthisapproach We also review the use 
of angiogenesis inhibitors in cancer and the proposal that 
this new class of drugs might be used to c, ompkment 
telonwrase inhibitors 
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Trbmrres, lying at the ends of the linear DNA 
mok: uks, are subject to the end-replication probtern, " 
whereby the lagging strand of the molecule isincompletely 
replicated owing to removal of the last RNA primer 1 figure 
2'. " Telomrre sequence% may als., he lost by exoonu. kaw 
dit, Ystion" and oxidative damage, unless mes hanism+ are 
in place to counter this loss, the idonieres shrink with each 
cell division. In the germline, telomrre loss iscountered by 
the presence of telomer se, " which balances the loss by the 
direct addition of TTA(. ( t; repeats to the chromosome 
Telomeres and the end-replication problem 
Telom res consist of tandem repeats . ii the DNA sequence 
TTA(. (: (: and assrxiated proteins. they function to cap the 
ends of human chromosomes lapping prevents 
chromosomes from fusing together and stops their ends 
bring misinterpreted as I)NA double-strand breaks. - 
Teksnxres also act as repositories for DNA repair enzymes, 
and: an silence genes close to them' 
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end. " Trlomerase consists of at least two essential 
components, the RNA template PTERCi" and the iatah"tw 
subunit iT RTi. " There is now evidence that the final 
length of the tdomere is under very sophisticated control. 
In particular, in the germline. trlomrre length can he reset 
when animals ate : Wed from senescent somatic cells, but 
the mechanisms have vet to he defined " 
The telomere hypothesis of replicative 
senescence 
In the latter stages of human development, trbnxrase 
activity is completely repressed in most somatic cells" and 
doownregulated in haemopoieti: stern cells,, which nxans 
that trbnwre length is not adequately maintained 
throughout life. The ensuing telomerk attrition has been 
proposed is the basis of a cellular repli: ometer, which can 
'FE '-. ANC=-T _r,: )_I: gy VDI S Flai DQ I. KF: ' Yi r1.. 3r. tl aqn t rcy 
both count and remember the number of . ell divisions 
completed by a telomerase-deficient cell. " This idea is 
supported by the observations that telomeres, as assessed by 
the size of telomere repeat fragment lengths after 
restrütion-enzyme digestion of the CDNA, shorten both in 
vivo and in vitro w= that the replicative lifespan of human 
fibroblasts can be predicted on the basis of starting telomerc 
length: " and that telonwric attrition both in vivo and in 
vitro depends on cell division. " Most importantly, the 
correction of telomere dysfunction 1w the expression of the 
trlornerase catalytic subunit. TERT, can reconstitute 
telomerase activity" and extend the lifespan of human 
fibroblasts- without causing kar otvpic changes or features 
of transformation. ' Binh the cloning of the first essential 
trlumerase component, TERI" the creation of strains of 
telumerase-deficient mice TER(; -. -i that show telomeric 
attrition has become possible' Even though mice have 
much longer trlomer s than human being%. '° breeding of 
TF. RI: i- mice through four tu six generations leads to 
compromised proliferation and loss of viability of the 
termline and Ivmphoc ies, sterility, poor wound healing, 
and many features of human ageing' 
In human brings, a mutation in the product of the 
dvskeratosis <ungenita gene, d? ^skerin, leads to instability of 
the TER' transcript and a reduction in telornerase activity 
Fibroblasts from these individuals cannot he immortalised 
by the expression of the TERT gene because there is too 
little of the subunit to generate the required enzyme 
activity lhskeratosis congenua is characterised by early- 
onset anaemia and hone-marrow failure, resembling the 
disorders seen in telumzrase-null mice at later generations. 
Therefore, c lkctively, these studies support the notion that 
telumrric attrition prevents indefinite clonal proliferation 
in vivo 
Human cellular mortality and the role of 
telomeres 
Most somatic human cells, including the keratinxýies of 
squamous epithelium, are telomerase deficient and mortal 
in s"itns. In: ultured epithelial cells, replicative sene ne is 
thought to be controlled first by the accumulation of 
pit, "" mortality mechanism o or toi. MO is not directed 
b" tdlomere length, " but it seems to depend on the rate of 
oxidative damage, the cell type, and the culture 
environment, " Putative telomere-independent mechanisms 
of replicatise ageing reflect inadequate growth conditions. 
However, we emphasise that there is no direct evidence that 
oxidative damage drives the accumulation if p1i+°'4', or 
Ato, and the role of Mo as a checkpoint to the development 
of cancer in vivo has not been firmly established. After 
further divisions and a period of telomrro loss, these elk 
then encounter mortality mechanism IiMI; figure 30' Alo 
and X1l are biologically indistinguishable; " loth are cell- 
cycle arrest states and are referred to as replicative 
senescence. After disruption of the cell-cycle control 
Pathways and M1o and Al Ii by, for example. INA tumour 
viruses, the telonxres shorten still further, until one or 
more becomes dysfunctional At this time, as a consequence 
of trbnxric hisions, mans di: entrü chromosomes and 
ýN I 
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anaphase bridges form and result in much cell death. " 
This checkpoint on the pathway' to immortality is known as 
crisis or mortality mechanism 2! N12, figure 3l. " From the 
unstable cultures arise .e is that are generally telomerase 
positive, maintain their telomeres, and are immortal " 
However, less commonly, telomerase-ne ative cells survive 
crisis and become irnnxonal because they use a 
recombination-based telumere elongation mechanism 
known as ALT iahernative lengthening of telomereso. '° 
Although this mechanism has not to date been 
demonstrated in S. (. HN, its possible relevance to the 
successful treatment by teh, merase inhibitors is discussed 
heksw. The role of telonierase deficiency in human cellular 
mortality is shown by the findings that the ectopic 
expression of teksmerase can bypass both senescence' and 
crisis- in these models. 
Telomere function and the development of 
cancer 
The possibility of reconstituting teIomrrase in cultured 
human cells has enabled my stigators to create human 
tumour cells with a small number of de1nral genetic 
changes, which is not possible in the absence of 
telnnxrose. " Thus, these observations establish telomerase 
activation as an important event in the conversion of a 
normal human cell to a malignant cell. In the telonserase- 
null mouse, the development of squarnuus cancer elicited 
ý. J 
by chemical carcinogens" is strongly repressed, and the 
development of other cancers is reduced in nice 
additionally deficient in the adenomatous p s}+osis /uli 
! Apo and ! NK4A-: - tumour suppressor genes °" However, 
when short telumeres are combined with pi) deficiency, 
there is an increased tumour vieW" and tumours with 
a"togenetk katures iunbalanced transl cations, 
Rohertsunian translocatiuns, regional gains and losses 
reminiscent of the human tumours are observed" The 
generation of genetic instability by dysfunctional telomeres 
and the acceleration of.. an: er development are speculated 
to occur during a short period in which man)- human 
cancer cells will die as part of crisis. " Once trlomeres 
he: onse functional again, through the upregulation of 
telomerase, the genetic stability of the tumours is predicted 
no he restored. The concept that in human tumours the 
genetic instability generated dunng crisis contributes to the 
upregulation of telomerase is certainly plausible. The 
combination of short dysfunctional telonxres and pia 
mutation is likely to exist in the latter stages o( development 
4 many human . ancers, " and the inhibition of telunxrase 
may accelerate the development of subsets of tumours that 
can use ALT mechanisms to maintain telomeres. 
SCCHN immortality and the role of telomerase 
T'hr immortal phenotype can arise early in CHN 
progression' but generally is more common in the 
? }ý `A`: C_7 Cr, T>-1.4y 'I :IS Flay = 
-l'' 
rdq : ': n7ib_cry. ItrJrr_. I ._ _r 
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advanced stages of the disease. ' Almost all immortal 
S4 LHN. ells have dyshuwtiunal genes for pi n"r'", p; 3, and 
retinoic-acid-receptor P. "" these markers are associated 
with the bypass of lsII. The bypass of M2 is most likely 
achieved by the upregulation of telomerase, which is 
ubiquitous in A tHN lines, there are no reports of ALT 
pathway activation. " These characteristics are found in a 
large subset of . s_HN in siso: '"ý' and the size of this 
subset matches very closets' the proportion of SL. lHN 
tumours that are immortal in vitro. 
Nomtal basal squamous keratinoc tes have substantial 
telomerase activity demonstrable in vitro, ' but there is no 
evidence that the enzyme is functional. First, the telorneres 
of normal squamous epithelium from old people, " 
immortal S4 t. HN cells iunpublished,. and squamous-cell 
carcinomas in vivo" are much shorter than normal. Second, 
immortal st. t. HN lines have cvtogenetic changes, such as 
Robertsonian transkxations I }a . Ellington, unpublished i 
that result from the telomerie is skw of two chromosomes 
Iusualh" acrocentricsi. u. CHN . ell lines also have many 
chromosomal gains and kisses, which together with 
R. bertvmian transkscations, are consistent with the cells 
having passed through crisis-"" Finally, we have obtained 
direct evidence of the existence in vivo of post-NI I. pre-M2 
u r; HN cells iunpuhlishedi . (. (. HN cells with mutant 
p53, deleted INK4A. short telomeres, and low tebnwrase 
activity <an he detected in vitro. Such cells show features of 
crisis, including dicentric chromosomes and anaphase 
bridges The ect. s. ic expression of telomerase in these cells 
reduces numbers of dicentrw chromosomes and anaphase 
bridges and improves growth. Furthermore, some I(: t_HN 
tumours have high anaphase-bridge indices in s"ivo Taken 
together. our findings are consistent with the idea that 
Si (. HN cells reactivate telomerase after a king period of 
telomere shortening. 
The vor}, short telomeres of most u CHN compared 
with the normal tissues of the body should ensure that. after 
the inhibition of telomerase, the cancer cells will die before 
the normal cells are afkcted. 
Telomerase-based cancer therapies in SCCHN 
New are several ways in which telomeres and Ielonxrasr 
could theoretically be exploited in the treatment of human 
. oncer. First, when telomerase inhibition is achieved 
experimentally by various procedures. the phenotypic lag 
before death is always proportional to the starting telomere 
kngth. """' Inhibition of telomerase by antisense' or 
dominant-negative - telomrnse components. oliFo- 
nuckotides, " or unknown suppressor genes, " drives many 
turn. xus bark into M. crisis and . ruses them tu undergo 
apoptosis The same manipulations do not affect cells that 
maintain their telomeres by means of the ALT pathway. " 
Furthermore, the killing of tumour cells through telomerase 
inhibition does not require the genes for p53 or INK4A to be 
intact. ", which is important, given the frequency of the 
inactivation of these genes in human tun uas. Thaw studies 
show the usefulness of telomerase as an anticancer target. 
Thar are now reports of the first drugs that can achieve 
telomrrose inhibition. '''' Such drugs include reverse- 
transcriptase inhibitors, nucleoside analogues, 
isothiazolone derivatives, a rhudoxvanine, and a catechin 
component of green tea' A lusher class of agents are those 
that target C. quadruplex or tetraplexi structures rather 
than duplex I)NA' Although there is no evidence to 
support the existence of quadrupkx structures in 
mammalian telomeres, quadruplex structures are formed 
by the c: -strand overhang at the telomere in vitro. The aim 
of t: -quartet-interacting drugs is to hkkk the interaction 
between telomerase and its substrate. ' 
The drawback with most of these drugs is that they 
atkit the growth of telonterase-negative cells, " so they 
may influence biological processes other than telometase 
activity However, a new non-nucleosidic drug, designated 
RIRRI532, has recently been shown to inhibit tebmerase, 
elicit telomere reduction, and trigger cell-cycle arrest in a 
highly selective way, in several immortal human cancer cell 
lines. " At the same concentration, the drug did not affect 
telomerase-negative normal cells or immortal cells that use 
the ALT mechanism of teksmere maintenance. RIRR1532 
can be administered orally. It inhibits growth of human 
tumour xenografts in nude mice and represents the most 
promising antitelomerase agent discovered to date. 
Although cryptic damage, in the form of telonxrc 
reduction, may he sustained by normal telomerase-unitive 
cells, the available evidence suggests that on removal of 
telomerase inhibition, the telumeres return to their original 
length. ' This evidence suggests that normal cells mas" be 
able to reset their telomere lengths once antitelomerase 
therapy has been withdrawn. This idea is also supported hv 
the ability of senescent bovine cells to produce cloned 
animals with normal telomere lengths-' 
A second approach that has been used is to exploit the 
absence of TERT transcription in most normal human cells 
and to express pnsapoptotic wspases under the control of 
the active TERT promoter in cancer cells. With this 
approach, a substantial cancer-specific cell kill has been 
reported. - However, the presence of almost equivalent 
amounts of PERT transcript in the basal layers of normal 
squanxws epithelium and immortal keratirw: s"te lines' 
argues against the use of this approach in -(, (. HN. 
A further approach has been to incorporate 
oligonuckotides encoding dysfunctional telonxrase 
templates into cells" In this strategy, only cells with 
functional telomerase incorporate the mutant sequences 
into telomeres to render them dysfunctional and only the 
telomerase-expressing cells die. This idea may be usefully 
applied to S(, ( I-IN of the tebmerase in the basal layer of 
squanxous epithelium is dyshuxtiunali and has the 
added 
advantage of producing telomerase-dependent : ell death in 
cancer cells with long average telotnere repeat fragments. 
As with many gene-therapy approaches, these strategies 
depend on the development of suitable gene-delivery 
systems. 
Telomere dysfunction and radiosensitisation 
A role of trlonxrrs in : hrmosensitivity and radiosensitivity 
has lately emerged"" When telonterasr is inactivated in 
mice by the targeted disruption of the T[Rc: gene, the 
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trh. meres progressively shorten with each generation until a 
radiosensitivity syndrome is induced, leading to accelerated 
mortality on exposure to ionising radiatk"n'" These 
experiments showed that the radiosensitivit . was related to 
telontere d sfunrtion rather than the mere absence of 
telomerasr 1 figure 41. At the cellular level. crypt stem cells in 
the gastrointestinal tract and primary thymocytes in 
TER(.; - mice were shown to have increased rates of 
apoptosis. Furthermore, mouse embryonic fibroblasts had 
diminished clonugrnic survival. This cellular-level 
radiosensitivit' y correlates with the persistence of complex 
chromosomal aberrations and retarded [ANA repair 
kinetics, showing an intimate relation between intact, 
functioning telnmrres and the cellular and whsle- rganism 
response to ionising radiation 
( oytisulo and colleagues have also shown a correlation 
between tekomere length and radiosensitivitv"' They found 
that fifth-generation telomerase-deficient mice, which had 
telonxrcs 40% shorter than wild-type control animals, were 
hypersensitive to ionisint; radiation. The mice died of acute 
radiation poisoning in the gastrointestinal tract, I5"mphoid 
organs, and kidneys, and the telomerase-deficient animals 
showed greater chromosomal damage and higher numbers 
of apoptoth cells than the similarly irradiated control mice. 
All these findings suggest that telomerase-inhibitor 
chemotherapy, pr iu: ing shortened telorneres in cancer 
cells, should increase the radiosensitivity of the tumour 
selectively and therefore improve tumour kill. This 
proposition is very attractive, not least because this 
anticancer therapeutic strategy makes use of the already 
existing treatment infrastructure. Furthermore, it may 
allow use of lower doses of ionising radiation, thus 
achieving greater selective tumour kill with less severe side- 
effects of radiotherapy However, the finding that telomere 
dysfunction can elicit rapid ap, ptosis via a p5? -dependent 
pathway in nice" could present an obstacle to the 
radiosrnsitisatbn of u!. HN by telonxrase inhibition, 
sincevirtually all u. (. HN lines with high telotnerase activity 
have lost pi; function ° Encouragingly, the situation is 
dif 'rent in human cancer cell lines, where in mam" cases 
1»3 is unnecessary for apoptosis when trbmerase is 
inhibited. " Furthermore, the p53 status of St. t, HN cultures 
does not intluen: e their radiosensitivits" " However, the role 
of p53 in telumere-dysfunrtiun-related ph notyes clearly 
needs to he examined in S(, ( HN. 
Telomere dysfunction, chemotherapy, and the 
role of p53 
Recent evidence from work in on. ogene-transformed 
telomerase-deli lent mouse cells has shown that telomere 
dvsfun. tion rather than the lack of the telomerasr enzY"mr 
itself is the main determinant of sensitivity of tumours it. 
certain chenxvherapeuti< agents- Telomerasz-deficient 
transformed cells with short, dysfunctional telomeres were 
sensitised to killing by hugs inducing d xthk strand hteaks 
1duxorubkin, daunorulsicin, and dactinomvrim, but not 
drugs working through other mechanisms ocisplatin, 
etoposide, or Iluorourasilo. Sensitisation was associated 
with increased rhromosnnul fragmentation and fusion. 
Moreover, all the effects were reversed hr the 
reintroduction of telomerase. This evidence of specific 
sensitisation of tumour cells highlights one of the most 
attractive features of the telon erase and telomere target. 
However, the effects were somewhat muted in mouse cells 
without wild-type p53. The introduction of a hammerhead 
ribon"me into human breast tumour cells and an immortal 
breast cell line produced cleavage of TERT mRNA and 
attenuation of tdomerase activity. " resulting in sensitivity 
to doxoruhi: in. Furthermore, the introduction of 
telomerase into human fibroblasts reduced sensitivity to the 
same drug. " As in the first study, sensitivities lt) other 
cytotoxic drugs, such as cisplatin, were not affected, 
These studies suggest that in certain situations the 
combined use of chemotherapy and telomerase inhibition 
may he effective against u. CHN, but the role of p53 in 
telomere-drsfwxtion-mediated chemosrnsitisation needs 
to he investigated 
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ALT pathway and other mechanisms of 
resistance to tel om erase- based therapies 
tither mechanisms of maintaining the telomeres are known 
to exist, including one that depends on homologous 
r«ombinatkm, in both yeast' and mammals. - such cell 
lines are telomerase negative and have very heterogeneous 
telomere lengths. - However, we emphasise that human 
tumours and immortal tumour cell lines with katures of 
ALT are not common and represent only n_7° of the 
samples analysed to date. " Furthermore, there is no 
evidence that ALT is used to maintain untreated I, ((HN 
telorneres. " By contrast, Jysfun: tksnal DNA mismatch- 
repair pathways facilitate ALT in trwnwrase-srfkient yeast 
strains, and many human tumours that are resistant to 
various chemotherapy regimens lack efficient mismatch- 
repair pathways. ' These findings raise the possibility that 
' t. HN tur ours previously dehulked hr radiotherapy or 
chemotherapy may lack efficient mismatch-repair pathways 
and be predisposed to activating ALT after the 
administration of a telomerase inhibitor i figure 51 
There is, as set, no evidence at all to show that tumours 
debulked by radiotherapy or chemotherapy an a: th"ate 
ALT more easily; unfortunately, mismatch-repair pathways 
have not been extensively investigated in A-(. HN. 
However, the one published study did not find any 
significant selection for cells deficient in mismatch-repair 
pathways after : hemother3py. ' The possibility that 
deficiency in these pathways may assist telomere 
maintenance by ALT is a key issue in combined use of 
antitelomerase and conventional therapies. t. ombinatkm 
therapy is likely to he necessary to create telonxre 
dysfunction in the : sses of ýt CHN with longer stoning 
telomere lengths. The status of mismatch-repair pathways 
in u. CHN that have recurred after conventional therapy 
therefore needs to be examined before combination of 
telonserase inhibitors with such therapies . an be 
considered. 
Another possible means by which a tumour might be 
resistant to a telomerase inhibitor is by inactivating 
apoptosis mechanisms that act downstream of a critically 
short telomere. ' There is some evidence that this process 
occurs after the experimental inactivation of telomerase in 
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certain human cells, immortalised by adenm"irus, " but not 
so far in human : an: er : el Is "° Nevert hekss, we need to 
understand in more detail the mechanisms governing 
alkoptosis after tekonxre dr^sfunction and how this process 
kads to cell death during crisis 
Can telomerase inhibition increase the 
likelihood of second primary tumours? 
a«ond primary tumours remain 3 substantial cause of 
treatment failure in 't a: HN I As detailed above, there is 
now evidence that a combination of tebmrre and p53 
dvshtn<tion could contribute to the progression of 
i aneer. ""'- Ntanv p; 3-deficient clones exist at distant sites 
in the normal oral mucosa of patients with SC( HN, and 
these clones may contribute to cases of second primary 
tumours. " Whether the inhibition at tekomrrise over a Tong 
period increases the progression of second primary tumour, 
in tit. t. HN patients remains to he seen. 
Telomerase inhibitors in combination therapy 
In principle, any therapy. conventional or otherwise, 
resulting in large-wale tumour-sell death would require the 
tumour to regrow from a small number of cells. All such 
therapies would therefore be expected to be synergistic with 
telonterase inhibitors, because, to achieve a given tumour 
mass more divisions will occur and therefore teksmeres will 
be much shorter 
A specific approach in the long term might he to 
combine telornerase inhibitors with new drugs that do not 
damage DNA and thus do not select for potentially 
undesirable phenotypes such as deficiency of mismatch- 
repair pathways and, as 3 consequence, ALT 
One such class of drugs is the angiogtnesis inhibitors. 
Several clinical trials of these agents are under way, both in 
combination with conventional therapy and Acme. " 
Strategies used to inhibit tumour angiogenesis fall broadly 
into three categories interference with angiogenic ligands, 
receptors, or downstream signalling; upregulation or 
delivery of endogenous inhibitors; and direct targeting of 
the tumour rasculature. " Antiangiogenic strategies are 
generally directed at targets that are characteristic of 
immature blood vessels, and this feature gives specificity to 
this anticancer treatment, mature native vessels being 
relatively spared. One recent study investigated inhibition 
of vascular endothelial growth factor 21 %'E(-, F' i, it showed 
a reversal of resistance to radiotherapy in two radioresistant 
tumour types. ' There are, however, limitations in 
preclinical trials, which mean that caution is needed. 
Subcutaneous human tumour xenografts in mice may be 
less robust than human tumours in vivo, and the endpoint 
commonly used in preclinikal studies is tumour regression 
rather than elimination. With tumour progression, a wider 
array of angiogenic molecules is produced. Hence, any 
therapy directed against a single agent ieg, VEt. F, mav 
produce selection of cells expressing another molecule leg, 
interleukin 8.1. Agents against many targets used 
synchron ousl}" may he the most effective strategy. 
The available evidence suggests that angiogenesis 
inhibitors can limit the expansion of tumours but do not 
Search strategy and selection criteria 
Published and unpublished data for this review wore collated 
by searches of Medlin and Web of Science and from review 
of work presented at a recent International cancer meetings 
(American Association of Cancer Research. 2001) up to and 
Inck ding Jerwary. 2002. The search terms 'talonwraso'. 
'tolomaros", 'cancer", and "head and neck cancer were 
used. Only papers published In English were Included. We 
have used recent reviews whore possible. so that we could 
comply with the journal's policy on tafel number of 
references. Where more than one reference Is reI i nt. we 
have used the first published. 
kill the tumour completely i figure ; i. The combined use of 
angiogenesis inhibitors and radiation is more effective than 
either alone in human xenogratts, " so if sufficient targeting 
can he applied to tumours, greater success might he 
expected with angiogenesis-factor inhibitors in the future. 
Telomerase inhibitors are complementary to angiri enesis 
inhibitors in that they kill the tumour ver7 efficiently but 
generally would ixet he expected to limit its size at first 
k figure 51. Thus the combined use of telumerase and 
angiogenesis-factor inhibitors t see comment hs"' hav may 
provide optimum tumour kill in both the immediate and 
intermediate treatment phases, and in the king term may 
help prevent the growth of residual tumour after therapy. 
The use of angio enesis and telomerase inhibitors is 
envisaged to he particularly useful in preventing the growth 
of occult mierumetastases, which are a common ivason for 
the relapse of patients with solid tumours. 
Conclusions 
The discovery of a mitotic clock and further elaboration of 
the role of the telumere in mammalian tells have stimulated 
many ideas in research connected with cancer. The current 
state of knowledge is that the telomrre length, and 
specifically the telomerase enivme and its cofactors, provide 
very attractive targets for anticancer therapeutic strategies. 
The reactivation of telomerase in tumour cells and, in many 
cues, very short average telunsere repeat fragments, provide 
the possibility pof the long-sought specificity in the targeting 
of chemotherapeutic agents. Further insight into the exact 
degree of shortening required to provoke crisis and 
correlation with observed tetomere lengths in cancers are 
required In particular, the high degree of telomerase 
activation in squamous cancer of the upper aets digestive 
tract promises exciting possibilities in the coming years. 
The combined use of tekomerase inhibitors with 
radiotherapy, more selective new drugs such as angio enesis 
inhibitors, or both, to kill tamer cells selectively is an 
exciting prospect. The publication of a report on the first 
highly selective antitelomerase drug" ! rings us closer to the 
point where the ideas discussed in this review can be 
realised and tested in vitro and then in vivo "sch new 
initiatives, if successful, may finally herald a new era in 
which the prognosis for S( CHN may finally improve. 
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